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Abstract
This thesis is focused on the role of the Tuberous Sclerosis Complex 
(TSC)/mammalian Target of Rapamycin (mTOR) pathway in the proliferation, survival 
and differentiation of T cells and PC 12 nerve cells. TSC and mTOR play important roles in 
these cellular processes in different cell models. We wondered which could be the 
contribution of these pathways in T cells and in particular in thymic development and in 
another cellular model of differentiation like the PC 12 cells.
In the first part of the thesis the results of the studies on the differentiation of 
mature T cells are presented. The involvement of mTORCl and mTORC2 was analysed in 
these processes by pharmacological inhibition with Rapamycin. The mTOR complexes 
were found to affect cytokines expression by influencing DNA methylation of their 
promoters.
The role of the TSC pathway in thymic development was then evaluated. TSC1 was 
genetically inactivated early on during thymic development. It was possible to observe an 
increase in proliferation and cell death of TSC 1 deleted cells. The increased proliferation 
was due to increased mTORCl signalling, while the increased cell death results from 
increased FoxO activity, a consequence of defective mTORC2/Akt signalling.
The last part of the thesis focuses on the study of the TSC pathway in PC 12 cells, a 
model of neuronal differentiation. The TSC complex plays a critical role in balancing the 
processes of proliferation and neurosecretory functions in these cells by its ability to affect 
the P-catenin and REST pathways. The signalling loop that connects these three central 
players can alternatively control these important processes.
II
1. General introduction
The interest of Dr. Mondino’s lab is to define signalling pathways controlling cell 
growth, proliferation, differentiation and survival in T lymphocytes. This thesis reports 
results from the study of several of these events, relative to the activity of Tuberous 
Sclerosis Complex (TSC) and the mammalian Target of Rapamycin (mTOR), able to 
coordinate cell growth and cell metabolism, and by that the potential of T cells and nerve 
cells to proliferate, differentiate and survive. The thesis has been organized as follows: a 
general overview of TSC and mTOR and of the upstream and downstream signalling 
events implicated in cell growth, proliferation, differentiation and survival and three 
distinct chapters dealing with the role of TSC/mTOR in CD4+ T cell differentiation, in T 
cell development and in nerve cell functions.
1.1 TSC
Tuberous Sclerosis Complex (TSC) and the mammalian Target of Rapamycin 
(mTOR) are important regulators of cell growth and proliferation. They can integrate many 
different signals such as nutrients, the energy status of the cell and growth factors and can 
orchestrate diverse processes such as autophagy, ribosome biogenesis and metabolism. 
Deregulation of these complexes can lead to serious diseases, such as cancer, diabetes or 
degenerative syndromes, involving many different systems and organs.
Tuberous Sclerosis Complex (TSC) is an autosomal dominant genetic disease with 
formation of hamartomas in multiple organ systems with an incidence of 1 in 6000 births, 
arising from mutations in either hamartin (TSC1) or tuberin (TSC2). Mutations in both 
TSC1 or TSC2 range from nonsense, missense, insertion and deletion mutations, while 
large genomic deletions are more common for the TSC2 gene [1]. TSC1 and TSC2 form a 
complex in cells [2, 3], involved in many different cellular mechanisms such as cell size, 
cell cycle, cellular proliferation and cell death [4-7] . This is due to critical positioning of 
the TSC1/TSC2 complex at the crossroad of many different signalling pathways
integrating the energy status of the cell with nutritional availability and extracellular 
growth factor signalling. Binding of TSC1 to TSC2 stabilizes TSC2 by preventing its 
ubiquitin-mediated degradation [8, 9]. TSC1 and TSC2 are both regulated by 
phosphorylation.
TSC1 is phosphorylated at multiple Thr and Ser sites by Cyclin-Dependent Kinase 
1 (CDK1) during the G2/M phase of the cell cycle [10] in HEK293 cells. CDK1 is active in 
late cell cycle phases and it favours entry into mitosis when it is bound to Cyclin B1 
(review by Nigg E. A. [11]). CKD1 phosphrylates TSC1 at three residues (Thr417, Ser584 
and Thr1047) that lie within the TSC1-TSC2 interaction domain. Hamartin 
phosphorylation by CDK1 decreases the inhibition of p70S6K [10], suggesting that 
regulation of TSC1/TSC2 during G2/M could be important for the integration of cell 
division with activities regulated by p70S6K such as cell size, protein synthesis and growth 
factor signalling.
TSC1 can also be negatively regulated through IKKP-mediated Ser 
phosphorylation [12]. IKKp is a major downstream kinase in the TNFa signalling 
pathway. TNFa is an important proinflammatoiy cytokine that is thought to be a potential 
mediator involved in different human disease such as cancers [13]. Lee et al. [12] 
demonstrated that TNFa activates the mTOR pathway through IKKp. In MCF-7 and 
MDA-MB-453 cells, IKKp, in fact, phosphorylates TSC1 at Ser487 and Ser511 and thus 
suppresses its function and consequently impairs the antiangiogenic function of TSC 1 [12]. 
The results from Lee et al. [12] hint at a possible mechanism linking the TNFa and mTOR 
signalling pathways and at their connection to TNFa-mediated human tumour 
angiogenesis.
Also TSC2 is the substrate for many upstream kinases. It can be phosphorylated by 
the AMP-activated protein Kinase (AMPK) [14]. AMPK is one of the most important 
energy sensors in cells. AMPK role is quite conserved during evolution. The primary role
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of the AMPK orthologue in yeast is in the response to glucose starvation [15]. Also in cells 
from mammals [16] and Drosophila [17] AMPK can be activated by glucose starvation. 
AMPK senses the AMP/ATP ratio of the cell. Decrease in ATP levels and increase in 
AMP levels activate AMPK [15]. Inoki et al. [14] demonstrated that in HEK293 cells, 
under energy starvation conditions, AMPK phosphorylates TSC2 in Thr1227 and Seri 345 
and in this way enhances TSC2 function. This phosphorylation is required for translation 
regulation and for the control of cell size following energy deprivation. The authors also 
showed that AMPK mediated phosphorylation of TSC2 can protect cells from apoptosis 
induced by energy deprivation [14].
Also, Glycogen Synthase Kinase 3p (GSK3P) can phosphorylate TSC2 [18]. 
GSK3p is inhibited following activation of the Wnt pathway. The Wnt family is important 
for many different cellular functions such as cell growth, proliferation, polarity, 
differentiation and development [19, 20]. Deregulation of different components of the Wnt 
signalling pathway has also been involved in benign colorectal adenomas and cancers [21, 
22]. Activation of the Wnt pathway inhibits GSK3p, this leads to decreased 
phosphorylation and thus stabilization of p-catenin. p-catenin can then translocate to the 
nucleus and form a complex with the DNA binding protein T Cell Factor (TCF) [21, 23] 
inducing the transcription of different genes such as Cyclin D and VGF [24, 25]. Inoki et 
al. [18] for the first time reported a role for the Wnt signalling in protein translation and not 
only in the regulation of gene transcription. The authors, in fact, demonstrated that Wnt 
activates the mTOR pathway and increases cell size through inhibition of GSK3p. In the 
different mammalian cells analysed (HEK293 and LEF), GSK3p phosphorylates TSC2 on 
Seri337 and Seri341 and activates it. The inhibition of GSK3p thus leads to inhibition of 
TSC2 and subsequent activation of mTORCl. By the use of Rapamycin, an inhibitor of 
mTOR, the authors further demonstrated that activation of mTOR by Wnt is important for 
mammary tumour cells growth linking the TSC2/mTOR pathway to tumorigenesis induced
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by hyperactivation of the Wnt pathway.
Erk is another kinase that can phosphorylate TSC2 [26]. The Raf-MEKl/2-Erkl/2 
signaling pathway is important in the regulation of differentiation and cell growth. This 
pathway can be activated by growth factors, inflammatory cytokines or physical stress and 
has as targets nuclear transcription factors, cytoplasmic translation initiation factors and 
members of the Bcl-2 family [27]. Ma et al. [26] showed that Erk associates with TSC2 
and phosphorylates it on Ser664 in 293 cells. Erk phosphorylation leads to the disruption 
of the TSC1/TSC2 complex and thus to inhibition of TSC2 activity. As a consequence of 
ERK-mediated TSC2 phopshorylation, the TSC1/TSC2 complex was inactivated, 
contributing to deregulation of mTOR signalling, cell proliferation and oncogenic 
transformation. Accordinly, by expressing a form of TSC2 that cannot be phosphorylated 
by Erk in tumour cells with constitutive activation of Erk the authors observed that this 
particular form of TSC2 could block tumorigenecity in vivo, suggesting that the 
Ras/MAPK pathway could affect mTOR signalling through TSC and thus contribute to 
tumour progression [26].
The other key kinase in the regulation of TSC2 is Akt. Three isoforms of Akt have 
been identified: Aktl, Akt2 and Akt3. All of them are activated by growth factors and 
insulin through PI3K and are inhibited by the tumour suppressor PTEN [28]. Akt controls 
cellular functions such as cell survival, cell growth, differentiation, angiogenesis and 
glucose metabolism [28-30]. Akt has been shown to phosphorylate and thus regulate 
TSC2. Akt can phosphorylate TSC2 at Ser924 and Thrl518 [31] in Drosophila. The 
phosphorylation of TSC2 inhibits the stability of the TSC1/TSC2 complex favouring in 
this way cell growth in Drosophila melanogaster [31]. In NIH 3T3 and HEK 293 cells 
Manning et al. [32] demonstrated that Ser939 and Thrl462 are the phosphorylation sites 
phosphorylated by Akt on TSC2. These sites align with the phosphorylation sites found by 
Potter et al. to be target of Akt in Drosophila TSC2 [31]. TSC2 mutants that cannot be 
phosphorylated in these sites inhibits insulin-stimulated S6K1 phosphorylation and
activity, underlying the importance of Akt control of TSC2 in cell growth [32]. Akt 
inhibition of TSC2 activity results in increased phosphorylation of two mTORCl targets: 
S6K and 4E-BP1[33]. In HeLa cells Akt phosphorylation of TSC2 results also in the 
degradation of the cyclin-dependent kinase inhibitor p27 and thus favours cell proliferation 
[34].
The different signalling pathways described above that influence TSC1/TSC2 
activity are activated in many cellular processes of key importance for the life of diverse 
kind of cells. In particular these pathways are quite active during different stages of T cell 
development and activity. To date, however, there are no reports in the literature that link 
TSC1/TSC2 phosphorylation and activity to any of these processes in T cells.
The TSC complex thus, being at the point of convergence of key regulators of 
many cellular functions, controls a widespread array of signalling molecules. Among these 
is the mammalian Target Of Rapamycin (mTOR). The TSC2 protein acts as a GTPase 
activating protein toward Ras homolog enriched in brain (Rheb), a GTPase of the Ras 
family. When GTP-bound, Rheb activates mTOR Complex 1 (mTORCl) by preventing its 
association with the endogenous inhibitor FKBP38 [35, 36]. By stimulating the conversion 
of active Rheb-GTP to the inactive form, Rheb-GDP, the TSC1/TSC2 complex inhibits 
mTORCl, and signalling downstream to mTORCl [37]. The TSC1/TSC2 complex also 
controls activation of mTOR Complex 2 (mTORC2) [38]. In addition to the mTOR 
pathway, the TSC1/TSC2 complex also directly repress p-catenin activity [39-41] thus 
impacting on proliferation and survival [42],
Positioning of the complex both downstream and upstream several 
signalling pathways accounts for TSC being a multisystem disorder [43] characterized by 
the development of benign tumours and hamartomas in the brain, heart and kidney [44]. 
Dermatological abnormalities, such as hypomelanotic macules, are also evident in pediatric 
patients [45]. Another clinical manifestation of TSC is the lymphangioleiomyomatosis 
(LAM). This disease can be sporadic or associated with TSC. LAM is characterized by the
development of lung tumours with abnormal smooth muscle cell growth, cystic destruction 
of the lungs and loss of pulmonary function [46-50]. The central nervous system might 
also be affected by mutations in either TSC1 or TSC2. The hallmarks are cortical tubers 
and subependymal nodules [51-53]. The affected subjects can exhibit cognitive defects, 
epilepsy, autism and attention-deficit hyperactive disorder [51, 54].
1.2 mTOR
The Target of Rapamycin (TOR) is a serine-threonine kinase first identified in yeast 
as results of efforts aimed at understanding the mechanism of action of the macrolide 
Rapamycin (Rapa). In yeast two genes have been described TORI and TOR2, which 
function has been linked to cellular growth [55]. mTOR is the mammalian homolog of 
TOR. mTOR plays critical roles in cell metabolism, growth, proliferation and survival and 
in many physiological and pathological processes such as angiogenesis, adipogenesis, 
innate and adaptive immune responses, tumour formation or insulin resistance. 
Accordingly inhibitors of mTOR and mTOR-dependent pathways are under evaluation for 
the treatment of human diseases such as cancer, type 2 diabetes and neurofibromatosis type 
1.
mTOR is a 289-kDa protein that is part of the Phospho-Inositide 3-Kinase (PI3K)- 
related Kinase (PIKK) family [56]. Other members of this family include ATM, ATR, NA- 
PK and hSMGl. These proteins are characterized by a C-terminal protein kinase domain 
similar to the lipid kinase PI3K. The C-terminal end of mTOR contains several important 
elements, including the kinase catalytic domain (KIN). The KIN domain also contains a 
small region that is probably a site of phosphoregulation called the Negative Regulatory 
Domain (NRD) or ‘Repressor Domain’ [57, 58]. This domain contains sites of 
phosphorylation that are conserved in other kinases with similar structure. In this region 
there are key sites of phosphorylation for the activity of mTOR, in particular threonine 
2446, serine 2448 and serine 2481. These sites of phosphorylation are associated with
increased mTOR activity. Serine 2448, in particular, is a target of Akt as well as p70S6 
Kinase (S6K) [59-62]. Other sites of phosphorylation are substrates of the downstream 
effectors of mTOR itself. In this way they make possible mechanisms for feedback 
regulation [57, 58]. Finally, adjacent to the KIN domain is the FKBP12-Rapamycin 
Binding domain (FRB), the site of inhibitory interaction between Rapa and mTOR.
mTOR can form at least two different complexes. mTOR complex 1 (mTORCl) 
and mTOR complex 2 (mTORC2) [63, 64]. mTORCl is a homodimer [65-68] composed 
by mTOR itself and by other four different proteins: the scaffolding protein regulatory- 
associated protein of mTOR (raptor) as well as mammalian Lethal with Sec 13 protein 8 
(mLST8), the Proline-Rich Akt Substrate 40 kDa (PRAS40), and DEP-domain-containing 
mTOR-interacting protein (Deptor). The interaction between mTOR and its binding 
partners is thought to be mediated by the many heat domains in the mTOR N-terminal. 
Raptor is important for mTORCl assembly and because it recruits some of mTORCl 
substrates such as 4E-BP1 [69, 70]. Raptor has also been shown to be important for the 
subcellular localization of mTORCl and as a sensor of the amino acids levels [71]. The 
role of mLST8 is not clear. Its deletion, in fact, has no consequences on mTORCl activity 
[72]. Both PRAS40 and Deptor are substrates of mTORCl. When they are in the 
dephosphorylated state they seem to repress mTORCl activity. After activation mTOR 
phosphorylates both of them leading to their dissociation from the complex and thus 
increasing the activity of the complex itself [73-78]. PRAS40 is also a target of Akt. The 
phosphorylation of PRAS40 by Akt blocks the PRAS40 inhibition of mTORCl [77]. Main 
substrates of mTORCl are S6 Kinase 1 (S6K1) and 4E-BP1, important for mRNA 
translation.
The central component of mTORC2 is Rictor (RAPTOR-independent companion 
of mTOR). mTOR can bind only to Rictor or to Raptor, so the binding with one of these 
prevents binding with the other [63, 79]. Also mTORC2 is a multimer like mTORCl [80]. 
Also like mTORCl it can bind to mLST8 and to Deptor [63, 73, 79]. Proteins specific of
HEAT repeats FAT FRB Kinase FATC 
domain
B
Raptor
RNC HEAT WD40 repeats
C
rnLSTS
WD40 repeats
D
PRAS40 H l l l l i i l l l i  ■ WD40repeats
Proline-rich region
Rictor 4 T H f T T Q T » I 3 DD
Conserved domain structure
Sin1 O >
CRiM RBD PH
Fig I. mTOR domains. Schematic representation of the different domains of proteins 
belonging to the mTOR complexes. HEAT: a protein interaction structure of two tandem 
anti-parallel ahelices found in /rantingtin, elongation factor 3, PR65/A and TOR; FAT: a 
domain structure shared by FRAP, ATM  and 7RRAP, all of which are PIKK family 
members; FRB: RKBP12/rapamycin binding domain; FATC: FAT C-terminus; RNC: 
Raptor iV-terminal conserved domain; WD40: about 40 amino acids with conserved W and 
D forming four anti-parallel beta strands; CRIM: conserved region in the middle; RBD: 
Ras binding domain. Yang Q., Cell Research, 2007 [81]
mTORC2 instead are mammalian stress-activated protein kinase interacting protein 
(mSINl) and protein observed with Rictor-1 (Protor-1, also known as PRR5). Rictor is 
essential for mTORC2 catalytic activity [79]. Probably it is important for the recruitment 
of mTORC2 targets to the complex in a way similar to what Raptor does for mTORCl. 
Rictor and mSINl stabilize each other and they may thus be important for the integrity of
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mT0RC2 [82, 83]. mSINl however probably has other roles beside the structural one of 
helping in keeping the integrity of mTORC2. mSINl, in fact, has regions homologous to 
the Ras-binding domain and a Pleckstrin Homology (PH)-like domain that could be 
functional [84]. Protor-1 binds Rictor. This protein is not essential for mTORC2 activity 
[76]. While mLST8 is not essential for mTORCl activity, it is of fundamental importance 
for mTORC2 function [72]. In a similar way to what happens with mTORCl, Deptor binds 
to the FAT domain of mTOR and it inhibits also mTORC2 [73]. Main substrates of 
mTORC2 are Akt, Serum- and Glucocorticoid-induced protein Kinase 1 (SGK1) and 
Protein Kinase Ca (PKCa), important for cell proliferation and survival and for regulation 
of cytoskeletal organization.
mTORCl
Growth
Factors
Amino
Acids
mTORC2
Growth
FactorsEnergy
•  •  •
PR R 5/Prctor  i___
mTOR^
RictormTOR
hSINl
Raptor X HM-SiteTM-Site
T4S0PRAS40
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T389
inase
E B P f  f3 6 K 1
C ap-In d ep en dent^ /translation
Cell growth & proliferation Actin cytoskeleton organization  Cell proliferation & survival
Fig II. mTOR complex components. Schematic of the different proteins of the mTOR 
complexes. Foster K.G., The Journal of Biological Chemistry, 2010 [85]
Both mTORCl and mTORC2 were reported to be sensitive to Rapamycin (Rapa), 
although to different extents, and with different kinetics. Rapa is a macrolide produced by 
Streptomyces hygroscopicus, a soil bacterium found on Easter Island [86]. For years Rapa
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has been considered a specific inhibitor of mTORCl, via its binding to FKNP12. When 
Rapa binds to the FKNP12 protein it forms a drug-receptor complex that can interact with 
the FKBP12-Rapamycin Binding (FRB) domain of mTOR. In this way it can directly 
inhibit mTORCl function (reviewed by Guertin D. A. and Sabatini D. M. [87]). Prolonged 
treatment with Rapa, however, in certain cell types can inhibit also mTORC2. In this case 
Rapa-FKBP12 cannot directly bind to mTORC2. Rapa however can bind to free mTOR 
and prevent its binding to Rictor and assembly of the mTOR complex 2 [88]. Recent 
reports highlighted the fact that while mTORCl is sensitive to very low doses of the drug 
(100-500 pM), mTORC2 can be inhibited only at higher doses (5 nM-1 uM) [89]. Recent 
reports also showed mTORCl functions resistant to Rapa. By using a cap-dependent 
translation reporter vector Choo et al. [90] demonstrated that Rapa exhibits differential 
regulation of S6Ks and 4E-BP1 in a cell specific manner. While Rapa could potently 
inhibit S6K activity during the whole duration of the treatment (24 hours) in HEK293 and 
MEFs cells, the authors observed an initial inhibition of 4E-BP1 phosphorylation that 
recovered over time and this recovery in phosphorylation correlated with reinitiation of 
cap-dependent translation. Catalytic inhibitors of mTOR could prevent Rapa-resistant re­
phosphorylation of 4E-BP1 [90].
Thoreen et al. [91] demonstrated that Torinl, a highly potent inhibitor of mTOR 
that can directly inhibit both mTORCl and mTORC2, is able to impair cell growth and 
proliferation to a greater degree that Rapa, revealing Rapa-resistant functions of mTOR. 
Torinl treatment of MEFs, in fact, completely inhibited proliferation and caused a Gi/S 
cell cycle arrest compared to the reduction in the proliferation rate of Rapa treated cells. 
Torinl decreased also cell size to a greater degree than Rapa. These effects were not due to 
Torinl inhibition of mTORC2 as Torinl continued to dramatically suppress proliferation 
and reduce cell size also in Rictor KO MEFs. The authors also showed that mTORCl 
regulation of 4E-BP1 phosphorylation and binding to eIF-4E reveals rapamycin-resistant 
functions [91] by looking at MEFs treated with Rapa or Torinl. By using other two TOR
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inhibitors: PP242 and PP30, Feldman et al. [92] demonstrated that these inhibitors affect 
proliferation of primary myotubes more completely than Rapa. While PP242 does not have 
an evident effect on actin stress fibers in NIH 3T3 cells, the authors show that it can inhibit 
proliferation of primary MEFs more completely than Rapa. Also 4E-BP1 phosphorylation 
and Cap-Dependent translation in primary MEFs are more strongly inhibited by PP242 
than Rapa, revealing mTORCl Rapa-independent activity. By using SIN KO MEFs the 
authors demonstrated that the effect observed with administration of PP242 was due to its 
inhibitory activity on mTORCl [92]. The phosphorylation pathways addressed by these 
different groups may vary among different cell types. Rapa has been shown, in fact, to 
cause substantial decrease in overall protein translation in some cell types such as NIH 3T3 
cells [93] while having little effect in other cells such as HEK293 [94].
The use of Rapa has helped the understanding of some key functions of mTOR in T 
cells. It was found to be a poor antibiotic and instead to have potent immunosuppressive 
activities. It was initially thought to exert this activity by inhibiting IL-2-induced 
proliferation of T cells [95], and by that induce T cell unresponsiveness [96]. This is in 
contrast to Cyclosporine A (CSA), which inhibits calcineurin and TCR signalling, and 
overall T cell activation [97]. Results generated by Sara Colombetti, a previous PhD 
student in the lab, and by others, showed that Rapa does not block T cell proliferation, but 
only delays initial Gi to S cell cycle transition. Most recent studies have provided evidence 
that Rapa, rather than being an immunosuppressant, exerts immunomodulatory activity, by 
preventing effector cell differentiation, and favouring the generation of regulatory T cell 
[98-103].
1.3 Signalling events controlling TSC/mTOR
Many different signals have been identified as regulators of the TSC/mTOR 
pathway. Among these growth factors, amino acids, glucose, energy status and many forms 
of stress (e.g. osmotic stress, DNA damage). All of these signals can cooperate or
antagonize each other. The result of the integration of all of these inputs is the precise 
activation of TSC/mTORCl. The regulation of mTORC2 is not so well known, it seems 
that only growth factors can directly regulate the complex.
The regulation of mTORCl may be mainly through the direct regulation of proteins 
of the complex, such as PRAS40, or through the modification of Rheb, the GTPase that 
when bound to GTP can directly interact and activate mTORCl [35].
1.3.1 Growth factors
Several growth factors such as insulin and IGF-1 promote anabolic process such as 
translation, lipid biosynthesis and nutrient storage, through activation of mTORCl. After 
insulin binds to its receptor, it activates phosphoinositide 3-kinase (PI3K) through Insulin 
Receptor Substrate 1 (IRS1). PI3K then is able to generate phosphatidylinositol-3,4,5- 
triphosphate (PtdIns(3,4,5)Ps) by direct phosphorylation of phosphatidylinositol-4,5- 
bisphosphate (PtdIns(4,5)P2) [104].
In lymphocytes PI3K activation has been demonstrated to follow antigen-receptor 
engagement [105]. Naive T cells get activated when they encounter a cognate antigen 
presented by major histocompatibility (MHC) complexes on the surface of antigen- 
presenting cells (APCs). This leads to engagement of different signal transduction proteins 
that control processes such as proliferation. Among these signaling pathways the PI3Ks are 
of fundamental importance [106]. Costello et al. [107], by using a fusion protein made of 
the PKB PH domain (that binds PIP3) and GFP, demonstrated that naive T cells produce 
PIP3 within seconds after the encounter with APCs loaded with their cognate peptide. PIP3 
production was sustained for several hours and occurred both inside and outside the T cell- 
APC contact zone. Different molecules downstream the TCR have been shown to be able 
to regulate PI3K activity. Among these components of the TCR itself such as TCR £ [108] 
and different CD3 chains (y, 5, s) [109, 110]. Also adapter molecules like Linker for 
Activation of T cells (LAT) [111], T cell receptor interacting molecule (TRIM) [112] and
She [113] and also the small GTPase Rac [114] have all been shown to activate PI3K. The 
Lck kinase as well has been demonstrated to recruit PI3K to the CD4 coreceptor [115].
Activation of PI3K was also linked to costimulation by CD28 [116-118] and also to 
signals triggered by cytokines such as IL2 [119, 120] and IL15 [121]. IL2 and IL15, 
however, can activate the PI3K pathway with different kinetics. As shown by Cornish et al. 
[121] regulation of S6 phosphorylation by IL2 and IL15 is similar during an early 6-hour 
time point, but during prolonged exposure to the cytokines only IL-2 stimulated CD8+ T 
cells were able to maintain high levels of S6 phosphorylation [121].
PtdIns(3,4,5)P3 is bound both by 3-phosphoinositide-dependent protein kinase 1 
(PDK1) and by Akt through their pleckstrin homology (PH) domain. The binding of PDK1 
to PtdIns(3,4,5)P3 its not essential for its catalytic activity. However it favours its 
recruitment to the plasma membrane where it can interact with Akt and phosphorylate this 
protein on the residue Thr308. In addition to Thr308 by the way of PDK1, Akt also 
requires phosphorylation in Ser473 by mTORC2 [122] for full activation. Active Akt can 
then phosphorylate TSC2, inhibit it and thus lead to the activation of mTORCl.
Growth factors can phosphorylate mTORCl also through mechanisms not 
involving TSC. Akt, for example, can directly phosphorylate PRAS40, the component of 
mTOR complex 1. PRAS40 inhibits the function of mTORCl. Following phosphorylation 
by Akt it does not exert any more this inhibitory function, thus Akt activity results in 
activation of mTORCl [74-78, 123]. Salmond et al. [124] demonstrated that also in CD8+ 
T cells Akt can control mTOR activity. Administration of Wortmannin, in fact, can 
decrease S6 phosphorylation in these cells. We obtained similar results in CD4+ purified T 
cells. Treatment of cells with wortmannin, in fact, reduced S6 phosphorylation (data not 
shown).
Following activation by growth factors, mTORCl is able to turn off the activation 
signal by a negative feedback loop, mediated by S6K1, one of the mTORCl main targets. 
S6K1 can phosphorylate IRS1. This prevents its binding to the insulin receptor, and thus
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terminates insulin-mediated PI3K activation. Zhang et al. [125] demonstrated that in MEFs 
S6K1 can inhibit the activity also of other growth factor receptors independent on IRS1, 
suggesting that probably it has other targets besides it [125]. Tzatsos A. [126] showed that 
in HEK293 cells mTORCl can also directly interact with IRS1 through Raptor and prevent 
IRS1 association to PI3K [126]. The feedback loop was initially revealed following Rapa 
treatment or in the presence of constitutive mTORCl activation. Harrington et al. [127] 
demonstrated that in MEFs Rapa treatment and thus mTOR inhibition leads to increased 
PI3K signalling, evaluated by Akt phosphorylation, due to increased IRS-1 function. In 
the case of hyperactivation of mTORCl, due to loss of TSC2, the PI3K signalling was 
found to be suppressed, because of lack of activation by IRS-1, found to be a substrate of 
S6K [127]. This feedback pathway is active also in different cellular models. Tremblay et 
al. [128] demonstrated the presence of the feedback loop in L6 muscle cells. The authors 
showed that incubation of these cells with amino acids leads to time-dependent 
deactivation of IRS1/PI3K activity. In particular after 30 min of stimulation with insulin 
Tremblay et al. observed a strong decrease of the activity of this pathway compared to the 
maximal activation at 5 min of stimulation. This deactivation was associated with a 
concomitant increase in the phosphorylation of p70S6K. Treatment with Rapa, instead, 
maintained PI3K maximally active for up to 30 min [128]. Tremblay et al. [129] 
demonstrated the presence of the feedback loop also in 3T3-L1 and human adipocytes. In 
particular they showed that insulin stimulated the mTOR pathway assessed by increase in 
p70S6Kl phosphorylation. Treatment with Rapa increased insulin-stimulated glucose 
transport. They authors showed also that treatment with Rapa prevented the relocalization 
of IRS1 from the low-density membranes to the cytosol in response to insulin [129]. 
Martin et al. [130] showed the presence of the loop in vascular smooth muscle cells while 
Tremblay et al. [131] confirmed the presence of this feedback loop in many different 
cellular models such as L6 muscle cells, 3T3-L1 adipocytes and Fao hepatoma cells. The 
presence of the loop has been demonstrated. It is thus possible that this mechanism of
regulation is present also in other cellular models such as lymphocytes, cells in which the 
PI3K and mTOR pathways plays key roles in different cellular processes.
1.3.2 Glucose and energy
TSC/mTOR have also been shown to be under the control of glucose levels. 
Glucose deprivation leads to decreased ATP levels and inhibition of mTORCl via a 
mechanism involving AMPK and TSC2 [14, 132]. This is due to the fact that a high ratio 
of AMP/ATP signals to TSC2 through the 5’ AMP-activated protein kinase (AMPK) [14]. 
Activated AMPK decreases processes that are particularly demanding from an energetic 
point of view and increases processes that lead to generation of ATP such as fatty acid 
oxidation. Once AMPK is activated it can hinder cell growth and the ATP consumption 
resulting from this process [133]. AMPK is activated when phosphoiylated by its upstream 
kinase LKB1 [134]. AMPK, when active, phosphorylates TSC2 leading to its activation. 
This in turn suppresses mTORCl activity [14, 135, 136]. AMPK can also directly 
phosphorylate raptor and lead to its sequestration by 14-3-3, a protein that by binding to 
specific phosphopeptides of its targets can regulate the activity of its binding partners. The 
net result is again inhibition of the kinase activity of mTORCl [137].
1.3.3 Oxygen
Oxygen levels also impacts on TSC/mTOR signalling events. Hypoxia, a situation 
characterized by reduced levels of oxygen, has been shown to lead to inhibition of 
mTORCl. Hypoxia indeed can decrease ATP levels and thus activate AMPK. This leads to 
activation of the TSC1/TSC2 complex and thus mTORCl inhibition. Hypoxia, as well as 
energy depletion, can also activate the Reddl/RTP801/DDIT4 pathway [138, 139]. Reddl 
phosphorylates and activates TSC2 [140] by stabilizing the interaction between TSC1 and 
TSC2 [141, 142], and by that inhibits mTORCl activity. Another way in which hypoxia 
can further suppress mTORCl is through the promyelocytic leukemia (PML) tumour
suppressor. PML has been shown to bind to mTOR and inhibit it by sequestering it in 
nuclear bodies [143].
1.3.4 Amino acids
mTOR has also been described as a sensor of amino acids availability. A decrease 
in amino acids intake leaves the cell without substrates essential for protein synthesis. 
Amino acids starvation, especially of leucine, leads to a fast dephosphoiylation of the 
mTORCl effectors S6K1 and 4E-BP1, while re-addition of amino acids re-establishes 
proper levels of phosphorylation of both mTORCl targets (reviewed by Hay N. and 
Sonenberg N. [57]). So different amino acids have been shown to signal to mTORCl. 
However it is not clear how they can do this. It seems that in this process of activation 
mTORCl recruitment to lysosomal membranes, where it can bind to Rheb, is of key 
importance [71, 144]. On the lysosomes can be found a particular complex termed 
Ragulator composed of MP1, p i4 and pi 8 [144]. This complex is a scaffold protein for 
Rag GTPases. Rags loading with GTP seems to be regulated by amino acids. Amino acids 
stimulation leads to the activation of the Ragulator that then interacts with raptor, serving 
as a docking site for mTORCl and thus bringing the mTORCl complex to the lysosomal 
surface. Once on the surface of the lysosomes mTORCl can interact with Rheb-GTP 
[144]. Another way in which amino acids have been proposed to activate mTORCl is 
through inhibition of TSC1/TSC2. Gao et al. [145] showed that loss of TSC2 makes cells 
resistant to amino acids withdrawal. This seems to correlate with the fact that amino acids 
can signal through TSC1/TSC2. Other studies propose a mechanism independent of 
TSC1/TSC2 and Rheb. These studies demonstrate that hVPS34 can signal directly to 
mTORCl the amino acids levels of the cell without using the TSCl/TSC2-Rheb pathway 
[146,147].
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1.4 TSC/mTOR and cell growth and proliferation
Cell growth is the consequence of a series of processes involving macromolecules 
synthesis. These lead to the increase in cell size and the increase in production of substrates 
important for the increased energy consumption required by the growing cell. mTORCl 
directly controls the synthesis of both proteins and lipids, and by that cell growth.
Protein synthesis requires high amounts of ATP and GTP and also the production 
of a large number of ribosomes. That’s why it is quite a costly process, from the energetic 
point of view, for the cell. mTORCl is of fundamental importance in regulating the 
translational machinery of the cell and also in translating a particular subset of messenger 
RNAs (mRNAs), important for cell growth and proliferation. mTORCl phosphorylates the 
eukaryotic Initiation Factor 4E (eIF4E)-binding protein 1 (4E-BP1) and the p70 ribosomal 
S6 kinase 1 (S6K1). By phosphorylating 4E-BP1 mTORCl precludes its binding to eIF4E. 
eIF4E can thus favour cap-dependent translation (reviewed by Richter J. D. and Sonenberg 
N. [148]). Some particular mRNAs such as Cyclin D3 and VEGF are particularly sensitive 
to 4E-BP1 function. It is not clear which are the specific features of these mRNAs, but 
probably their specific sensitivity is due to the fact that they are characterized by extensive 
secondary structures in the 5’ untranslated regions (UTRs). These structures require 
unwinding by the eIF4F complex (reviewed by Ma X. M. and Blenis J. [149]). The other 
class of mRNAs controlled by mTORCl is that of the 5’ TOP mRNAs. These mRNAs 
have short 5’ UTRs characterized by stretches of pyrimidines [150]. They encode for 
components of the translational machinery.
mTORCl control of S6K1 contributes to increase protein synthesis as well. S6K1 
belongs to the AGC family of protein kinases. It is activated when phosphorylated at two 
sites, a site in the C-terminal hydrophobic motif and a site in the T loop of the kinase 
domain. mTORCl phosphorylates the Thr380 in the hydrophobic motif, the site on the T 
loop, instead, is phosphorylated by PDK1. By acting on S6K1 mTORCl can increase 
mRNA biogenesis and cap-dependent translation of ribosomal proteins (reviewed by Ma
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X. M. and Blenis J. [149]). The activation of S6Ks by mTORCl leads to the subsequent 
activation of proteins such as S6K1 aly/REF-like target (SKAR), Programmed Cell Death 
4 (PDCD4), eukaryotic Elongation Factor 2 Kinase (eEF-2K), eukaryotic initiation factor 
4B (eIF4B), and ribosomal protein S6 (reviewed by Ma X. M. and Blenis J. [149]). S6K1 
can directly phosphorylate the 40S ribosomal protein S6. While it was thought that this 
would lead to the translation of a subset of mRNAs characterized by a 5’ tract of 
oligopyrimidine (TOP), this was recently shown not to be the case [151,152].
mTORCl can also promote ribosome biogenesis by acting on protein phosphatase 
2A (PP2A) and the Transcription Initiation Factor IA (TIF-IA) [153]. Experiments 
performed in yeast and in mammalian cells have shown that Rapa can inhibit ribosome 
biogenesis by inhibiting the transcription of RNA polymerase I (Pol I)-dependent rRNA 
genes, Pol Independent ribosomal protein genes (RP genes), and Pol Ill-dependent tRNA 
genes and also by inhibition of the processing of 35S rRNA (reviewed by Martin D. E. and 
Hall M. N. [154]), and thus ribosome biogenesis.
Lipid biogenesis is also critical for cell growth. The involvement on mTOR in this 
process has emerged only recently. It has been shown that mTORCl can increase the 
activity of Sterol Regulatory Element Binding Protein 1 (SREBP1) [155] and of 
Peroxisome Proliferator-Activated Receptor-y (PPARy) [156]. These transcription factors 
control the expression of genes that encode for proteins important in lipid and cholesterol 
homeostasis. The involvement of mTOR in cell growth has been demonstrated in different 
models from yeast to Caenorhabditis elegans and Drosophila melanogaster [157-159]. 
Inhibition of mTOR by rapamycin has further proved the involvement of mTOR in cell 
growth in different cells such as renal epithelial cells, pancreatic beta cells, T cells, and 
different kinds of tumour cells like hepatocellular carcinoma cells [160-163].
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Molecular Biology, 2010 [164]
TSC and mTOR, being at the crossroad of many different signalling pathways 
integrating the energy status of the cell with nutritional availability and extracellular 
growth factor signalling, play a critical role in cell proliferation [4-7]. TSC1/TSC2 has 
been shown to play a critical role in proliferation by different groups either by over­
expressing but also by down-regulating the function of the complex. The first experiments 
that demonstrated a role for TSC2 in cell proliferation were performed by Orimoto et al. 
and Jin et al. in cells coming from the Eker rat [165, 166]. This rat is characterized by a 
germ-line mutation in the TSC2 gene and it is inclined to the development of neoplasias in 
a variety of organs such as the kidney, uterus and spleen. The over-expression of TSC2 in 
different tumour cell lines derived from this rat [165, 166] decreases the proliferation rate
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of these cells. On the other hand, decreased functional activity of the complex leads to an 
increase in cell proliferation, making these cells prone to undergo a transformation process. 
For example Soucek et al. [167] by silencing TSC2 expression in Rati fibroblasts made 
these cells enter the cell cycle and they also noticed a shortening of the Gi phase. Other 
TSC2 negative cells reveal an increased rate of proliferation, as shown by fibroblast and 
smooth muscle cells from the Eker rat [168, 169]. Similar evidences were found also in the 
gigas mutant in Drosophila, another animal model of TSC2 loss. The mutant cells 
endoreplicate their DNA and this can be an indication that TSC2 is essential for the 
decision of entering the M or S phase. However the molecular mechanisms responsible for 
these effects have remained obscure for a long time. Even now it’s not exactly clear which 
is the role of TSC1/TSC2 in controlling cell proliferation and whether it plays a direct or 
indirect role. A possible explanation of the link between TSC1/TSC2 and proliferation may 
be through the GTPase Rap la. Tuberin act as GAP for this protein [170]. Yoshida et al. 
[171] demonstrated that Rapl can induce DNA synthesis when microinjected into 3T3 
cells. Thus a possible mechanism through which TSC2 may affect cell proliferation could 
be by indirectly acting on Rapl. Another interesting player affected by TSC1/TSC2 is the 
cyclin-dependent kinase inhibitor p27 [169]. In a recent report Lacher et al. [172] 
demonstrated that TSC2 control of proliferation pass through Rheb. In TSC2-deficient 
cells Rheb is constitutively functional, this leads to activation of AMPK through a 
mechanism mTORCl independent. Short et al. [173] showed that active AMPK can 
decrease nuclear levels of p27. In a similar way Rheb can also control p27 activity and thus 
proliferation of TSC deficient cells. Nuclear p27, in fact, hinders cell cycle progression 
(reviewed by Assoian R. K. [174]). mTORCl is also critical for cell proliferation both 
during fetal and adult life [175-178]. Although Rapa has been proposed as anti­
proliferative agent, several reports now have identified Rapa-independent or resistant 
mechanism of proliferation. This is also the case for T cells. Indeed, Sara Colombetti in the 
lab demonstrated that mTOR inhibition by Rapa only delays initial cell cycle entry, and
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that once the cells start to proliferate they do so via a Rapa-insensitive pathway [179].
1.5 TSC/mTOR and cell survival
TSC1/TSC2 complex also controls cell death. In a recent work carried on in 
Drosophila melanogaster Hsieh et al. [180] showed a connection between 
TSC/Rheb/Tor/S6k and sE2Fl. The E2F family of proteins controls a variety of cellular 
processes involving cell cycle progression and survival [181]. Another important player of 
life and death that has a key role in acting together with TSC1/TSC2 in this model is 
Retinoblastoma (Rb). This family is composed by proteins that are other factors that 
control survival [181, 182]. It is now emerging a picture of the integrated signalling of 
these proteins in which mutations of TSC1 and Rb act together in favouring S-phase entry 
and apoptosis by increasing the expression of dE2Fl at the post-transcriptional level [180].
TSC1/TSC2 complex can also play a role in another kind of cell death that is ER 
stress-induced apoptosis. Kang et al. [183] demonstrated that TSC1/TSC2 and Rheb are 
key players in the Unfolded Protein Response (UPR). UPR is an important cellular process 
that by sensing ER stress can bring about cellular responses such as the general inhibition 
of protein synthesis and the transcription of stress responsive genes. In this way UPR is 
supposed to protect cells from harmful conditions. An excessive UPR however can induce 
apoptosis [184-187]. Kang et al. [183] further investigated the previously studied role of 
TSC1/TSC2 in UPR [188]. They demonstrated that TSC1/TSC2 is involved in a wide 
variety of ER stress responses and its role seems to be to protect cells from apoptosis 
induced by UPR. They also show that TSC1/TSC2 accomplish this by acting on 
Rheb/mTORCl, but quite interestingly, this effect is Rapa insensitive, showing another 
Rapa-independent function of mTORCl.
TSC1 and TSC2, together with mTORCl, are some of the most important proteins 
involved in the sensing of the energy levels of the cells. It is thus not surprising that 
TSC1/TSC2 plays a role also in energy deprivation-induced apoptosis. Inoki et al. [37]
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demonstrate that TSC2, following phosphorylation by AMPK, is activated and leads to 
mTORCl inhibition. Under stressful conditions this predisposes the cell to survive in a 
hostile environment. Loss of TSC function in low glucose conditions, in fact, leads to cell 
death. The involvement of mTORCl in this process is of key relevance. Choo et al. [189], 
in fact, demonstrated that metabolic stress and apoptosis is prevented in TSC KO cells by 
inhibition of mTORCl [189].
1.6 TSC/mTOR and disease
Mutation in negative regulators of mTOR, such as LKB1 and PTEN, can give rise 
to familial cancer syndromes. Sporadic mutations in important proteins in the mTOR 
pathways such as PI3K, Akt and PTEN, together with p53, are among the most common 
alterations in human cancer [190].
The inactivation of 4E-BP1, one of the main mTORCl targets, plays a role in the 
growth of sporadic cancers. MEFs that do not express 4E-BP1 and 4E-BP2 show increased 
proliferation, suggesting that mTORCl inhibition of 4E-BP1 is important for cell cycle 
progression [191].
Also the other mTOR complex, mTORC2, can play a role in tumorigenesis. 
mTORC2, in fact, activates Akt and SGK [192] and by this can lead to tumour initiation. 
Akt favours cell proliferation, survival and nutrient uptake in tumour cells (reviewed by 
Hsu P. P. and Sabatini D. M. [193]). Many different tumours result from inactivation of 
PTEN (the inhibitor of Akt signalling) or by activating mutations of PI3K. These kinds of 
tumours are heavily dependent on the pro-survival role of Akt. Inhibiting mTORC2 in 
these situations may be of key importance. In PTEN-deficient mice, in fact, Rictor is 
essential for the growth of tumour cell lines and prostate tumours [194-197].
T cells development, survival and cell metabolism needs the coordinate regulation 
of proliferation, survival and cell metabolism. We hypothesised a role for TSC/mTOR in
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these processes and we thus investigated their possible involvement by pharmacological 
inhibition of the mTOR complexes or by genetic inactivation of the TSC complex in T 
cells. We also analysed the contribution of TSC/mTOR to PC 12 nerve cell, used to model 
nerve cell proliferation and differentiation.
The thesis is divided in three chapters that cover these points. The first chapter 
focuses on the pharmacological inhibition of mTOR by Rapa in mature T cells. The role of 
Rapamycin inhibition of mTOR in T cells differentiation was investigated. The second 
chapter presents the data obtained from conditional TSC1 KO mice in which the TSC1 
gene has been conditionally silenced during thymic development. Results show that the 
TSC complex affect T cells development and maturation by influencing proliferation and 
survival of these cells. The third chapter revolves around the analysis of the TSC pathway 
in PC 12 cells. Data demonstrate TSC involvement in nerve cell proliferation and 
differentiation.
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2. mTOR controls T cells differentiation
2.1 Introduction
2.1.1 T cell activation
mTOR has been shown to play essential roles in many different aspects of a T cell 
life. It is important during T-cell activation, anergy induction and maintenance, lineage 
commitment and other immune responses (reviewed by Mondino A. and Mueller D. L. 
[198]). Inhibition of mTOR activity by the way of Rapa leads to T-cell anergy [199], 
induction of regulatory T cells [98-103], impairment of effector T-cell generation (results 
discussed in this thesis and by Delgoffe G. M. et al. [103]) and enhanced memory T-cell 
responses to microbial pathogens [200]. mTOR is also of primary importance for T-cell 
trafficking in vivo and it can accomplish this by regulating the expression of CCR7 [201]. 
In T cells mTOR has mainly being described to be controlled by the PI3K-PDK-Akt-TSC 
pathway (reviewed by Zhong X. P. et al. [202]). This pathway can be activated by many 
different events such as TCR and CD28 engagement and IL-2, IL-7, IL-4, IL-12, IFN-y 
and Wnt signalling [179, 203-206].
In response to TCR and CD28 engagement, CD4 nai've T cells express and secrete 
IL-2, and also high-affinity IL-2R. In this way they can respond to IL-2 and initiate IL-2- 
dependent proliferation [95, 120, 207, 208]. T cells proliferation is also controlled by TCR 
and CD28-dependent, IL-2 independent signalling events. The degree and length of TCR 
and CD28 stimulation are important for triggering exit of the Go stage and they are also 
critical for establishing how many cycles of proliferation a cell can complete [209-213]. 
Colombetti et al. [179] showed that prolonged TCR/CD28 activation leads to cell 
proliferation via an mTOR dependent mechanism that does not require IL-2. However in 
the presence of optimal concentrations of IL-2 T cells can proliferate in an mTOR 
independent manner [179].
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2.1.2 T cell differentiation
Once naive T cells are activated and induced to proliferate they can undergo a 
process of differentiation into effector, memory or regulatory cells. Several events are 
known to control helper T cell differentiation (reviewed by Bonnevier, J.L. and Mueller D. 
L. [214]). Engagement of the TCR and the costimulatory receptor dictates initial T cell 
activation and early transcription of cytokine genes [215]. Later on, helper T cell 
differentiation is regulated by cytokines. In particular when naive CD4+ T cells are 
activated in the presence of IFN-y and IL-12 they become Thl effector cells, while in the 
presence of IL-4 they become Th2 effector cells. If they are stimulated with IL-6 and TGF- 
P they will become Thl 7 cells while when stimulated in presence of high concentrations of 
TGF-P they will acquire a regulatory phenotype and become Foxp3+ T cells [216].
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Fig IV. Th cell differentiation. Naive CD4+ T cells are activated by Antigen-Presenting 
Cells (APCs) and CD28. After activation they start to produce low levels of cytokine and 
cytokine receptors. The differentiation towards a specific phenotype depends on the 
environment in which a cell is activated. Dong C., Nature Reviews Immunology, 2006 
[217]
25
IL-4 and IL-12, through cytokine receptors and Signal Transducer and Activator of 
Transcription (STAT) 4 and STAT6 respectively [218], induce or repress the transcription 
of genes encoding key transcription factors [214, 219] needed for effector cytokine gene 
expression (7/hyand 114). Transcription factors control cytokine gene transcription and also 
control chromatin landscape remodelling of lineage-specific genes (Ifny and 114) [220]. For 
instance in the case of Thl differentiation, TCR/CD28 as well as IL-2 driven signals 
induce the expression of T-bet. This transcription factor acts via autocatalytic and feed­
forward mechanisms that involve signal and transcriptional networks. When activated T- 
bet can ensure its stabilization, its epigenetic remodelling activity and induces polarization 
of CD4+ T cells. Epigenetic modifications of cytokine loci mainly consist of modification 
of DNA and histones. Typical modifications are DNA CpG methylation, histone 
methylation and acetylation and DNase I HS induction. Agarwal et al. [221] were able to 
discover Th cell specific HSs in the 114 and 7/hyloci. Another key epigenetic modification 
that can play a role in Th cell differentiation is DNA CpG methylation. Makar et al.[222] 
demonstrated that DNA methyltransferase 1 (Dnmt-1) binding to the 114 locus decreases in 
the process of Th2 differentiation. The events leading to transcription factors stabilization 
and to epigenetic remodelling of effector cytokine-encoding genes, however, remain 
largely to be characterized. Recent reports, published during the course of the research 
activity reported in this thesis, support a role for mTOR in such events. These will be 
reviewed and discussed, in relation to the experimental findings, in the discussion.
mTOR has also been implicated in controlling T cell trafficking. In the case of 
CD8+ T cells some of the surface markers such as CD44, CD62L and CCR7, useful for the 
identification of naive, effector or memory T cells, have also a function in controlling T 
cell migration [223]. Naive T cells express CD62L and CCR7, these molecules facilitate 
their trafficking between secondary lymphoid organs. After activation of the cells these 
receptors are down-regulated while others such as Very Late Antigen 4 (VLA4), ligands 
for P-selectin and E-selectin, CXC3 and CCR5 are upregulated [224, 225]. In this way
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activated cells are driven to the inflamed tissues. The regulation of these proteins is 
controlled by the PI3K-mTOR pathway. Indeed, Sinclair et al. [201] showed that T cell 
activation in the presence of LY294002 and Rapa caused upregulation of KLF2, a 
transcription factor that controls CD62L and CCR7 expression [201].
Rapamycin controls T cells functions. The drug delays IL-2-induced Gi-S cell 
cycle transition by preventing Cdk2 and Cdc2 kinase activation [226] and p27Kip 
downregulation [95], favours the establishment of T cell unresponsiveness [96, 227] and 
prevents its reversal by IL-2 [179]. This drug has been indeed extensively used as 
immunosuppressant in solid organ as well as in pancreatic islet transplantation [228]. In 
mouse models, Rapa prevents graft rejection, graft versus host disease, and graft versus 
leukemia, but also induces an autoimmune-like syndrome when administered as single 
agent [229]. Dr. Mondino’s lab has also reported the ability of T cells to overcome Rapa- 
mediated cell cycle arrest, and the existence of Rapa-insensitive lymphocyte proliferation 
[179], thus questioning the interpretation for the immunosuppressive activity of the drug. 
More recently, it was found that Rapa influences the development of CD4+ CD25+ 
regulatory T cells in vitro [99, 101, 230], T cell migration [201] and the accumulation of 
central memory-like T cells in vivo [200]. Preliminary experiments in the lab indicated that 
Rapa might work as an immunomodulator and impact on T cell differentiation, rather than 
on T cell expansion. To better define this possibility the impact of Rapa on TCR/CD28- 
driven T cell activation, expansion and differentiation was investigated. Results indicate 
that TCR/CD28 engagement evokes mTORCl and mTORC2-dependent signalling, both 
sensitive to Rapa, and these are critical for proper expression of T-bet and GAT A3, of Ifny, 
114 and Foxp3 genes, and impact on the control of the DNA methylation state of promoter 
regions of genes important for cell fate determination.
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2.2 Materials and methods
2.2.1 Mice
BALB/c mice were obtained from Charles River (Calco). DO 11.10 mice (H-2d) 
were bred and maintained in the SPF animal facility according to the Institutional 
Guidelines. These mice express a transgenic ap TCR specific for the CD4-restricted 
chicken ovalbumin derived peptide (OVA323-339) on the majority of the CD4+ T cells. 
The Ethical Committee of the San Raffaele Scientific Institute approved the animal usage.
2.2.2 Primary T cell cultures
CD4+ T cells were purified by negative selection using anti-CD8 (clone KT1.9) 
and anti-I-Ab-d/I-E (clone B21-22) rat Abs and sheep anti-rat-coated magnetic beads 
(Dynal Biotech LTD., UK) to a purity of >95%. Cells were then stimulated on 
immobilized anti-CD3 and anti-CD28 mAb (0.5 pg/ml and 5 jag/ml) in the absence or in 
the presence of RAPA (100 nM) or of Recombinant Mouse TRAIL R2/TNFRSF10B Fc 
Chimera (50 ng/ml, R&D Systems).
After 3-7 days cells were stimulated with PMA (0.05 pg/ml) and Ionomycin (1 
pg/ml) for 4 hours, of which the last 2 in the presence of Brefeldin, and intracellular 
cytokine staining was performed and evaluated on a BD Biosciences FACSCalibur dual­
laser cytometer using Flowjow acquisition analysis software.
Cell were always kept in RPMI-1640 medium (Invitrogen) with 5% FBS until lysis. 
This prevented inactivation of S6 phosphorylation.
2.2.3 FACS analysis
Abs (conjugated with FITC, PE, PerCP, PB, Pecy7 or allophycocyanin) directed 
against the following surface markers were obtained from eBioscience, BD Pharmingen, or 
Caltag Laboratories and used PE and PerCP in 1/200; PB, APC and Pecy7 in 1/400 and 
FITC in 1/100 dilution to analyze immune cell subsets in single cell suspensions of
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lymphonodes: CD4, CD8, Foxp3, T-Bet, GATA-3, Phospho-Tyr694-Stat5. Software as 
well as FlowJo Software (Tree Star).
2.2.4 Western blot analysis
CD4+ purified cells were stimulated on immobilized anti-CD3 and anti-CD28 mAb 
(0.5 pg/ml and 5 pg/ml). When indicated cells were treated with Rapa (1 or 100 nM, 
Calbiochem), SL0101 (3 or 30 uM, Toronto Research Chemicals Inc.) or U0126 (10 uM, 
Promega). T cells and thymocytes extracts were washed twice with ice-cold PBS and lysed 
in lysis buffer containing SDS 2% and Tris-HCl 62.5 mM pH 6.8.
Proteins were quantified by BCA assay and appropriate amounts (30 or 50 pg) were 
separated on standard 10-15% SDS-PAGE. For Western blotting, gels transferred to 
nitrocellulose filters were first blocked for 1 h with 5% nonfat dry milk in PBA, and then 
incubated o.n. with the primary antibody diluted in PBS with 5% Bovine Serum Albumin 
(BSA), washed in PBST (3-fold for 10 min), incubated for 1 h with the peroxidase- 
conjugated secondary antibody, washed again in PBST as described above and once in 
PBS. Photographic development was by chemiluminescence (ECL, Amersham Bioscience 
or Immobilon substrate, Millipore). Western blot bands were quantified by the ImageJ 
program (rsb.info.nih.gov/ij).
anti-Akt, anti-P(S473)-Akt, anti-P(T308)-Akt, anti-4E-BPl, anti-GSK3p, anti- 
P(Ser235/236)-S6 and anti-S6, anti-STATl, anti-P(S727)-STATl, anti-STAT5, anti- 
P(T389)-P70S6K: Cell Signalling Technology (Milan, Italy); T-bet, GATA-3 and actin, 
which were obtained from Santa Cruz Biotechnology Inc, and anti H3K27-me3 histone, 
which was obtained from Millipore. Horseradish peroxidase-conjugated goat antimouse 
and anti-rabbit pAbs: Bio-Rad. The BCA Protein Assay Kit from Pierce.
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Antibody anti- Company Cat. N°
T-Bet Santa Cruz Biotechnology Sc-21749
STAT1 Cell Signaling 9172
H3-K27me3 abeam ab6147
STAT5 Cell Signaling 9358
Phospho-STATl (Ser727) Cell Signaling 9177
Phospho-Akt (Thr308) Cell Signaling 2965
Phospho-Akt (Ser473) Cell Signaling 9271
4E-BP1 Cell Signaling 9452
Phospho-S6 (Ser235/236) Cell Signaling 2211
Phospho-p70S6K (Thr389) Cell Signaling 9205
Actin Santa Cruz Biotechnology Sc-1616
2.2.5 CFSE proliferation assay.
Cells were labelled with CFSE (Molecular Probes). They were washed and 
resuspended in PBS at a final density of 20xl06/ml, were mixed with the same volume of 
CFSE fluorescent dye (1 pM) in PBS and incubated for 8 min at room temperature. 
Deacetylated CFSE was quenched by the addition of FBS.
Cells were then washed with complete medium and seeded in 24 well dishes at a 
density of 1 x 106/well in the presence of immobilized anti-CD3/CD28 mAb (0.01 pg/ml 
and 5 pg/ml respectively) or recombinant mouse IL-7 (0.5 ng/ml). When indicated cells 
were treated with Rapa (1 or 100 nM, Calbiochem). After 3-5 days of culture CFSE- 
labelled cells were collected, costained with anti-CD4, anti-CD8 mAb, and TOPRO-3 and 
analyzed by flow cytometric using a FACSCalibur.
2.2.6 Quantitative real-time RT-PCR (qPCR)
RNA was extracted with RNeasy Mini Kit (Qiagen) following manufacturer’s 
instructions and its concentration was determined by spectrophotometry.
1-2 pg of total RNA were used to generate cDNA templates for RT-PCR, using 
01igo-(dT)12-18, dNTPs and RNAsin RNAse (from Promega). Retrotranscriptase M-MLV 
was from Invitrogen.
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q-PCR was performed using Real Time Taqman universal master mix (Applied 
Biosystems) according to a standard protocol, using 50 ng template cDNA. All primers 
were used at the final concentration of 900 nM. Values were normalized to the 
concentration of GAPDH mRNA. q-PCR was performed using an ABI PRISM 7700 
Sequence Detection System.
Specific mRNA expression was normalized by housekeeping GAPDH expression 
according to theAACT method. In the other cases, data were expressed as AACT fold 
increase over control cells.
2.2.7 Methylated DNA Immunoprecipitation (MeDIP)
DNA was sonicated to yield fragments ranging in size between 300 and 600 bp. 
Sonicated DNA was then used as a whole-genome reference for comparative analysis 
(Input DNA), or immunoprecipitated with a mouse monoclonal anti-5-methylcytidine 
antibody from Eurogentec (#BI-MECY-1000). The methylation status of Ifny, H4 and 
foxpS genes was analyzed by standard real time quantitative PCR by employing primers 
targeting proximal promoter regions (IFN-y: left -163:
AACATGCCACAAAACCATAGC; right-25: CACCTCTCTGGCTTCCAGTT; IL-4: left 
-226 GGTCCTCTGGAAGAGCAACA; right -96 CTTCGGTGCTGCAGATACAA; 
FoxP3 left -454 CCTCCAACGTCTCACAAACA; right -300 
CCCCTCACCACAGAGGTAAA). with a mouse monoclonal 5-methylcytidine antibody 
from Eurogentec (#BI-MECY-1000). Real Time PCR was performed using the Sybr Green 
technique (LightCycler 480 SYBR Green I Master). Fractional methylation DNA recovery 
in MeDIP fractions was expressed relative to input (CTIp-CTinput=ACT). To compare 
different experiments data were expressed relative to control cells (Nil) as follows: 2 -  
(ACT-ACTNil). Unmethylated and methylated housekeeping genes (p-actin and Xist 
respectively) were used as controls.
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2.2.8 Statistical analysis.
The significance of the data was assessed using the two-tailed t-Test when two 
groups are compared, the one-tail ANOVA test with Dunns post test when three or more 
groups were compared and the two-way ANOVA test with Bonferroni post test when 
curves with different time points were compared. Data shown are means ± S.E.M. The 
number of experiments is specified in the Figures or Figure legends. P<0.05 is considered 
significantly different. In the Figures ****=p< 0,0001; *** = p<0.001; **= p<0.01; *= 
p<0.05.
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2.3 Results
2.3.1 Rapamycin prevents differentiation of IFN-y producing cells
To study the role of mTOR in T cell activation and differentiation, the ability of 
Rapa to interfere with differentiation of IFN-y-producing cells was analysed.
Stimulation of T cells with antigen leads to proliferation of the cells that is partially 
sensitive to Rapa (Fig. 2.1 A) after 3 days of stimulation. After 7 days of stimulation Rapa- 
treated cells are not sensitive any more to Rapa-inhibition (Fig. 2.1 A) suggesting that 
mTOR blockade by Rapa only delays T cells proliferation. A high percentage of cells 
stimulated with antigen for 7 days produce IFN-y following optimal restimulation with 
PMA/Ionomycin. Cells treated with Rapa, instead, fail to produce IFN-y after 
PMA/Ionomycin restimulation (Fig. 2.1 B) suggesting defective T cell differentiation in 
the presence of Rapa. A higher percentage of cells treated with Rapa, however, produce 
IL-2 compared to control cells not treated with the drug (Fig. 2.1 C).
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Fig 2.1 Rapa affects CD4+ T cells differentiation. A-C) CFSE labelled purified CD4+ T 
cells from LN of ovalbumin specific DO 11.10 TCR transgenic mice were stimulated with 
antigen ( O V A 3 2 3 - 3 3 9 )  (0.25 uM) and irradiated APC (syngeneic splenocytes) in the absence 
or in the presence of Rapa (R) (100 nM). After 3 and 7 days of culture cells were analyzed 
by flow cytometry (A). In B and C cells were stimulated as in A for 7 days and then re­
stimulated for 4 hours with medium only (-) or with PMA (0.05 ug/ml) and Ionomycin (1 
ug/ml) (P/I), and analysed following staining with IFN-y (B) and IL-2 (C). In A histograms 
represent the CFSE profile of CD4+ cells after 3 and 7 days of culture. In B and C dot plots 
depict viable CD4+ cells. The percentage of cytokine producing cells is reported. 
Cytokines producing cells were below 2% in unstimulated cultures.
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2.3.2 Activation of mTORCl and mTORC2 signalling following TCR/CD28 
stimulation.
To better understand the ability of Rapa to interfere with differentiation of IFN-y or R e ­
producing cells the role of mTOR in T cell activation was investigated. Purified primary 
CD4+ T cells were analyzed after stimulation with TCR/CD28. The activity of mTORCl 
and mTORC2 was evaluated by assessing the phosphorylation of p70S6K (Thr389), S6 
(Ser235/236) and 4EBP-1 (mTORCl) and of Akt in ser 473 (mTORC2) [57] (Fig. 2.2). 
Stimulation caused the phosphoiylation of all the kinases analysed, in particular of p70S6K 
(Thr389), S6 (Ser235/236), 4EBP-1, and Akt both in Ser 473 and in Thr 308. p70S6K 
(Thr389) and 4EBP-1 phosphorylation readily decreased after Rapa treatment. S6 
(Ser235/236) phosphorylation instead was only partially sensitive to Rapa treatment. Also 
treatment of the cells for 30 min with U0126 (an inhibitor of MAPK) and with different 
concentrations of SL0101 (an inhibitor of RSK) partially inhibited S6 (Ser235/236) 
phosphorylation. Only the combination of Rapa and U0126 or Rapa and the higher 
concentration of SL0101 completely inhibited S6 (Ser235/236) phosphorylation (Fig. 2.2 
C). This is in accordance with previous published data in which CD8+ T cells were 
analysed [124].
Akt phosphorylation was already detectable after 30 min but peaked by 1-2 hours 
of stimulation but decreased at later time points. After 1 hour of stimulation the 
phosphorylation of Akt in Ser 473 was higher in stimulated cells that were treated with 
Rapa but after 4 hours of stimulation it was lower than in the control stimulated cells (Fig.
2.2 A, B). While the initial increase of phosphorylation in Akt on ser 473 could be 
indicative of the existence of the mTORCl-dependent negative feedback loop, the decrease 
in AKT phosphorylation in ser 473 could indicate mTORC2 inhibition by Rapa [88]. To 
further prove TCR/CD28 effect on the mTOR pathway, the phosphorylation of different 
targets of mTORCl and mTORC2 was evaluated not only during the first phases of
34
activation but also at later time points, cells were thus stimulated for 24 hours. This 
experiment demonstrated that the effect seen during acute treatment is preserved also at 
later time points, suggesting that the effects observed in Rapa treated cells (described in the 
following paragraphs) are probably due to mTORCl and mTORC2 down-regulation rather 
than to compensatory mechanisms. Treatment with Rapa for 24 hours strongly inhibited 
Akt phosphorylation in Ser 473, the cells in culture with the drug in fact show less than 
10% residual phosphorylation (Fig. 2.2 D).
These results show that both mTORCl and mTORC2 are activated by TCR/CD28 
and they are sensitive to Rapa inhibition with different kinetics.
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Fig 2.2 TCR/CD28 activates both mTORCl and mTORC2 signalling. CD4+ T cells 
purified from lymph node pools of 5 BALB/c mice were left untreated (Nil) or stimulated
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with immobilized anti-CD3 (0.5 ug/ml) and anti-CD28 (5 ug/ml) mAb for 30 min and 3 
hours (A), for 1, 2, and 4 hours (B), only for 30 min (C) and for 24 hours (D). Cells were 
cultured in the absence (0) or in the presence of RAPA (R; 1 and 100 nM in A and D, only 
100 nM in B and C), of U0126 (10 uM in C), of SL0101 (3 or 30 uM in C) or with the 
combination of the drugs (C). In D, cells were activated on immobilized anti-CD3/CD28 
mAb for 24h (3/28 24 h) in the absence (0) or in the presence of RAPA (1 and 100 nM R), 
and then lysed (-) or re-stimulated with CD3/CD28 mAb for 30 min (3/28). SDS-PAGE 
analyses were performed as detailed in Materials and Methods 2.2.4. Phosphorylation of 
the mTORCl targets 4EBP1 and p70S6K (Thr 389), of p70S6K substrate S6 (Ser 
235/236), of the mTORC2 target Akt (Ser 473) and of PDK1 target Akt (Thr 308) were 
assessed by western blot analysis (A and D). Phosphorylation of p70S6K substrate S6 (Ser 
235/236) and of the mTORC2 target Akt (Ser 473) were assessed by western blot analysis 
(B and C respectively). Actin is depicted as loading control, and relative migration of 
molecular weight markers is depicted. One of 3-5 independent experiments is depicted. 
Molecular weight markers are indicated in KDa.
2.3.3 Rapamycin hinders TCR/CD28-driven Ifny,; 114 and Foxp3 gene 
expression.
TCR and CD28 engagement drives transcription of Ifny and U4 [220]. Next we thus 
investigated whether Rapa would interfere with TCR/CD28-induced cytokine expression. 
Real-time PCR experiments showed that IL-2, IFN-y and IL-4 mRNAs were induced in 
response to CD3/CD28 stimulation (Fig. 2.3 A). The peak of expression ranged between 
24 and 48 hours depending on the cytokine analyzed, and expression decreased thereafter. 
When cells were activated in the presence of Rapa, expression of IL-2, IFN-y and IL-4 was 
found to be lower within the first 24 hours of treatment (Fig. 2.3 A, B). However at later 
times IL-2 expression was recovered while IFN-y and IL-4 expression was severely 
decreased by Rapa treatment also at later time points (Fig. 2.3 A, B).
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Fig 2.3 TCR/CD28 induced cytokine transcription is sensitive to Rapa treatment. A,
B) CD4+ T cells were purified from lymph node pools of 5 BALB/c mice and left 
untreated (Nil) or stimulated with immobilized anti-CD3 (0.5 ug/ml) and anti-CD28 (5 
ug/ml) mAb in the absence (3/28) or in the presence of Rapa (100 nM, 3/28/R) for 24, 48 
or 72h. mRNA expression was quantified by RT-real time PCR in 5 (24/48h) and 3 (72h) 
independent experiments. A) Cytokine mRNAs were first normalized to the GAPDH 
housekeeping gene, and then expressed relatively to control unstimulated cells (Nil) 
according to the AACT method (±SE). Statistical significance was analysed by two-way 
ANOVA test with Bonferroni post test. B) mRNA levels of the indicated genes were first 
normalized to the GAPDH housekeeping gene, and then expressed relatively to the levels 
found in CD3/CD28 activated control cells. Statistical significance (two-tailed t-Test) was 
determined by comparing CD3/CD28-cultured control and drug-treated cells within each 
time point by the AACT method, using CD3/CD28 control cells as reference.
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Foxp3 levels were also examined. Following stimulation with CD3/CD28 also 
Foxp3 mRNA increased. At early time points Foxp3 expression was not sensitive to Rapa 
(Fig. 2.4 A, B). However at later time points while expression of Foxp3 mRNA decreased 
in stimulated cells, cells that were stimulated and treated with Rapa showed sustained 
levels of Foxp3 mRNA (Fig. 2.4 A, B). Also Foxp3 protein levels were already detectable 
in resting cells but declined after 72 hours of stimulation. In the presence of Rapa, instead, 
these levels were sustained also at later time points (Fig. 2.4 C). These results may suggest 
that mTOR blockade by Rapa limits TCR/CD28-dependent T cell differentiation by 
inhibiting Ifny and 114 expression and favouring Foxp3 expression.
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Fig 2.4 mTOR blockade favours Foxp3 expression. A-C) CD4+ T cells were purified 
from lymph node pools of 5 BALB/c mice and left untreated (Nil) or stimulated with 
immobilized anti-CD3 (0.5 ug/ml) and anti-CD28 (5 ug/ml) mAb in the absence (3/28) or 
in the presence of Rapa (100 nM, 3/28/R) for 24, 48 or 72h. Foxp3 mRNA expression was 
quantified by RT-real time PCR in 4 (24/48h) and 3 (72h) independent experiments. A) 
Foxp3 mRNA was first normalized to the GAPDH housekeeping gene, and then expressed 
relatively to control unstimulated cells (Nil) according to the AACT method (±SE). 
Statistical significance was analysed by two-way ANOVA test with Bonferroni post test. 
B) mRNA levels of Foxp3 were first normalized to the GAPDH housekeeping gene, and 
then expressed relatively to the levels found in CD3/CD28 activated control cells. 
Statistical significance (two-tailed t-Test) was determined by comparing CD3/CD28- 
cultured control and drug-treated cells within each time point by theAACT method (±SE), 
using CD3/CD28 control cells as reference. C) At the indicated times cells were recovered 
and analyzed by flow cytometry after staining with anti-CD25 and Foxp3 or isotype 
control mAb. Naive cells were used as controls (dotted line). Data are representative of two 
independent determinations. The frequency of naive cells is reported in brackets. The 
frequencies of control and Rapa-cultured cells are indicated in plain and bold text, 
respectively.
38
2.3.4 Rapa interferes with T-bet and GATA-3 expression and function.
Following TCR/CD28 stimulation T cells starts to produce IL-2. IL-2 then initiates Th cell 
polarization by activating Signal Transducer and Activator of Transcription 5 (STAT5) and 
in this way favours the entry of the cell into the cell cycle. The activated cell can 
differentiate into the different lineages in response to the cytokine milieu in which it is 
activated. The different cytokines can induce the activation of particular lineage-specific 
transcription factors. For example in Thl development IFN-y and IL-27 induce STAT1 
activation and thus the transcription factor T-bet. T-bet then can further increase the 
transcription of Ifny. For Th2 differentiation instead GATA-3 is the key transcription factor 
responsible for 114 expression. Thus STAT-1 and STAT-5, T-bet and GATA-3 expression 
was evaluated following TCR/CD28 stimulation of primary cells with or without Rapa 
(Fig. 2.5). Following stimulation with CD3/CD28 both STAT-1 and STAT-5 protein levels 
and phosphorylation were increased to similar extents in control cells and cells treated with 
Rapa (Fig. 2.5 A, B). In nai've cells T-bet and GATA-3 proteins and mRNA were 
undetectable (Fig. 2.5 C-G). Following stimulation mRNA and proteins were induced. The 
peak of expression was reached at 48 hours, by 72 hours the levels already started to 
decrease. Rapa induced a reduction in the mRNA and protein levels of both factors at the 
population and at the single cell level (Fig. 2.5 C-I). T-bet and GATA-3 activity was 
evaluated by looking at the mRNA levels of some of their important target genes. In a 
similar way to IFN-y, also IL12 receptor-p chain (IL12Rp) and the transcription co­
activator Hlx-1, two important T-bet target genes [231] were not properly induced when 
the cells were treated with Rapa (Fig. 2.5 J). Likewise, GATA-3 target genes IL-5 and IL- 
13 were expressed at very low levels in Rapa treated cells (Fig. 2.5 K). These results 
indicate that activation in the presence of Rapa delays expression of T-bet and GATA-3 
and expression of their target genes while it favours Foxp3 expression.
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Fig 2.5 mTOR blockade hinders T-bet and GATA-3 expression and transcriptional 
activity. CD4+ T cells purified from BALB/c LN were left untreated (Nil) or stimulated 
with immobilized anti-CD3 (0.5 ug/ml) and anti-CD28 (5 ug/ml) mAb in the absence (-) 
or in the presence of Rapa (100 nM, R) for 24 and 48h (A, D, E, H, I), 48h (B, J, K), 24, 48 
and 72h (C, F, G). Protein and mRNA levels were determined by SDS-PAGE (A, C), flow 
cytometry (B, D, and E) and RT-real time PCR (F-K). A, C) SDS-PAGE analyses were 
performed as detailed in Materials and Methods 2.2.4. Phosphorylation of STAT1 (Ser 
727), total levels of STAT1, STAT5 and T-Bet were assessed by western blot analysis (A 
and C). Actin and histone H3 are depicted as loading controls, and relative migration of 
molecular weight markers is depicted. One of 3 independent experiments is depicted. 
Molecular weight markers are indicated in KDa. B, D, E) Cells were left untreated (Nil) or 
stimulated as in A and stained for intracellular Phospho-STAT-5-Tyr 694, T-Bet and
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GATA-3 contents (Nil: thin line; 3/28; thick line; 3/28/R; dotted line). F-K) T-Bet (F, H), 
GATA-3 (G, I), Hlx-1 (J), IL12-R0 (J), IL-5 (K) and IL-13 (K) mRNA expression was 
quantified by RT-real time PCR in 5 (24/48h) and 3 (72h) independent experiments. F, G) 
T-Bet and GATA-3 mRNA was first normalized to the GAPDH housekeeping gene, and 
then expressed relatively to control unstimulated cells (Nil) according to the AACT method 
(±SE). Statistical significance was analysed by two-way ANOVA test with Bonferroni post 
test. H-K) mRNA levels of the different genes were first normalized to the GAPDH 
housekeeping gene, and then expressed relatively to the levels found in CD3/CD28 
activated control cells. Statistical significance (two-tailed t-Test) was determined by 
comparing CD3/CD28-cultured control and drug-treated cells within each time point by 
the AACT method (±SE), using CD3/CD28 control cells as reference.
2.3.5 Rapa-sensitive events control methylation of Ifny, 114 and Foxp3 
promoter regions.
Epigenetic modifications are important in controlling the transcription of genes involved in 
T cell differentiation. Gene expression is favoured by increased histone acetylation both of 
the Ifny and the 114 loci [221, 232]. DNA methylation is another important epigenetic 
marker that shapes the chromatin landscape of differentiating T cells [222]. T-bet is 
important in remodelling the Ifny locus [231]. As T-bet expression and activity is impaired 
by Rapa treatment, the influence of Rapa on promoter methylation of different cytokines 
was evaluated by MeDIP. MeDIP is a technique that requires precipitation of DNA and 
then recognition of the methylated CpG islands. DNA was sonicated to obtain fragments of 
300-600 bp. The DNA was then immunoprecipitated with an Ab that recognized the 
methylated CpG islands and the proximal promoter region of the different cytokines was 
analyzed by real-time qPCR. As control genes p-actin and Xist were used. P-actin as a 
representative of a hypo-methylated gene and Xist of a gene that is fully methylated in one 
of the two copies (Fig. 2.6 A). After stimulation with CD3/CD28 the methylation of Ifny 
and IL4 promoter regions decreased compared to the methylation of nai've unstimulated 
cells (Fig. 2.6 B, C). The cells treated with Rapa, instead, showed methylation profiles 
similar to those of na'ive cells. Foxp3 promoter behaved in a completely different way. 
Following CD3/CD28 stimulation the methylation of Foxp3 promoter increased, but not in
41
the presence of Rapa (Fig. 2.6 B, C). These results suggest that mTOR blockade by Rapa 
could affect the methylation of the promoter regions of cytokines important in the process 
of T cell differentiation.
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Fig 2.6 mTOR-dependent signalling controls DNA methylation. CD4+ T lymphocytes 
were purified from BALB/c LN and left untreated or stimulated with immobilized anti- 
CD3 (0.5 ug/ml) and anti-CD28 (5 ug/ml) mAh in the absence (-) or in the presence of 
Rapa (100 nM, R) for 48 hours. Cells extracts were analyzed by MeDIP assays with a 
mouse monoclonal anti-5-methylcytidine Ab (see Materials and Methods 2.2.7). A) 
Fractional methylation was expressed relative to input (CTIp-CTinput=ACT) (±SE). 
Numbers in brackets in A represent CpG hits in the regions of interest. B, C) DNA 
recovery in MeDIP fraction over input is expressed relative to that found in control cells. 
Changes in promoter region methylation following activation, either absolute (B) or 
relative to unstimulated (Nil) (C) are reported. Data are representative of 5 (IFN-y and IL- 
4) and 3 (Foxp3) independent determinations. Trends depicted in the figure were found in 
all of the experiments. Statistical significance was analysed by one-tail ANOVA test with 
Dunns post test.
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2.4 Discussion
Before the beginning of the experiments reported in this thesis it was known that 
mTOR was critical for T cell proliferation, and for the maintenance of T cell 
responsiveness [96, 198]. The results reported in this thesis support the idea that mTOR is 
also central to TCR/CD28 activation of naive T cells and for controlling acute Ifny, 114 and 
Foxp3 transcription, methylation of critical promoter regions and for differentiation of 
IFN-y and IL-4 secreting cells in ThO conditions. While in the process of completing these 
studies, this notion has been confirmed by a number of reports [89,103, 233], which, using 
genetic approaches allowing inactivation of mTOR, Rictor and Raptor, provided elegant 
evidences for the role of mTORCl and mTORC2 in polarization of Thl, Th2, Thl7 and 
Treg cells in response to polarizing conditions. Thereafter will follow a discussion of the 
findings reported in this thesis that correlates them with these recent publications.
The process of T cell differentiation has been linked to several events. These are 
initiated by TCR/CD28 and IL-2/IL-2R signalling, which drives cell cycle transition, 
concomitantly starts Ifny,; 114, 115, and 1113 transcription [220] and favours histone 
acetylation and other epigenetic changes such as the fixation of particular DNA 
methylation patterns at the Ifny and the 114 loci [221, 222, 232, 234]. In the case of the Ifny 
gene, for instance, the promoter is in a “poised” state that results in low Ifny expression in 
nai've CD4+ T cells. After activation in Thl conditions (IL-12 and anti-IL-4 mAb) the 
epigenetic landscape of the Ifny promoter changes. The most relevant epigenetic 
modifications during activation are the increase in CpG demethylation and progressive 
polarized histone acetylation patterns [215] and the acquirement of DNAse 
hypersensitivity in the Ifny promoter and in multiple cis-regulatory regions [235]. 
Chromatin modifications are brought about by different proteins, among these one of the 
most important is T-bet. This transcription factor can further modify the Ifny gene by 
leading to chromatin looping of this locus [236]. In the case of IL-4 the key transcription
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factor that allows epigenetic modifications important for IL-4 transcription is GATA-3 
[237].
We found that mTOR was recruited by acute TCR and CD28 engagement and that 
Rapa inhibited both mTORCl and mTORC2 signalling, even if with different kinetics. 
Activation of nai've T cells in the presence of Rapa resulted in delayed expression of T-bet 
and GATA-3, and in defective demethylation of Ifny and 114 promoter regions. The reasons 
for delayed T-bet and GATA-3 expression remain to be determined. We found that STAT1 
and STAT5 proteins were induced upon CD3/CD28 activation and phosphorylated to 
similar extents in both control and Rapa treated cells. Lee et al. [233] demonstrated that 
Rictor KO cells could not up-regulate T-bet and GATA-3, suggesting that mTORC2 was 
directing T-bet and GATA-3 expression. Accordingly these authors found that the 
expression of constitutively active mutants of Akt and PKC-0, two of the mTORC2- 
controlled substrates could revert defective T-bet and GATA-3 expression in Rictor- 
deficient cells [233]. A most recent report by the Powell group, instead demonstrated that 
mTORCl and mTORC2 control T-bet and GATA-3 via STAT4 and STAT6 respectively 
[89]. Our studies are consistent with the contribution of both mTORCl and mTORC2 to 
transcription factor expression and cytokine gene transcription. Indeed while mTORCl and 
cell cycle entry can be inhibited acutely and at low Rapa doses, mTORC2 and cytokine 
gene expression and differentiation requires higher doses and more prolonged treatments. 
We found that Rapa treatment hinders Akt phosphorylation in Ser473, supporting 
inhibition of mTORC2. Although we did not obtain convincing results on the state of PKC 
phosphorylation, inhibition of Akt might impede PKC0 recruitment and by that impinge on 
GATA-3 expression and consequently 114 transcription. Likewise, inhibition of mTORCl 
can lead to decreased T-bet activity and thus decreased Ifny transcription. A delay in T-bet 
and GATA-3 expression leads to the preservation of DNA methylation at Ifny and 114 
promoter regions. Whether delayed T-bet expression is causative of defective Ifny de­
methylation and transcription, or whether defective de-methylation precedes optimal T-bet
44
expression and consequent binding to the DNA remains to be understood. It’s important to 
underline that even if T-bet expression was mostly recovered after 48h of activation in the 
presence of Rapa, its target genes never recovered in their mRNA expression. This could 
be due to suboptimal binding to promoter regions that may remain methylated in the 
presence of Rapa.
While Rapa hindered activation-induced demethylation of Ifny and 774 loci, it 
prevented activation-induced methylation of Foxp3 promoter region, which normally 
inhibits its transcription [238], and instead prolonged Foxp3 expression in the presence of 
Rapa. In cells treated with Rapa we observed a block in the methylation of Foxp3 
promoter, this is reflected by the higher mRNA and protein levels observed in Rapa treated 
cells compared to control stimulated cells.
In accordance to our data, Delgoffe et al. [103] demonstrated that CD4+ T cells that 
lack mTOR, and thus both mTORCl and mTORC2, cannot differentiate into Thl, Th2 or 
Thl 7 cells [103]. The lack of differentiation was associated to the lack of up-regulation of 
the appropriate effector-specific transcription factors such as T-bet for Thl cells, GATA-3 
for Th2 cells and RORyt for T hl7 cells [103]. mTOR deficient T cells could not 
differentiate thus in effector T cells, but they differentiated into Foxp3+ regulatory T cells 
[103]. In a recent paper the same group demonstrated that specific inactivation of 
mTORCl, through deletion of Rheb, prevents CD4+ T cells from becoming Thl or T h l7 
cells both in vitro and in vivo. T cells lacking mTORC2, in which Rictor gene has been 
deleted, instead, cannot differentiate to Th2 cells [89]. Both mTORCl and mTORC2 
activity, instead, is necessary for the acquisition of a regulatory phenotype [89]. Lee et al. 
[233] demonstrated the role of mTORC2 in Thl and Th2 differentiation. The authors 
showed that by silencing Rictor in T cells they prevented differentiation of T cells into Thl 
and Th2 subsets. Deletion of Rictor had no impact on cell survival, but affected cell 
proliferation. They further showed that mTORC2 exerts its effect through activation of Akt 
and PKC0 [233]. The results from Lee et al. [233] and Delgoffe et al. [89, 103] show that
mT0RC2 plays different roles in T cell differentiation. These discrepancies between the 
reports may be due to the fact that they make use of two different animal models. While 
Delgoffe et al. silence Rictor at the DP stage of thymocyte differentiation, Lee et al. use a 
CRE mouse under the Lck promoter, thus silencing Rictor early on during thymic 
development, at the DN2 stage. In our model we acutely inhibit mTORCl. The defect in 
IFN-y production could reflect the data from mTORCl deficient mice that show problems 
in Thl differentiation. However we were able to demonstrate that Rapa can block 
mTORC2 as well, albeit with different kinetics. The defect in IL-4 expression thus, could 
be the result of inhibition of mTORC2.
Our results recapitulate, but only to some extent, recents reports. Delgoffe et al. 
[103] and Lee et al. [233] demonstrated that by genetic inactivation of mTOR and Rictor, 
respectively, they could prevent T cells differentiation towards Thl and Th2 phenotypes. 
Our experiments performed on CD4+ purified T cells demonstrated that by 
pharmacological inhibition of mTOR we could not fully recapitulate the findings obtained 
in the conditional KO animals cited above. In particular Rapa administration affected T 
cell differentiation in ThO conditions leading to a decrease in the percentage of IFN-y and 
IL-4 producing cells, but Rapa treatment did not completely block differentiation of these 
cells, which was instead found in mTOR and Rictor deficient cells. Furthermore, in the 
presence of Thl conditions (i.e. ricombinant IL-12 and anti-IL-4) Rapa did not affect 
differentiation of IFN-y producing cells, in contrast with the findings obtained in KO 
animals [89, 233]. These discrepancies might infer the presence of Rapa-resistant functions 
of mTOR in primary lymphocytes.
Recent reports evidenced the importance of mTOR in the generation of effector and 
memory CD8+ T cells as well. The group of Rao et al. [239] demonstrated that blocking 
mTORCl with Rapa leads to loss of T-bet expression, a transcription factor of key 
importance for the generation of effector T cells. Rapa, instead, favours sustained Eomes 
expression and thus differentiation towards a memory phenotype in CD8+ T cells [239].
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Araki et al. [200] demonstrated that treatment with Rapa of mice infected with 
lymphocytic choriomeningitis virus (LCMV) led to a rise in the number and quality of 
antigen-specific CD8+ T memory cells [200]. Rapamycin can do this by increasing the 
number of memory precursors during the phase of T cell expansion. By using an RNAi 
system the authors show that this regulation of memory vs effector differentiation is 
mediated specifically by mTORCl [200].
mTOR thus appears to be of fundamental importance for differentiation of T cells. 
Inhibition of mTOR leads to impaired differentiation to effector cells in CD4+ and CD8+ 
cells [240]. Block of mTOR, in fact, favours the conversion of cells to a regulatory 
phenotype or to a memory phenotype, both in CD8+ T cells [200, 239] and in CD4+ T 
cells. In CD4+ T cells, in particular, we demonstrated that following Rapa treatment for 5- 
7 days, Rapa-cultured cells showed a proliferative profile similar to untreated cells. These 
cells were characterized by a decreased percentage of IFN-y and IL-4 producing 
populations, while IL-2 producing cells were enriched in Rapa-treated cultures, suggesting 
a more memory like phenotype.
Our data, although in line with those obtained with Frap, Rictor and Raptor 
deficient T cells, show some differences between genetic inactivation and pharmacological 
inhibition of mTOR. For instance, while Frap, Rictor and Rheb deficient lymphocytes 
failed to differentiate into IFN-y secreting cells in Thl polarizing conditions [89,103, 233], 
cells activated in the presence of Rapa, retained both IFN-y and IL-2 expression. After 
Rapa treatment we observe a partial block in IFN-y and IL4 production and a skewing 
towards Foxp3 producing cells, similar to what is observed by genetic inactivation of the 
genes of the mTOR complexes. This discrepancy with the fact that with genetic 
inactivation the authors observe a complete block might be due to the failure of Rapa to 
fully inhibit mTORC2, or to the ability of IL-12 to control Ifny expression via mTOR- 
dependent Rapa-insensitive mechanisms.
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Future challenge will be to identify the mechanisms by which Rapa affects 
TCR/CD28/IL-2 controlled methylation of cytokines promoter regions. DNA methylation 
occurs at proximal and distal promoter sites of genes important for immune function [241]. 
DNA methyltransferases (Dnmt) maintain specific patterns of DNA methylation during 
DNA replication. Dnmtl, Dnmt3a and b have different roles in the cell. Dnmtl is the Dnmt 
important for preserving the pattern of the parental-strand methylation in the newly 
synthesized daughter strand during DNA replication. Dnmt3a and b, instead, are of key 
relevance for the de novo introduction of methyl groups on cytosine residues [242]. 
Defective Dnmtl expression or function causes passive demethylation of specific regions 
and leads to transcriptional up-regulation of previously suppressed cytokine genes and to 
auto-immune manifestations [222, 243]. Dnmt3a is induced following TCR engagement 
and controls Ifny and 114 promoter methylation [244]. The existence of DNA demethylases 
is a matter of intense debate [245], however in some cases active demethylation was 
observed soon before DNA replication [246]. mTOR might also influence DNA 
methylation by controlling expression/activity of yet to be defined DNA demethylases or 
of histone acethylases/deacetylases/methylases, also involved in epigenetic changes. In this 
respect it is of interest that TOR was linked to the Esal histone acetylase pathway in yeast 
[247].
Given the role of mTOR in differentiation of both helper and cytotoxic effector 
cells, of Treg cells and of T central memory lymphocytes, understanding whether and how 
mTOR controls epigenetic modifications and by that T cell fate will be instrumental to 
define the mechanism of action and long-term consequences of Rapa administration in 
vivo.
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3. TSC1 is critical for T cell development and homeostasis
3.1 Introduction
While studying the role of mTOR in activation and differentiation of mature T 
cells, we became aware of the availability of TSC1 fl/fl mice within the Institute. To define 
the impact of TSC signalling in developing and mature T cells we decided to generate T- 
lineage restricted deficient mice by crossing the TSC1 fl/fl mice to the Lck-CRE and CD4- 
CRE deleters. Thereafter is reported a brief review of the principal events characterizing 
thymic lymphocyte development.
3.1.1 T cell development
The thymus is considered the primary lymphoid organ for the generation of T cells. 
Its microenvironment, in fact, makes available a particular combination of different 
stromal cell types important for the development and selection of thymocytes that will 
become mature T cells (reviewed by Gill J. et al. [248]). Anatomically, it can be divided 
into two principal areas: the outer cortex and the inner medulla.
Development of T cells in the thymus is a strictly controlled process involving 
different steps. Each phase of the process is characterized by the expression of particular 
surface markers. During each step of differentiation, developing thymocytes acquire the 
expression of receptors that can signal to the cell and induce it to transit to the next step in 
the process.
Two different T cells population come out from thymic selection: the a-p and y-S 
T cells. They are characterized by the expression of two different T Cell Receptors (TCR). 
While y-S cells respond to unprocessed antigens, a-p cells need presentation of the antigen 
by Major Histocompatibility Complex (MHC) [249]. 20% of the cells exiting the thymus 
are y-8 cells, the others are a-P T cells. Both of these cell types start their life in the thymus 
as Double Negative (DN) cells. They are defined in this way because they do not express 
either CD4 or CD8 coreceptors. At the earliest stages the DN cells are also negative for
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CD3/TCR complex. These DN cells can be divided in 4 different subsets (DN1, DN2, DN3 
and DN4) according to the expression of two different markers CD25 and CD44 (reviewed 
by Rothenberg E. V. and Taghon T. [250]). The earliest stage, the DN1, is characterized by 
cells that are CD44+ and CD25-. C-kit and Stem Cell Factor (SCF) genes have been 
proved important for DN1 cellularity [251]. The following step of differentiation is marked 
by the expression of CD25 in these cells. The passage from DN1 to DN2 cells is driven by 
IL-7 [252-255] signalling. The following step, the DN3, pre-T cell stage is characterized 
by the loss of expression of CD44. During this phase TCRy, 5 and p chain genes are 
rearranged and cells become fully committed to the T-cell lineage. After TCRp chain has 
been successfully rearranged it is expressed on the cell surface together with a surrogate 
light chain, the pre-Ta (pTa). They form the pre-T cell receptor. This receptor associates 
with the CD3 complex and together they signal to the cell (reviewed by von Boehmer H. 
and Fehling H. J. [256]). Cells that cannot express a functional P chain are arrested at this 
point, the beta-checkpoint [257]. The signals coming from the pre-TCR lead the cell to 
undergo several rounds of proliferation and to express both CD4 and CD8. These surface 
co-receptors associate with the TCR during antigen recognition and by binding to the 
MHC allow an effective T cell response [258]. These co-receptors bind to the lateral face 
of the MHC molecules. In particular CD4 recognizes MHC class II molecules while CD8 
recognizes MHC class I molecules.
This stage is referred to as Double Positive (DP) stage. At this point immature 
thymocytes shut off one of the two coreceptors to give rise to CD4+ or CD8+ Single 
Positive (SP) cells. The process involved in this maturation step is that of positive 
selection. This process is connected to the functional specialization of these cells. If they 
become CD4+ cells they will acquire helper function, otherwise if they turn into CD8+ T 
cells they will acquire cytotoxic functions [259].
The different developmental stages occur in distinct thymic niches. CD4-CD8- 
(DN) cells migrate across the cortex. CD4+CD8+ (DP) cells that are selected to become SP
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cells proceed with a reverse migratory path across the cortex towards the medulla. During 
their migration through the cortico-medullary junction and into the medulla, the developing 
thymocytes interact with dendritic cells and specialized medullary Thymic Epithelial Cells 
(mTECs) that present self-antigens.
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Fig V. T cell development in the thymus. Immature thymocytes migrate into the thymus 
through the vasculatures enriched at the cortico-medullary junction. The DN thymocytes 
migrate outward to the subcapsular region. In the outer cortex are generated the DP 
thymocytes that differentiate into SP cells. Takahama Y., Nature Reviews Immunology, 
2006 [260]
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3.1.2 Signalling pathways controlling thymocyte development.
During thymic development expression and function of the TCR play a key role in 
driving the immature thymocytes to become mature T cells (reviewed by Matthews S. A. 
and Cantrell D. A. [261]). Two key molecules downstream the TCR that are of 
fundamental importance for T cell development are the kinases Lck and Fyn (reviewed by 
Zamoyska R. et al. and by Salmond R. J. et al. [262, 263]). These proteins are important 
for TCR activation [264], Nika et al. [264] showed that high amounts of phosphorylated 
Lck and Fyn are present in naive T cells. TCR ligation did not increase basal 
phosphorylation of Lck and did not increase either its kinase activity. The reduction of this 
basal phosphorylation of Lck, instead, compromised TCR signalling initiation, underlying 
the importance of Lck in T cell activation [264]. Active Lck can in turn phosphorylate CD3 
and Immunoreceptor Tyrosine-based Activation Motifs (ITAMs) [265] favouring the 
recruitment of the ^-chain associated protein of 70 kDa (ZAP-70) kinase to the TCR [266]. 
In turn ZAP-70 phosphorylates and activates the protein Linker for Activation of T cell 
(LAT) [267] that in turn activates downstream kinases and enzimes important for T cell 
development such as the PI3K/Akt and ERK/MAPK pathway. The active form of Fyn can 
help in the activation of the signalling pathways described above. TCR is known to 
activate also the PI3K pathway.
The importance of these kinases is evidenced by the fact that Lck deficient mice 
show an incomplete block in the maturation of the DN3 thymocytes (this function is TCR 
independent as it occurs when the cells do not yet have a fully developed TCR) [268] and 
also in the maturation of DP thymocytes. The passage from DP to SP cells, in fact, leads to 
the maturation of very few mature peripheral T cells in mice lacking Lck. Fyn KO mice do 
not show particular problems in the number and percentage of different thymocytes subsets 
[269, 270], suggesting possible compensatory mechanisms carried out by Lck activation. 
The double KO of both Lck and Fyn, instead, completely blocks development at the DN3 
stage [271, 272], stressing again the importance of the two kinases for proper T cell
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maturation.
Besides signalling from the TCR, another key trigger of T cell development is IL7. 
Alves et al. [273] by using an IL7 reporter mouse demonstrated the existence of TEC 
expressing high levels of IL7. IL-7 driven survival and proliferative signalling is needed by 
early T cell precursors positioned in the inner part of the cortex and by SP mature T cells 
that reside in the medulla [274, 275]. The authors found IL-7 producing cells in both the 
compartments that are probably responsible for nurturing thymocytes during both early and 
late phases of development. In human thymocytes Johnson et al. [276] demonstrated that 
IL7 signalling can activate the PI3K/Akt signalling pathway.
Genetic inactivation of PI3K subunits and Akt underlined the importance for this 
pathway in T cell development. Mice lacking the p i lOy subunit of PI3K for instance show 
reduction by half in the size of the thymus [277]. DP cells from these mice reveal reduced 
survival after anti-CD3 stimulation in vivo. Thymocytes from pllOy KO mice are 
characterized by increased apoptosis following stimulation with anti-CD3 and adenosine 
analogues. Also mice lacking the PI3K subunits pllOyb show reduction in the size of the 
thymus and reduction in the DP population due to an increase in apoptosis of these cells 
[278].
Aktl KO mice show spontaneous apoptosis and increased susceptibility to different 
apoptotic stimuli [279] and reduction in the size of the thymus, followed by accumulation 
of DN cells [280]. Also combined silencing of different Akt isoforms leads to defective 
thymic development. Thymocytes lacking both Aktl and Akt2 show defective 
development after the DN3 stage and they have decreased glucose uptake. The 
developmental block is due to increased apoptosis in Aktl and Akt2 deficient cells [281]. 
Conversely DP thymocytes that express a constitutively active form of Aktl reveal a 
survival advantage [282]. Na et al. [283] demonstrated that by overexpressing a 
membrane-targeted constitutively active version of PKB they observed accumulation of 
CD4+ T cells in the spleen and lymphonodes of transgenic mice. Peripheral CD4+ T cells
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could survive better following different apoptosis inducing treatments, suggesting a role 
for PKB in triggering survival signals. The increased number of CD4+ T cells was shown 
to be due to the fact that PKB can favour thymic selection of these cells [283].
Interestingly enough PTEN-deficient thymocytes are resistance to apoptosis 
induced by adenosine analogues, by y irradiation and UV irradiation. These mice show an 
increase in the DP compartment [284] and elevated thymic cellularity [285]. PTEN 
heterozygous mice reveal autoimmune features and reduced Fas-dependent apoptosis 
[286], development of CD4+ T cell lymphomas, their T cells are characterized by 
enhanced proliferation and cytokine production and the thymocytes from these mice show 
decreased apoptosis [284].
From these results the picture that emerges is of PI3K and Akt as proteins 
important in preventing apoptosis in the thymus.
Also mTOR has been shown to play an important role in thymus development. 
Studies performed with Rapa demonstrated that pharmacological inhibition of mTOR 
interferes with the maturation of DP thymocytes. This results in an increase in TCR 
negative immature thymocytes [287]. Damoiseaux et al. [287] used two different rat 
models for their studies, the Lewis rats and the Brown Norway rats. They observed that in 
these rats treatment with Rapa led to thymic atrophy. Also Tian et al. [288] showed that 
Rapa treatment led to atrophy in the thymus of rats [288], by reducing the number of DP 
thymocytes accelerating their death. Luo et al. [289] showed that Rapa treatment led to 
strong thymic atrophy in mice. From a histological point of view Rapa caused the thinning 
of the thymic cortex. The authors did not show any effect on apoptosis, suggesting that 
thymic atrophy was caused by the decreased proliferation of thymocytes following Rapa 
treatment [289]. In a more recent report Kelly et al. [290] showed that Rapa treatment of 
DN thymocytes co-cultured with OP9-DL1 monolayers inhibited Notch-dependent 
proliferation of these cells in vitro. These DN cells, however, could still differentiate to DP 
cells, suggesting the importance of mTOR signalling for thymocytes proliferation rather
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than differentiation [290].
Together existing evidences thus support a role for mTOR in T cell activation and 
differentiation. To further investigate this point, we took advantage of the availability in 
the Institute of TSC1 fl/fl mice and generated mice with T-lineage restricted TSC1 
inactivation. Based on available data we hypothesized that TSC1 deletion might result in 
the inactivation of the TSC1/TSC2 complex. This in turn would perturb mTOR regulation, 
allowing the study of the contribution of this patway to mTORCl and mTORC2 signalling 
and thymocyte development.
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3.2 Material and methods
3.2.1 Mice.
TSC1 floxed mice [291] were crossed with Lck- and CD4-CRE deleter mice. 
Genotyping was performed using a PCR based approach with primers specific for TSC1: 
F4536 (5 ’ - AGGAGGCCT CTT CTGCT ACC-3 ’), R4830 (5’-
CAGCTCCGACCATGAAGTG-3’) and R6548 (5’-TGGGTCCTGACCTATCTCCTA-3’) 
and for the CRE recombinase: FORWARD (5’-TATATCTTCAGGCGCGCGGT-3’) and 
REVERSE (5’-GCAATCCCCAGAAATGCCAG-3’). For the TSC1 PCR the products are 
the band of the wt gene of 300 bp, the band of the floxed gene of 500 bp and the band of 
the deleted gene of 400 bp. The product of the CRE PCR is a band of 300 bp. For the 
TSC1 gene the conditions of PCR are: 94 °C for 2 min; 35 loops of 94 °C for 30 sec, 55 °C 
for 30 sec and 72 °C for 30 sec; 72 °C for 7 min. For the CRE gene the PCR conditions 
are: 94 °C for 2 min; 35 loops of 94 °C for 30 sec, 62 °C for 30 sec and 72 °C for 30 sec; 
72 °C for 7 min. Mice with T-lineage restricted conditional TSC1 deletion (TSC1AT) used 
for functional experiments have been backcrossed onto the C57BL/6J background for at 
least five generations and analyzed at 8 wk of age unless otherwise indicated. In all cases, 
age-matched littermates were used as controls. All mice were housed in a pathogen-free 
environment in accordance with the regulations of the San Raffaele Institute Institutional 
Animal Care and Use Committee.
3.2.2 Primary T cell cultures.
CD4+ T cells were purified by negative selection using anti-CD8 (clone KT1.9) 
and anti-I-Ab-d/I-E (clone B21-22) rat Abs and sheep anti-rat-coated magnetic beads 
(Dynal Biotech LTD., UK) to a purity of >95%. Cells were then stimulated on 
immobilized anti-CD3 and anti-CD28 mAb (0.5 pg/ml and 5 pg/ml) in the absence or in 
the presence of RAPA (100 nM) or of Recombinant Mouse TRAIL R2/TNFRSF10B Fc 
Chimera (50 ng/ml, R&D Systems).
56
Cell were always kept in RPMI-1640 medium (Invitrogen) with 5% FBS until lysis. 
This prevented inactivation of S6 phosphorylation.
3.2.3 Western blot analysis.
CD4+ purified cells were stimulated on immobilized anti-CD3 and anti-CD28 mAh 
(0.5 pg/ml and 5 pg/ml). When indicated cells were treated with Rapa (1 or 100 nM, 
Calbiochem), SL0101 (3 or 30 uM, Toronto Research Chemicals Inc.) or U0126 (10 uM, 
Promega). T cells and thymocytes extracts were washed twice with ice-cold PBS and lysed 
in lysis buffer containing SDS 2% and Tris-HCl 62.5 mM pH 6.8.
Proteins were quantified by BCA assay and appropriate amounts (30 or 50 pg) were 
separated on standard 10-15% SDS-PAGE. For Western blotting, gels transferred to 
nitrocellulose filters were first blocked for 1 h with 5% nonfat dry milk in PBA, and then 
incubated o.n. with the primary antibody diluted in PBS with 5% bovine serum albumin 
(BSA), washed in PBST (3-fold for 10 min), incubated for 1 h with the peroxidase- 
conjugated secondary antibody, washed again in PBST as described above and once in 
PBS. Photographic development was by chemiluminescence (ECL, Amersham Bioscience 
or Immobilon substrate, Millipore). Western blot bands were quantified by the Image J 
program (rsb.info.nih.gov/ij).
Anti-Akt, anti-P(S473)-Akt, anti-P(T308)-Akt, anti-4E-BPl, anti-TSC2, anti-TSCl, 
anti-GSK3p, anti-P(S9)-GSK3p, anti- P(Ser235/236)-S6 and anti-S6, anti-FoxOl, anti- 
P(T24)-Fox01/P(T32)-Fox03a, anti-P(T389)-P70S6K: Cell Signalling Technology
(Milan, Italy); and actin, which was obtained from Santa Cruz Biotechnology Inc. 
Horseradish peroxidase-conjugated goat antimouse and anti-rabbit pAbs: Bio-Rad. The 
BCA Protein Assay Kit from Pierce.
57
Antibody anti- Company Cat. N°
FoxOl Cell Signaling 2880
Bcl2Al abeam ab45413
H3 Upstate 06-755
BclXL BD Transduction 556361
P53 Cell Signaling 2524
Phospho-p44/42 MAPK 
(Erkl/2) (Thr202/Tyr204)
Cell Signaling 9101
Phospho-Akt (Thr308) Cell Signaling 2965
Akt Cell Signaling 4685
Phospho-Akt (Ser473) Cell Signaling 9271
4E-BP1 Cell Signaling 9452
TSC2 Cell Signaling 3990
TSC1 Cell Signaling 4906
S6 Cell Signaling 2317
Phospho-S6 (Ser235/236) Cell Signaling 2211
Phospho-p70S6K (Thr389) Cell Signaling 9205
Actin Santa Cruz Biotechnology Sc-1616
Phospho-FoxOl 
(Thr24)/Fox03a (Thr32)
Cell Signaling 9464
3.2.4 miRNA analysis.
RNA was extracted with mirVana miRNA Isolation Kit (Applied Biosystems) 
following manufacturer’s instructions and its concentration was determined by 
spectrophotometry.
10 ng of RNA were used to generate cDNA templates for Real Time PCR using 
TaqMan MicroRNA Reverse Transcription (RT) Kit (Applied Biosystems). q-PCR was 
performed using Real Time Taqman universal master mix (Applied Biosystems) and 
primers of the TaqMan MicroRNA Assays. The primers used were mir-145 and snoRNA- 
202. Values were normalized to the concentration of snoRNA-202 RNA. q-PCR was 
performed using an ABI PRISM 7700 Sequence Detection System.
Specific mir-145 miRNA expression was normalized by housekeeping snoRNA- 
202 expression according to the AACT method.
3.2.5 CFSE proliferation assay.
As reported in 2.2.5
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3.2.6 Quantitative real-time RT-PCR (qPCR).
As reported in 2.2.6
3.2.7 Statistical analysis.
As reported in 2.2.8
3.3 Results
3.3.1 TSC1 deletion perturbs mTOR signalling in thymocytes and in 
peripheral T cells.
To identify the role of the TSC1/TSC2 complex in thymic development, T-lineage 
restricted inactivation of TSC1 was adopted. Mice that carry floxed TSC1 alleles [291] 
were crossed with mice that express the CRE recombinase under the Lck promoter. This 
strategy allows the deletion of the TSC1 gene early on during thymic development, at the 
DN2 stage. Mice with T cell restricted silenced TSC1 (TSC1AT) were generated at the 
expected mendelian ratio. These mice did not phenotypically differ from their age-matched 
wild type littermates (TSC1WT). In Fig 3.1 A the presence of CRE recombinase and the 
different TSC1 alleles were evaluated by PCR in cDNA from thymi, spleens, lymphonodes 
and purified T cells from LCK-CRE/TSC1AT and LCK-CRE/TSC1WT mice. The CRE 
recombinase was present in the cDNA from all the LCK-CRE/TSC1AT samples while was 
absent in the LCK-CRE/TSC1WT samples. Most thymocytes and lymphocytes from LCK- 
CRE/TSC1AT mice showed the deleted form of the TSC1 allele. In the spleen from the 
LCK-CRE/TSC1AT animals just a percentage of cells showed the deleted form of the 
allele. Purification of CD4+ cells from the spleen of the LCK-CRE/TSC1AT mice 
confirmed that the TSC1 locus was deleted in this cell subset. In the cDNA from the LCK- 
CRE/TSC1 WT mice all the TSC1 alleles were in the floxed form.
TSC1 and TSC2 expression was assessed also by western blot analysis in 
thymocytes and purified CD4+ T cells (Fig. 3.1 B, C). In samples from LCK- 
CRE/TSC1AT mice both TSC1 and TSC2 were not detectable. This could be explained by 
the fact that TSC1 has been shown to be important for TSC2 stabilization as it prevents 
TSC2 ubiquitin-mediated degradation [8, 9]. Also the mTORCl and mTORC2-dependent 
pathways were analysed to assess whether inactivation of TSC1 could affect these 
signalling cascades. Extracts from unfractionated thymocytes and mature CD4-purified T
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cells from LCK-CRE/TSC1AT but not LCK-CRE/TSC1 WT mice revealed constitutive 
phosphorylation of p70S6K (Thr389) and of S6 (Ser235/236) in resting conditions. 
Following stimulation with CD3/CD28 for 30 min p70S6K and S6 phopshorylation 
increased in LCK-CRE/TSC 1WT cells, while remained unchanged or was only modestly 
increased in LCK-CRE/TSC 1 AT cells. Rapa administration at the time of stimulation 
completely abrogated p70S6K and S6 in either cases, supporting the role of mTORCl. 
Phospho-S6 phosphorylation among thymocyte subsets was further investigated by 
intracellular staining (Fig. 3.1 D) . Result depict that constitutive phosphorylation of S6 
starts to be detected in a fraction of DP cells from LCK-CRE/TSC 1 AT mice, and is most 
evident at the SP stage. The constitutive activation of mTORCl liklely also accounted for 
an increase in cell size (Fig. 3.1 E) and protein content (Fig. 3.1 F). Indeed CD4SP, CD8SP 
thymocytes, mature CD4 and CD8 cells, and DP thymocytes, although to a lower extent, 
but not DN thymocytes or mature B cells from LCK-CRE/TSC 1 AT mice revealed a larger 
FSC when compared to those derived from LCK-CRE/TSC 1WT littermates (Fig. 3.1 E). 
Likewise protein content of LCK-CRE/TSC1AT thymocytes is higher than that of LCK- 
CRE/TSC 1WT cells (Fig. 3.1 F). We measured mTORC2 activity by looking at the 
phosphorylation of Akt on ser 473. After stimulation of LCK-CRE/TSC 1WT thymocytes 
and of CD4+ T cells we could observe an increase in Akt phosphorylation. This was 
strongly reduced in LCK-CRE/TSC 1 AT thymocytes and absent in LCK-CRE/TSC 1 AT 
mature T cells (Fig. 3.1 B, C).
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Fig 3.1 Deletion of TSC1 at the DN stage perturbs mTOR-signalling in developing 
thymocytes and mature T cells. TSC1WT and TSC1AT LCK-CRE mice were sacrificed
at 8 weeks of age. A) Genomic DNA was obtained from unfractionated thymocytes, 
splenocytes and lymphonodes cells, or from CD4+ T cells purified from spleens and 
analyzed by PCR with primers able to amplify the wt, floxed and deleted TSC1 allele and 
the CRE recombinase. B, C) Unfractionated thymocytes (B) or purified peripheral CD4+ T 
cells (C) from TSClf/f, LCK-CRE- mice (TSC1WT) and from TSClf/f, LCK-CRE+ 
(TSC1AT) mice were left untreated (Nil) or stimulated with anti-CD3 (0.5 ug/ml) and anti- 
CD28 (5 ug/ml) mAb for 30 min in the absence (3/28) or in the presence of Rapa (100 nM) 
(3/28/R). TSC1 and TSC2 levels, as well as relative phosphorylation of the mTORCl 
target p70S6K (Thr389) and of its substrate S6 (Ser 235/236) and of the mTORC2 target 
Akt (Ser473) were assessed by western blot analysis. Actin is depicted as loading control, 
and relative migration of molecular weight markers is depicted. SDS-PAGE analyses were 
performed as detailed in Materials and Methods 3.2.3 with the indicated Ab. Molecular 
weight markers are indicated in KDa. D) Flow cytometry analysis of thymocytes subsets 
identified by electronic gate after staining with anti-CD4, anti-CD8 and anti-phosphoS6 
(Ser235/236) Ab (dotted line TSC1AT cells; dark solid line TSC1WT cells, light solid line 
II Abs control). E) Flow cytometry analysis of thymocytes and lymphocytes subsets 
identified by electronic gate after staining with anti-CD4, anti-CD8 and anti-B220 mAb 
(dotted line TSC1WT cells; solid line TSC1AT cells). F) Protein concentration per cell, as 
determined by BCA assay, in TSC1WT and TSC1AT total thymocytes. Data are mean 
(±SE) of protein extracts made from 4 separate experiments. In E) statistical significance 
was evaluated with two-tailed t-Test.
This might be due to the failure of TSC1/TSC2 to activate mTORC2 [38], or to the 
presence of an mTORCl-dependent negative feedback loop. This was previously described 
in non-lymphoid cells to occur via an S6 Kinase-dependent downregulation of upstream 
activators of PI3K, such as the PDGF receptor and IRS-1 [125-127]. Our results support 
the existence of this loop also in TSC1 deficient T cells, as TSC-mediated signals failed to 
induce phosphorylation of Akt in Thr308 (PI3K-dependent) and also of MAPK in LCK- 
CRE/TSC1AT cells (Fig. 3.2 A, B).
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Fig 3.2 Constitutive mTORCl hinders TCR-induced PI3K and MAPK activation in 
LCK-CRE TSC1AT mice. TSC1WT and TSC1AT LCK-CRE mice were sacrificed at 8 
weeks of age. Purified peripheral CD4+ T cells were left untreated (Nil) or stimulated with 
anti-CD3 (0.5 ug/ml) and anti-CD28 (5 ug/ml) mAb for 30 min in the absence (3/28) or in 
the presence of Rapa (100 nM) (3/28/R). A) Phospho-Akt (Thr 308), Pan-Akt and 
Phospho-Erk (Thr 202, Tyr 204) levels were assessed by western blot analysis. Actin is 
depicted as loading control, and relative migration of molecular weight markers is 
depicted. SDS-PAGE analyses were performed as detailed in Materials and Methods 3.2.3 
with the indicated Ab. Molecular weight markers are indicated in KDa. B) Independent 
experiments were compared by densitometric analyses. Expression levels are normalized 
on actin and shown as relative to TSC1-sufficient cells (±SE). Statistical significance was 
analysed by one-tail ANOVA test with Dunns post test.
Fig. 3.3 A, B shows the quantification of different western blot experiments pooled 
together in which the mTORCl and mTORC2 targets were assessed.
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These findings suggest that loss of TSC1 leads to constitutive mTORCl signalling 
and reduced TCR-driven mTORC2 signalling, both at the central and peripheral level.
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Fig 3.3 mTOR signalling in TSCl-sufficient and TSC1 deficient cells from LCK-CRE 
TSClf/f mice. TSC1WT and TSC1AT LCK-CRE mice were sacrificed at 8 weeks of age. 
Unfractionated thymocytes (A) or purified peripheral CD4+ T cells (B) were left untreated 
(Nil) or stimulated with anti-CD3 (0.5 ug/ml) and anti-CD28 (5 ug/ml) mAh for 30 min in 
the absence (3/28) or in the presence of Rapa (100 nM) (3/28/R). Relative phosphorylation 
of the mTORCl target p70S6K (Thr389) and of its substrate S6 (Ser235/236) and of the 
mTORC2 target Akt (Ser 473) and expression of S6 and Akt were assessed by western blot 
analysis. Independent experiments were compared by densitometric analyses. Expression 
levels are normalized on actin and shown as relative to TSCl-sufficient cells (±SE). 
Statistical significance was analysed by one-tail ANOVA test with Dunns post test.
3.3.2 TSC1 loss hinders T cell development.
Loss of TSC1 starting at the DN stage hindered proper T cell development and peripheral 
representation, as evidenced by the reduced cellularity of the thymus and the spleen (Fig. 
3.4).
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Fig 3.4 Defective T cell development in the absence of TSC1 in LCK-CRE TSClf/f 
mice. TSC1 WT and TSC1AT LCK-CRE mice were sacrificed at 8 weeks of age. A) Thymi 
and spleens recovered from TSC1WT and TSC1AT individual mice (n=14) were reduced 
to single cell suspension. Total cell count (±SE) is depicted.
By flow cytometry analyses we found that DN subsets were equally represented both in 
frequencies and total numbers (Fig. 3.5).
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Fig 3.5 TSC1 deletion at the DN level in TSClf/f LCK-CRE mice does not influence 
DN1-4 subsets. TSC1WT and TSC1AT LCK-CRE mice (n=9) were sacrificed at 8 weeks
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of age. Thymi were recovered, reduced to single cell suspension and individually analyzed 
by flow cytometry. A) Representative dot plots depict DN1-4 cells after gating on viable 
DN (CD4- and CD8-) thymocytes. B) The frequency and number (± SE) of DN thymocyte 
subsets, identified by electronic gating, is depicted. Data were analysed comparing WT and 
KO subsets by the student t-test. No statistical difference was found. C) Ratio between 
DN3 and DN4 thymocytes.
In contrast, while the percentage of DP, and CD4SP/CD8SP was comparable among WT 
and LCK-CRE/TSC1 AT mice, the total number of DP, CD4SP and CD8SP cells was 
severly reduced in the LCK-CRE/TSC 1 AT thymus when compared to WT ones (Fig. 3.6).
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Fig 3.6 Defective T cell development in the absence of TSC1 in LCK-CRE TSClf/f 
mice. TSC1WT and TSC1AT LCK-CRE mice were sacrificed at 8 weeks of age. Thymi 
were recovered and analyzed by flow cytometry after staining with anti-CD4 and anti-CD8 
Ab. A) Representative dot plots depict CD4 and CD8 cells after gating on viable 
thymocytes. C) The frequency (±SE) of thymocyte subsets, identified by electronic gating, 
is depicted. FACS-generated percentages were multiplied by viable counts to define 
absolute thymocyte cell numbers. Statistical significance was evaluated with one-tail 
ANOVA test with Dunns post test.
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In peripheral lymphoid organs, both the frequency and the total number of CD4+ and 
CD8+ mature T cells was lower in LCK-CRE/TSC 1 AT mice when compared to wt ones 
(fig. 3.7).
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Fig 3.7 Defective T cell development in the absence of TSC1 in LCK-CRE TSClf/f 
mice. TSC1WT and TSC1AT LCK-CRE mice were sacrificed at 8 weeks of age. Spleens 
were recovered and analyzed by flow cytometry after staining with anti-CD4, anti-CD8 
and anti-B220 Ab. A) Representative dot plots depict CD4 and CD8 cells after gating on 
viable splenocytes. B, C) The frequency (±SE) of splenocyte subsets, identified by 
electronic gating, is depicted. FACS-generated percentages were multiplied by viable 
counts to define absolute lymphocyte cell numbers. Statistical significance was evaluated 
with one-tail ANOVA test with Dunns post test.
As deregulated AKT/PKB has been shown to alter thymocyte and T cells migration [223], 
we analyzed the possibility that reduced number of mature T cells might derive from 
accumulation of mature thymocytes in the thymus. To this purpose we enumerated 
CD24high and dim SP cells, which respectively identify immature and mature SP
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thymocutes. Results depicted in Fig. 3.8 A and B indicate that thymi of LCK- 
CRE/TSC 1 AT mice and LCK-CRE/TSC 1WT controls contain comparable frequencies of 
CD24 low cells. This suggests that SP LCK-CRE/TSC 1 AT mature SP thymocytes do not 
accumulate in the thymus. In contrast to young mice, mature SP cells were found to 
accumulate in great numbers in the thymi of aged (older than 18 months) LCK- 
CRE/TSC 1 AT mice (Fig. 3.8 C). Although this data might support a partial defect in 
homing properties, further investigation is still needed.
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Fig 3.8 CD24 negative mature CD4SP and CD8SP cells are not enriched in TSC1AT 
LCK-CRE mice. A,B) TSC1WT and TSC1AT LCK-CRE mice (n=3) were sacrificed at 8 
weeks of age. Thymi were recovered, reduced to single cell suspension and individually 
analyzed by flow cytometry after staining with CD4, CD8, CD24 and TCRp Ab. A, B) 
Representative dot plots of CD4SP (A) and CD8SP (B), TCRphlgh cells. CD24 expression 
is shown on TCRphlgh/CD4 or TCRphlgh/CD8 SP thymocytes. Data is representative of 3 
experiments. C) TSC1WT and TSC1AT LCK-CRE mice (n=3) were sacrificed at 18 
months of age. Thymi were recovered, reduced to single cell suspension and individually 
analyzed by flow cytometry after staining with CD4, CD8, CD3, CD24 and TCRp Ab. C) 
Representative dot plots of CD4SP TCRphlgh cells. CD24 expression is shown on 
TCRphigh/CD3 thymocytes.
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Of note, the CD4:CD8 ratio was higher in the LCK-CRE/TSC 1 AT compared to the LCK- 
CRE/TSC 1WT mice both in the thymus and in peripheral lymphoid organs (Fig. 3.9), 
suggesting that TSC1 might contribute to different extents to CD4 and CD8 subsets 
development.
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Fig 3.9 Defective T cell development in the absence of TSC1 in LCK-CRE TSClf/f 
mice. TSC1WT and TSC1AT LCK-CRE mice were sacrificed at 8 weeks of age. The ratio 
between CD4 and CD8 positive cells is shown (±SE). Statistical significance was 
evaluated with two-tailed t-Test.
We also bred TSC1 floxed mice with mice expressing CRE under the CD4+ 
promoter. These mice started to express the CRE recombinase during the DP phase of 
differentiation [292]. In these mice no difference was detected in the percentages and 
number of DN, DP, CD4SP or CD8SP cells in thymi of CD4-CRE/TSC1AT or CD4- 
CRE/TSC1WT animals (Fig. 3.10 A, C), while a decrease in the percentage of CD4+ and 
CD8+ T cells in the peripheral organs of the CD4-CRE/TSC1AT mice compared to the 
CD4-CRE/TSC1WT ones was still detectable (Fig. 3.10 B, D). These results suggest that 
the timing of silencing of the TSC1 pathway is quite important for consequences on the 
thymus development and can explain the discrepancy between our data on the LCK-CRE 
TSC1AT mice and the Frap KO mice [103].
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Fig 3.10 TSC1 deletion at the DP stage leads to peripheral lymphopenia in CD4-CRE 
TSC117f mice. TSC1WT and TSC1AT CD4-CRE mice were sacrificed at 8 weeks of age. 
Thymi (A, C) and spleen (B, D) from individual mice (n=7) were recovered, reduced to 
single cell suspension and analyzed by flow cytometry after staining with anti-CD4, anti- 
CD8 and anti-B220 Ab. The frequency (±SE) of thymocyte (A) and splenocyte (B) 
subsets, identified by electronic gating, is depicted. FACS-generated percentages were 
multiplied by viable counts to define absolute thymocyte and lymphocyte cell numbers 
(±SE), respectively depicted in C and D. Statistical significance was evaluated with one- 
tail ANOVA test with Dunns post test.
By further analysis of the peripheral T cells, the representation of CD4+, CD25+, 
Foxp3+ Treg cells was evaluated (Fig. 3.11 A) in LCK-CRE/TSC1 mice. No difference 
was observed between LCK-CRE/TSC 1 AT and LCK-CRE/TSC 1WT mice. Instead CD44 
high cells were increased in LCK-CRE/TSC 1 AT mice compared to their WT counterpart, 
probably this increase is a response to the peripheral lymphopenia that was detected (Fig. 
3.11 B). From these results we can conclude that TSC1 is important for appropriate T cell 
development, and in particular for the passage from DN to DP cells.
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Fig 3.11 TSC1 deletion in LCK-CRE mice leads to an unbalance in memory vs 
effector cell populations. TSC1WT and TSC1AT LCK-CRE mice were sacrificed at 8 
weeks of age. Spleen were recovered and analyzed by flow cytometry after staining with 
anti-CD4, anti-CD8, anti-CD44 and anti-CD62L or anti-CD25 (A, B) and then 
permeabilized and further stained with anti-Foxp3 Ab (A). Representative dot plots depict 
viable, CD4+ events.
This transition is strictly regulated by rearrangement and signalling of the TCRp 
chain that together with the preTa chain forms the pre-TCR. For this reason TCR levels on 
developing thymocytes were evaluated by FACS analysis, both at the extracellular and the 
intracellular level. The majority of DN and the DP, CD4SP and CD8SP cells showed 
comparable expression of the TCR in LCK-CRE/TSC 1 AT and LCK-CRE/TSC 1WT cells. 
In CD8SP cells the LCK-CRE/TSC 1 AT mice showed an increased population of TCR- 
cells (Fig. 3.12 A). We wondered whether this could be due to a faster progression of DN4 
cells to iSP cells. Thus iSP cells were identified as CD8+ CD24- CD5+ cells. These cells 
are increased in percentage in LCK-CRE/TSC 1 AT thymi (Fig. 3.12 B). These cells do not 
express detectable TCR surface levels, but they express comparable intracellular TCR 
levels in LCK-CRE/TSC 1 AT and LCK-CRE/TSC 1WT animals. Then the CD8SP 
population was re-analyzed excluding this iSP cells and in this new analysis LCK- 
CRE/TSC1AT and LCK-CRE/TSC 1WT mice showed a similar surface TCR staining 
pattern (Fig. 3.12 C). These results indicate that the partial block in T cell development that 
was observed is probably due to events independent on the TCR rearrangement and 
signalling.
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Fig 3.12 Proper TCR expression and faster DN to iSP transition in TSC1AT LCK- 
CRE mice. TSC1WT and TSC1AT LCK-CRE mice were sacrificed at 8 weeks of age. 
Thymocytes were analyzed for surface or intracellular TCRp chain expression after 
staining with anti-CD4 and anti-CD8 Ab. A) Relative TCRP levels are depicted on gated 
subpopulations. B-C) Cells were stained with anti-CD4, anti-CD8, anti-CD5 and anti- 
CD24/HSA Ab to identify iSP cells. The frequency and number (±SE) of iSP thymocytes 
within viable thymocytes is shown (B). In C, relative TCRp levels of CD8dim iSP or 
CD8SP without iSP cells are depicted. In B statistical significance was evaluated with two- 
tailed t-Test.
3.3.3 TSC1AT thymocytes show a proliferative advantage.
Signalling from the pre-TCR induces several rounds of proliferation at the DN level 
and allows for the differentiation of these cells. We wondered whether the decreased
number of thymocytes in the LCK-CRE/TSC 1 AT mice could be due to a defect in the 
proliferative phase of development. Thus thymocyte proliferation was measured with two 
different assays. BrdU incorporation was analysed in the DN and DP cells. Cells were 
labelled with BrdU by injecting the mice 40 min prior to the sacrifice and analysed ex vivo. 
While there was no difference in BrdU incorporation in DN cells from LCK-CRE/TSC 1 AT 
and LCK-CRE/TSC 1WT mice, there was an increase in BrdU incorporating cells in DP 
thymocytes from LCK-CRE/TSC 1 AT mice (Fig. 3.13 A). This was confirmed by Ki67 
staining. Again there was no difference in Ki67 intracellular staining in DN cells, but iSP, 
DP, CD4SP and CD8SP cells from LCK-CRE/TSC 1 AT animals showed an increase in the 
percentage of positive cells compared to the WT littermates (Fig. 3.13 B). These results 
could possibly be explained by the fact that LCK-CRE/TSC 1 AT cells show 
hyperactivation of mTORCl that could lead to increased cell size and an increase in cell 
proliferation.
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Fig 3.13 TSC1 deficient thymocytes reveal a proliferative advantage in LCK-CRE 
TSC1AT mice. A, B) TSC1WT and TSC1AT LCK-CRE mice were sacrified at 8 weeks of 
age. Thymocytes from individual mice (n=3) were surface stained with anti-CD4, anti- 
CD8, anti-CD5 and anti-CD24/HAS Ab to identify iSP cells, and then permeabilized to 
measure BrdU and Ki67. The relative frequency of BrdU (A) and Ki67+ (B) positive cells
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within the gated thymocyte subsets is depicted (±SE). Statistical significance was 
evaluated with two-tailed t-Test.
3.3.4 TSC1AT thymocytes reveal an increase in cell death.
Another important mechanism that regulates thymic development and maturation is 
cell death. So we investigated whether the decreased number of cells we detected could be 
due to an increase in apoptosis of the LCK-CRE/TSC 1 AT cells. Cell death in the thymus 
was analysed by Annexin V and Topro-3 staining. A clear increase in the percentage of 
Annexin V/Topro-3+ cells ex vivo was evident in all the populations of LCK- 
CRE/TSC 1 AT thymocyte with the exception of DN cells (Fig. 3.14 A, B). Thymocyte 
were also kept in culture for 14 and 24 h. Beside DN cells the LCK-CRE/TSC 1 AT DP, 
CD4SP and CD8SP populations had a higher tendency to undergo apoptosis also when 
kept in culture (Fig. 3.14 C).
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Fig 3.14 TSC1 deficient thymocytes reveal a higher apoptotic rate ex vivo and in vitro 
in LCK-CRE TSC1AT mice. A, B) Thymocyte subsets were identified by flow cytometry 
after staining with anti-CD4, anti-CD8, anti-CD5 and anti-CD24/HAS Ab. The presence of 
dying cells was determined by TOPRO-3 and Annexin V staining. Dot plots from 
representative CD4SP cells (A). Panel B depicts quantification of cumulative frequencies 
(±SE) of TOPRO-3+ and AnnexinV+ cells in 11 independently analyzed mice. C) 
Unfractionated thymocytes were analyzed ex vivo and after 14 and 24 hours of culture in 
complete medium. Thymocyte subsets were identified by flow cytometry after staining
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with anti-CD4 and anti-CD8 and the frequency of dying cells was determined by Annexin 
V staining. One representative experiment of 11 is depicted. In B statistical significance 
was evaluated with two-tailed t-Test, in C with two-way ANOVA test with Bonferroni post 
test.
We further investigated which could be the molecular mechanism underlying this 
increased cell death. Akt was shown before to be less phosphorylated in the LCK- 
CRE/TSC 1 AT cells. Akt is known to play a key role in cellular processes such as 
acceleration of cell cycling and suppression of apoptosis (reviewed by Manning B. D. and 
Cantley L. C. [293]). Some of the Akt targets involved in cell proliferation and cell death 
were analysed. By western blot analysis the levels of p53, BclXL or Bcl2Al and by RT 
PCR the Bax/BclXL ratio were evaluated. These levels were similar in LCK- 
CRE/TSC1AT and LCK-CRE/TSC 1WT cells (Fig. 3.15 A, B). mRNA expression of other 
three genes involved in cell survival was analyzed. Thymocytes from LCK-CRE/TSC 1 AT 
mice showed an increase in the mRNA levels of the pro-apoptotic gene Trail and decreased 
levels of the pro-survival gene Cyclin D1 compared to cells from LCK-CRE/TSC1WT 
mice (Fig. 3.15 C).
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Fig 3.15 Analysis of intrinsic and extrinsic death pathways in TSC1WT and TSC1AT 
cells from LCK-CRE mice. A, Unfractionated thymocytes were left untreated (Nil) or 
stimulated with anti-CD3 and anti-CD28 Ab for 30 min in the absence or in the presence of 
Rapa (100 nM). P53, BclXL and Bcl2Al levels were assessed by western blot analysis of
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total cell extracts. B, C) RNA was derived from TSC1WT and TSC1AT thymocytes from 
individual mice (n=5) and analyzed by PCR (B) or quantitative PCR (C). The Bax/BclXL 
ratio (±SE) is shown (B). In C mRNAs were first normalized to the GAPDH housekeeping 
gene, and then expressed relatively to TSC1WT cells (±SE). Statistical significance was 
evaluated with two-tailed t-Test.
3.3.5 TSC1AT mature peripheral T cells show a proliferative advantage.
To investigate whether also mature T cells showed an increase in cell proliferation 
similar to what was observed in the thymus, splenocytes were labelled with CFSE and kept 
in culture with IL7 and CD3/CD28. In both the conditions of culture LCK-CRE/TSC 1 AT 
CD4+ and CD8+ cells proliferated more than T cells from LCK-CRE/TSC 1WT mice (Fig. 
3.16 A, C, D). The proliferative advantage of LCK-CRE/TSC 1 AT cells compared to LCK- 
CRE/TSC 1WT ones observed when cells were kept in IL-7 did not seem to be due to 
altered expression of IL-7 receptor as CD 127 surface levels were comparable between 
LCK-CRE/TSC 1 AT and LCK-CRE/TSC 1WT CD4+ and CD8+ cells (Fig. 3.16 B). In 
order to address if this proliferative advantage could be due to increased mTORCl activity 
we treated the cells with Rapa and we could observe that the proliferative advantage of the 
LCK-CRE/TSC 1 AT cells was abrogated by treatment with the drug (Fig. 3.16 C, D). This 
confirms that mTORCl may be involved in the proliferative advantage of the LCK- 
CRE/TSC1AT cells. Treatment of LCK-CRE/TSC 1 AT cultures with Rapa showed that 
mTORCl is important not only for the increased proliferation of LCK-CRE/TSC 1 AT cells, 
but also for their increased cell size. Treatment with Rapa, in fact, decreased the size both 
of CD4+ and CD8+ T lymphocytes (Fig. 3.16 E).
In spite of the increased proliferation we observed in the CD4+ and CD8+ 
compartment, LCK-CRE/TSC 1 AT mice were lymphopenic up to 30 weeks of age. In fact a 
lower frequency of CD4+ and CD8+ T cells, but not B220+ B cells, was detected in these 
mice for the whole period (Fig. 3.16 F). These data could suggest that lack of TSC1 may 
perturb the homeostatic control of mature T cells or may be the result of lower production 
of T cells from the thymus.
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Fig 3.16 TSC1 deficient T cells reveal a proliferative advantage in TSC1AT LCK- 
CRE mice. A, C, D) TSC1WT and TSC1AT splenocytes were labelled with CFSE and 
cultured in complete medium in the absence (Ctrl) or in the presence of recombinant 
mouse IL-7 (0.5 ng/ml) or immobilized anti-CD3/CD28 mAb (0.01 ug/ml and 5 ug/ml) for 
3 days. Relative CFSE content on gated viable CD4+ or CD8+ events is depicted in A. 
Rapamycin (100 nM) was provided to parallel cultures. Quantification of the frequency 
(±SE) of T cells with a CFSE-diluted profile is depicted in C for CD4+ T cells and in D for 
CD8+ T cells. B) Flow cytometry analysis of expression levels of CD 127 on CD4+ and 
CD8+ lymphocytes subsets identified by electronic gate after staining with anti-CD4, anti- 
CD8 and anti-CD 127 Ab (dotted line TSC1 WT cells; solid line TSC1AT cells).
E) Flow cytometry analysis of lymphocytes subsets identified by electronic gate after 
staining with anti-CD4 and anti-CD8 Ab (dark dotted line TSC1WT cells -R ; light dotted 
line TSC1WT cells +R; dark solid line TSC1AT cells -R; light solid line TSC1AT +R). 
Cells were kept in culture with IL-7 (0.5 ng/ml) for 2 days with or without Rapa (100 nM).
F) TSC1WT and TSC1AT mice were bled at the indicated times (4, 5, 6, 20, 24 and 28 
weeks). The relative frequency (±SE) of CD4+, CD8+ and B220+ cells from TSC1WT
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(n=7) and TSC1AT (n=7) mice is shown. In B and C statistical significance was evaluated 
with one-tail ANOVA test with Dunns post test, in E with two-way ANOVA test with 
Bonferroni post test.
3.3.6 TSC1AT mature T cells show an increase in apoptosis levels and 
deregulated FoxO signalling.
When mature T cells were cultured in IL-7 or CD3/CD28, LCK-CRE/TSC 1 AT 
cultures contained a higher proportion of dying cells when compared to the LCK- 
CRE/TSC 1WT cultures. This increased cell death was basically insensitive to Rapa 
treatment (Fig. 3.17 A-E).
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Fig 3.17 Increased cell death in TSC1AT LCK-CRE mature T cells is not Rapa- 
dependent. TSC1WT and TSC1AT splenocytes were labelled with CFSE and cultured in 
complete medium in the absence (Ctrl) or in the presence of recombinant mouse IL-7 (0.5 
ng/ml) (B-E) or immobilized anti-CD3/CD28 mAb (0.01 ug/ml and 5 ug/ml) (A-E) for 3 
days. Lymphocytes subsets were identified by flow cytometry after staining with anti-CD4 
and anti-CD8 Ab. The presence of dying cells was determined by TOPRO-3 staining. Dot
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plots from representative CD4+ cells stimulated with immobilized anti-CD3/CD28 mAb 
(0.01 ug/ml and 5 ug/ml) for 3 days (A). Relative CFSE content on gated viable CD4+ or 
CD8+ events is depicted in B-E. Rapamycin (100 nM) was provided to parallel cultures. 
Quantification of the frequency (±SE) of CD4+ T cells with a CFSE-diluted profile is 
depicted in B and D for CD4+ T cells and in C and E for CD8+ T cells. Panels B-E depict 
quantification of cumulative frequencies (±SE) of TOPRO-3+ cells in 7 independently 
analyzed mice. In B and C quantification of CFSE undiluted cells, in D and E 
quantification of CFSE diluted cells. Statistical significance was evaluated with one-tail 
ANOVA test with Dunns post test.
To further investigate a possible molecular mechanism responsible for this increased cell 
death we focused on the Akt pathway. Akt controls an important family of transcription 
factors, the FoxOs. When FoxOs are phosphorylated they are retained in the cytoplasm and 
thus inhibited [294], when they are in the unphosphorylated form, they can enter the 
nucleus and direct the transcription of specific genes that control proliferation as well as 
cell survival. When LCK-CRE/TSC 1WT CD4+ T cells were stimulated with CD3/CD28 
an increase in the phosphorylation of FoxOl and Fox03a was detected (Fig. 3.18 A). This 
increase in phosphorylation was lost in LCK-CRE/TSC 1 AT cells. Also typical FoxO target 
genes were differentially expressed in LCK-CRE/TSC 1 AT and LCK-CRE/TSC 1WT cells. 
In accordance with reduced phosphorylation of FoxO in LCK-CRE/TSC 1 AT cells, TRAIL 
was expressed at higher levels in LCK-CRE/TSC 1 AT T cells compared to LCK- 
CRE/TSC 1WT cells both at steady state and following TCR/CD28 stimulation (Fig. 3.18 
B), while there was no difference in the mRNA levels of other FoxO target genes such as 
FasL and Bim and of the TRAIL-receptor (Fig. 3.18 B, C).
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FoxO family members recently have been shown to function also as tumour 
suppressors in vivo [295] and the members of this family have been demonstrated to be 
able to inhibit expression of c-Myc. Another indication that FoxO may be constitutively 
active in LCK-CRE/TSC 1 AT cells was that both Cyclin D1 and c-Myc levels were lower 
in LCK-CRE/TSC1AT cells (Fig. 3.18 D). The lower levels of c-Myc in LCK- 
CRE/TSC1AT cells could be explained by increased levels of mir-145 (Fig. 3.18 E), a 
miRNA that silence c-Myc and that has been shown to be controlled by FoxOs proteins
[296]. We thus think that FoxO regulation downstream of Akt could render the LCK- 
CRE/TSC 1 AT cells more prone to cell death.
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Fig 3.18 TSC1 deficiency favours FoxO-dependent signalling in TSC1AT LCK-CRE 
mice. A) CD4+ cells were purified from the lymphonodes of TSC1WT and TSC1AT mice 
(n=3) and left untreated (Nil) or stimulated with anti-CD3 and anti-CD28 mAb for 30 min
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in the absence or in the presence of Rapa (100 nM). Phosphorylation of FoxOI (Thr24)/3a 
(Thr32) was assessed by western blot analysis. Actin is depicted as loading control, and 
relative migration of molecular weight markers is depicted. B-D) CD4+ cells were purified 
from the lymphonodes of TSC1WT and TSC1AT mice (n=3) and left untreated (Nil) or 
stimulated with anti-CD3 and anti-CD28 mAb for 4 hours. mRNA was derived from naive 
cells and cells stimulated with CD3/CD28 for 4 hours. mRNA levels for the indicated 
genes was quantified by quantitative PCR. Results depict the mean ± SE of 3-7 
independent experiments. E) CD4+ cells were purified from the lymphonodes of TSC1WT 
and TSC1AT mice (n=3). Analysis of mir-145 expression by real-time PCR. The levels 
(±SE) of mir-145 were normalized on the snoRNA-202. In C and D statistical significance 
was evaluated with one-tail ANOVA test with Dunns post test, in E with two-tailed t-Test.
3.3.7 TRAIL induced cell death of TSC1AT T cells.
Having found that TRAIL is expressed to higher levels in LCK-CRE/TSC 1 AT T 
cells, we investigated whether mature T cells would show an increased propensity to 
undergo cell death, and whether this could be inhibited by the TRAILR2/Fc Fusion protein
[297]. Splenocytes from LCK-CRE/TSC1WT and LCK-CRE/TSC 1 AT mice were cultured 
overnight in the absence or in the presence of TRAILR2/Fc Fusion protein, and cell death 
was measured by Annexin V and TOPRO-3 staining. Results depicted in Fig. 3.19 A and B 
indicate that LCK-CRE/TSC 1 AT T cell cultures contained a higher frequency of 
AnnexinV+, TOPRO-3 + cells both ex vivo and after an overnight culture. The addition of 
the TRAILR2/Fc chimeric protein completely abrogated differences among LCK- 
CRE/TSC 1WT and LCK-CRE/TSC 1 AT cultures. Similar results were obtained by looking 
at CD3/CD28 and IL-7 driven cultures of CFSE-labelled LCK-CRE/TSC 1WT and LCK- 
CRE/TSC 1 AT splenocytes. In the case of both undividing and dividing (Fig. 3.19 C, D) 
CD4+ and CD8+ T cells, LCK-CRE/TSC 1 AT T cells revealed a higher propensity to die 
when compared to LCK-CRE/TSC 1WT cells, but differences were abrogated in the 
presence of TRAILR2/Fc chimeric protein (Fig 3.19 C, D).
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Fig 3.19 Increased cell death in TSC1AT LCK-CRE mature T cells is dependent on 
TRAIL. A, B) Lymphocytes subsets were identified by flow cytometry after staining with 
anti-CD4 and anti-CD8 Ab. The presence of dying cells was determined by TOPRO-3 and 
Annexin V staining. Dot plots from representative CD4+ cells analysed ex vivo (A). Panel 
B depict quantification of cumulative frequencies (±SE) of TOPRO-3+ and AnnexinV+ 
cells in 5 independently analyzed mice gated on CD4+ and CD8+ cells. Cells were 
analysed either ex vivo or were kept in medium o.n. with or without TRAILR2/Fc.
C, D) TSC1WT and TSC1AT splenocytes were labelled with CFSE and cultured in 
complete medium in the absence (Ctrl) or in the presence of recombinant mouse IL-7 (0.5 
ng/ml) or immobilized anti-CD3/CD28 mAb (0.01 ug/ml and 5 ug/ml) for 3 days. 
Lymphocytes subsets were identified by flow cytometry after staining with anti-CD4 and
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anti-CD8 Ab. The presence of dying cells was determined by TOPRO-3 staining. Relative 
CFSE content on gated viable CD4+ or CD8+ events is depicted. TRAILR2/Fc (50 ng/ml) 
was provided to parallel cultures. Quantification of the frequency (±SE) of CD4+ T cells 
with a CFSE-diluted profile is depicted for CD4 and for CD8+ T cells. Panels C and D 
depict quantification of cumulative frequencies (±SE) of TOPRO-3+ cells in 5 
independently analyzed mice. In C quantification of CFSE undiluted cells, in D 
quantification of CFSE diluted cells. Statistical significance was evaluated with one-tail 
ANOVA test with Dunns post test.
Of note the TRAILR2/Fc chimeric protein did not have any effect on the 
proliferative advantage of LCK-CRE/TSC 1 AT T cells in response to IL-7 and CD3/CD28 
(Fig. 3.20), consistent with the notion that this is mostly dependent on mTORCl 
hyperactivation. Thus, unchecked FoxOs activity reduces C-Myc and Cyclin D1 
expression, favours TRAIL expression and TRAIL-dependent cell death, accounting for 
decreased survival of LCK-CRE/TSC 1 AT T cells.
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Fig 3.20 Increased proliferation in TSC1AT LCK-CRE T cells is insensitive to TRAIL 
inhibition. TSC1WT and TSC1AT splenocytes were labelled with CFSE and cultured in 
complete medium in the absence (Ctrl) or in the presence of recombinant mouse IL-7 (0.5 
ng/ml) or immobilized anti-CD3/CD28 mAb (0.01 ug/ml and 5 ug/ml) for 3 days. 
Lymphocytes subsets were identified by flow cytometry after staining with anti-CD4 and 
anti-CD8 Ab. Relative CFSE content on gated viable CD4+ or CD8+ events is depicted. 
TRAILR2/Fc (50 ng/ml) was provided to parallel cultures. Quantification of the frequency 
(±SE) of T cells with a CFSE-diluted profile is depicted for CD4+ and for CD8+ T cells. 
Statistical significance was evaluated with one-tail ANOVA test with Dunns post test.
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3.4 Discussion
In this part of the thesis are reported the data on the role of TSC1 in thymocyte 
development and peripheral homeostasis. To address the role of TSC1 in T cell 
development and function, we adopted a TSC fl/fl strategy and crossed mice with Lck- and 
CD4+-CRE deleters, thus silencing TSC1 during thymic development. We adopted a 
conditional KO strategy due to the lethal phenotype of complete KO animals. Inactivation 
of both TSC1 or TSC2 genes, in fact, was previously shown to lead to death of embryos in 
midembryogenesis because of cardiac malformation and liver hypoplasia [298, 299]. Mice 
heterozygous for the TSC1 or TSC2 genes develop renal and liver tumours.
Silencing of the TSC1 gene early on during thymocyte development (DN2/DN3), 
using the Lck-CRE deleters, hindered the generation of normal numbers of DP, CD4SP 
and CD8SP thymocytes and of peripheral CD4+ and CD8+ T cells, and the homeostasis of 
mature T cells. We found that TSC1 expression was almost completely lost in thymocytes, 
and absent in peripheral mature T cells. Loss of TSC 1 was also paralleled by loss of TSC2, 
which is consistent with the idea that TSC1 is needed for TSC2 stability and for 
TSC1/TSC2 complex formation.
Given the fact that TSC is controlled by the PI3K-PDK-Akt pathway, and the 
notion that T cell conditional KO for proteins belonging to this pathway show problem in 
thymocyte development, the finding that TSC deletion might impact on thymocyte 
development was not unexpected. For example, deletion of a single allele of PDK1, the 
protein known to control phosphorylation, and thus activation, of Akt on thr308, prevents 
the proliferative expansion of a-(3 T cells in the thymus. The decreased number of 
thymocytes in these mice is due to the increased rate of apoptosis of PDK1 haplo- 
insufficient thymocytes [300]. Kelly et al. also demonstrated the fundamental role of PDK1 
in mediating Notch induced T cell development [290].
The first differences between LCK-CRE/TSC 1 AT and LCK-CRE/TSC 1WT 
animals can be detected at the DP stage. This does not appear to be due to defective TCRp
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chain rearrangement or suboptimal DN proliferation. TCRp level, Ki67 positivity and 
BrdU incorporation, in fact, were comparable between LCK-CRE/TSC 1 AT and LCK- 
CRE/TSC1 WT DN thymocytes.
Loss of TSC 1 in LCK-CRE/TSC 1 AT mice prompted hyperactivation of mTORCl, 
an increase of cell size and a higher propensity to proliferate starting at the DP stage, but 
mostly evident at the SP stage of development. The increase in cell size was quite evident 
in CD4SP and CD8SP thymocytes and in peripheral CD4+ and CD8+ T cells (Fig. 3.1 E). 
In the DP population of thymocytes the increase in cell size was less evident. This was in 
spite deletion of TSC 1 floxed gene was complete in DP cells, possibly due to limited S6 
phopshorylation at this stage as determined by intracellular pS6 staining (Fig. 3.1 D). S6 
phosphorylation is a dynamic process that varies in different thymocytes subpopulations 
[301]. Hinton et al. [301] showed that DN3 cells that express TCRp contained 
phosphorylated S6. Also the great majority of DN4 cells were positive for phospho-S6 
staining and expressed a preTCR complex that regulates the proliferation and 
differentiation of these cells [302]. Following the DN stage of development, thymocytes 
become DP cells that can go through cell death by neglect, when signalling via TCR is 
insufficient, or through negative selection when this signalling is too strong. A small 
percentage of cells that respond to TCR signalling in the right range go through the process 
of positive selection. This process allows the survival, proliferation and lineage 
commitment to mature CD4SP and CD8SP T cells. Hinton et al. [301] showed that SP 
cells and the majority of DP cells expressed low level of phospho-S6. Among DP cells the 
cells that were positive for S6 phosphorylation also expressed CD69, an activation marker 
that identifies TCR activated thymocytes [301]. This correlation between CD69 and S6 
phosphorylation suggests that activation of the TCR can in turn activate PDKl/mTOR 
signalling during the process of thymocytes selection. We found that in the absence of in 
vitro activation, a fraction (about 20%) of DP cells and the majority of SP cells have
constitutive phosphorylation of S6 phosphorylation in LCK-CRE/TSC 1 AT mice by
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intracellular staining. Thus, in LCK-CRE/TSC 1 AT mice a fraction of DP thymocytes and 
most of SP cells appear to have constitutive mTORCl activity in the absence of TCR 
ligation. This might also account for the increased cell size and augmented proliferation 
observed in these cells and in mature T cells (both CD4+ and CD8+).
Loss of TSC 1/2 also hindered proper Akt phosphorylation. This might be due to 
defective mTORC2 activity or to a negative feedback loop from mTORCl. The latter was 
previously described in non-lymphoid cells to occur via a p70S6 Kinase-dependent down- 
regulation of upstream activators of PI3K, such as the PDGF receptor and IRS-1 [125- 
127]. The presence of this loop in LCK-CRE/TSC 1 AT T cells is suggested by the finding 
that TCR mediated signals do not induce proper phosphorylation of Akt in Thr308 and also 
of MAPK, at least at the time examined during the experimental work performed so far. It 
is possible that MAPK activity might be suboptimal or recovered at later times, which 
might explain preserved CD69 upregulation (not shown) and cell proliferation. Another 
important pathway for thymocyte proliferation, the Rho GTPase pathway, has not been 
investigated. In T cell progenitors proliferation and differentiation rely on both PDK1 and 
RhoA-dependent signalling pathways [303-305]. PI(3,4,5)P3 signaling, in fact, has been 
linked also to signalling pathways mediated by the Rac/Rho family of GTPases, important 
regulators of thymocyte proliferation. Galandrini et al. [306] demonstrated that mice in 
which Rho GTPase activity was shut down early on during thymic development showed 
defects in fetal and adult thymopoiesis. By expressing C. botulinum C3 transferase (an 
inhibitor of Rho biological function) under the control of the p561ck proximal promoter the 
authors demonstrated that the mice were deficient in CD44+CD25+ pro-T cells and also in 
CD44'CD25+ early pre-T cells. Rho was essential for survival of these cells. By expressing 
C3 transferase under the control of the CD2 gene, Cleverley et al. [303] demonstrated that 
thymocytes numbers were reduced by 50- to 100- fold, similarly to what was found by 
using Lck proximal promoter. The main difference was that while in Lck-C3 mice the 
reduction in the number of thymocytes was mainly due to defects in cell survival of
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thymocyte progenitors, the CD2-C3 transgenic mice showed a pre-T cell differentiation 
block [303]. It is difficult to speculate what could happen to Rho activation following 
silencing of TSC1. Rho GTPases can be regulated in a very complex way (reviewed by 
Cantrell D. A. [307]). It is possible to conceive that cells lacking TSC1 can regulate 
proliferation through the modulation of Rho activity possibly through feedback loops on 
proteins of the Rho pathway.
As a result of defective Akt phopshorylation, phosphorylation of FoxO 1/3 was 
deregulated in LCK-CRE/TSC 1 AT mature T cells. FoxOs proteins are differentially 
regulated during T cell maturation. For instance Fox03 and Fox04 are down-regulated 
during maturation while FoxOI is up-regulated during CD4+ and CD8+ T cell maturation 
and in CD4+Foxp3+Treg cells [308]. FoxO proteins are central for inhibiting cell cycling 
and for increasing apoptosis [294], in fact they act as tumour suppressors in vivo [295]. 
When a T cell is stimulated, the PI3K pathway is activated as well and this leads to Akt 
phosphorylation and thus inhibition of FoxOI that is in turn phosphorylated and 
sequestered to the cytoplasm. In this way cell cycle progression can start [309]. It is quite 
peculiar that LCK-CRE/TSC 1 AT T cells are able to proliferate even if they cannot exclude 
FoxO from the nucleus. This could be due to constitutive activity of mTORCl or other yet 
to be defined pathways able to overcome the inhibitory effect of nuclear FoxO. This latter 
possibility alo might account for proper maturation and exit of SP cells in the thymus. 
Indeed, while Akt defective T cells should fail to properly regulate homing receptors 
(reviewed by Finlay D. and Cantrell D. [223]), LCK-CRE/TSC 1 AT thymocytes completed 
their maturation and homed to secondary lymphoid organs. Preliminary experiments show 
that KLF2, which expression is controlled by FoxO, and some of its targets (CCR7, 
CD62L and SI PI) are not upregulated in LCK-CRE/TSC 1 AT cells. This is possibly again 
due to constitutive activation of mTORCl and accounts for proper thymic egress of SP 
mature T cells.
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Among the FoxO target genes, TRAIL expression was found to be increased in 
LCK-CRE/TSC1 AT T lymphocytes when compared to LCK-CRE/TSC1WT controls. This 
nicely correlated with the higher propensity of the cells to undergo cell death. Accordingly, 
inhibition of TRAIL with a recombinant mouse TRAIL R2/Fc chimeric protein reduced 
cell death level in the LCK-CRE/TSC1AT cells to levels comparable to those of LCK- 
CRE/TSC1WT animals.
The expression of other two targets, c-Myc and Cyclin D l, instead, was decreased in LCK- 
CRE/TSC1AT compared to LCK-CRE/TSC1 WT cells. FoxOs have been shown to regulate 
Myc through mir-145 in renal cell carcinoma (RCC) samples [296]. We found that the 
expression of mir-145 was increased in mature T cells from LCK-CRE/TSC1AT mice 
compared to LCK-CRE/TSC1WT mice. c-Myc, together with Cyclin D l, is a well known 
target of p-catenin, an important factor implied also in thymic development by different 
groups. Xu et al. [310] showed that T cell-specific deletion of P-catenin impaired T cell 
development at the p-selection checkpoint. Mulroy et al. [311] showed that, conversely, 
overexpression of p-catenin enhances generation of mature thymocytes. We didn’t 
performed experiments aimed at evaluating the expression and activity of P-catenin in the 
LCK-CRE/TSC1AT mice. However by looking at c-Myc and Cyclin Dl levels it is 
possible to hypothesis that p-catenin in these KO cells is less active than in the WT ones. 
This could be explained by the effect of TSC1 loss on phosphorylation of Akt. When Akt 
is less phosphorylated it is less active and thus it does not phosphorylate and inhibit 
GSK3P activity. Active GSK3p can thus lead to p-catenin degradation. This could be 
another explanation for the decreased levels of c-Myc reported in the LCK-CRE/TSC1AT 
cells.
From the results reported in this part of the thesis it is clear that the TSC1/TSC2 
complex is fundamental in the control of proliferation and cell death in developing
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thymocytes and mature T lymphocytes. The LCK-CRE/TSC1AT mice however are 
characterized by a durable lymphopenia. This suggests that the increased cell death 
dominates over the increased proliferation. This could be due to the fact that in the KO 
cells we observed active FoxO. As Gan et al. [296] demonstrated, FoxO activity can act as 
a kind of brake to unrestrained progression of renal tumours by leading to cell cycle arrest 
and apoptosis of RCC cells. It could be possible that also in our model double inactivation 
of TSC1 and FoxO could lead to proliferation of leukemic cells and progression of 
lymphoma in LCK-CRE/TSC1AT mice in which hyperactive mTORCl could lead to 
unrestrained proliferation not checked by FoxO pro-apoptotic activity.
Further understanding of the crosstalk between TSC/mTOR and FoxO pathways 
will be relevant in order to design proper therapeutic strategies that address immune- 
related diseases.
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Fig VI. Effects of TSC silencing in T cells signalling. Loss of TSC1 leads to 
destabilization of TSC2 and lack of the TSC1/TSC2 complex activity. This lead to 
hyperactivation of mTORCl, increased S6K activity and thus higher cell proliferation. 
S6K can inhibit Akt activity through the feed-back loop. Akt activity could be further 
deregulated by loss of mTORC2 activity that could be a result of absent TSC1/TSC2 
signalling. Akt down-regulation favours Fox01/3a activity, increased transcription of its 
targets and this leads to a higher rate of apoptosis.
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4. TSC2 controls proliferation and neurosecretory functions in nerve cells. 
4.1 Introduction.
Proliferation and differentiation are interconnected events controlling homeostasis 
and functions of a numbers of cells besides those belonging to the immune system. Based 
on results obtained with T cells and developing thymocytes we became interested in 
evaluating the possible contribution of TSC and mTOR signalling to neural cells 
proliferation and differentiation. Thereafter will follow an introduction of existing 
evidences supporting the role of TSC and mTOR in neural functions.
4.1.1 Proliferation and differentiation in the central nervous system.
The adult central nervous system is characterized by the presence of mature non 
mitotic cells, the neurons. However, Altman and Das [312] described newly bom cells also 
in the mature CNS suggesting that the process of neurogenesis might persist during adult 
life and not be restricted to the phases of embryonic development. Neural Stem Cells 
(NSC) are mainly responsible for neurogenesis as capable of proliferation and 
differentiation.
NSC are particular cells present mainly in two principal areas in the CNS: the 
subventricular zone (SVZ) (reviewed by Gage F. H. [313]) and the subgranular zone. To 
be defined as NSC they must possess particular features such as an undifferentiated 
phenotype, the ability to go through different rounds of proliferation, the competence for 
self maintenance and self-renewal and the possibility of a broad developmental fate 
(reviewed by Potten C. S. and Loeffler M. [314]). It is possible to recapitulate in vitro the 
processes of proliferation and differentiation that occur during neurogenesis in vivo. In the 
presence of mitogens such as Epidermal Growth Factor (EGF) and Fibroblast Growth 
Factor 2 (FGF2), rapidly dividing precursors from the SVZ can be induced to proliferate in 
vitro. These precursors posses most of the features of stem cells reported above [315, 316]. 
If these mitogens are removed from the culture these progenitors can be induced to
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differentiate in astrocytes, oligodendrocytes and neurons, the main cell types of the CNS 
[317-319]. These processes of proliferation and differentiation can be thus finely tuned by 
activating different intracellular pathways.
4.1.2 Mouse models of Tuberous Sclerosis Complex
The TSC pathway has been shown to be critical within the nervous system. Patients with 
mutation in either TSC1 or TSC2 show many neurological abnormalities such as epilepsy 
[320], neurocognitive dysfunction [321] and disorders such as autism [322]. Conventional 
KO mice for either TSC1 or TSC2 die before brain development is complete. This renders 
impossible the study of TSC1 or TSC2 loss in formation of the brain and in cellular 
processes involving different kinds of neuronal cells. Because of this, several models of 
conditional KO mice have been generated that specifically silence TSC1 or TSC2 in 
different brain areas and neuronal populations.
Way et al. [323] used TSC2 floxed mice crossed with hGFAP-CRE transgenic mice 
in order to silence TSC2 in radial glial progenitor cells in the developing cerebral cortex 
and hippocampus. The TSC2AT mice showed post-natal megalencephaly and possible 
migration defects and the mice died between 3 and 4 weeks of age. The conditional KO 
mice presented brain pathology characterized by cortical and hippocampal lamination 
defects, hippocampal heteropias, enlarged dysplastic neurons and glia, abnormal 
myelination and astrocytosis. Loss of TSC2 in radial glia caused also myelin formation 
defects and increased number of oligodendrocytes [323].
Wang et al. [324] used a conditional TSC1 allele consisting of loxP elements 
upstream of exon 17 and downstream of exon 18, in this way both exons can be deleted by 
CRE-mediated recombination. They crossed these mice with Synapsinl-CRE transgenic 
mice so that the TSC1 gene was inactivated in neurons. Brain tissue sections from these 
mice did not show evident anatomic defects, loss of lamination or tuber formation. Instead 
extracellular recordings that were able to trace synaptic activity from neocortical slices
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showed differences in the excitability between TSC 1 AT and TSC1WT mice. Whole-cell 
patch-clamp recordings revealed excitatory synaptic currents characterized by long 
duration and epileptiform discharge pattern in TSC 1 AT mice suggesting that synaptic 
excitation was not normal and seemed to lead to seizure generation in TSC 1 AT brain 
tissues. This appeared to be independent from the presence of cortical tubers, absent in the 
TSC 1 AT mice used for this study [324].
Ehninger et al. [325] crossed TSC1 floxed mice with mice carrying CRE under the 
aCaMKII promoter to specifically silence TSC1 in neurons of the postnatal forebrain. The 
conditional KO mice died within the first postnatal weeks. The few surviving TSC 1 AT 
mice developed severe macroencephaly and the brains of these KO animals weighted 2.5 
times more than those of the control littermates. Brain enlargement was the result of 
neuronal hypertrophy and was accompanied by astrogliosis [325].
Ess et al. [326] used TSC1 floxed mice crossed with GFAP-CRE transgenic mice to 
generate astrocyte-restricted inactivation of the TSC1 gene. They demonstrated that brains 
from TSC 1 AT mice expressed markers of glia precursors such as vimentin and brain lipid 
binding protein (BLBP) at higher levels. This may suggest that astroglial cells from KO 
animals could be developmentally immature. Also several markers of neuroglial cell 
differentiation were aberrantly expressed in TSC 1 AT astrocytes supporting evidence for a 
developmental defect of neuroglial cell differentiation in the pathology of TSC [326].
Uhlmann et al. [327] silenced TSC1 in astrocytes by crossing TSC1 floxed mice 
with GFAP-CRE deleters. The authors showed that astrocyte-specific inactivation of TSC 1 
led to seizures and early death in the mice. The conditional KO mice presented astrogliosis 
and abnormal neuronal organization. Astrocyte-specific inactivation of TSC 1 resulted also 
in increased cell proliferation [327]. The same group demonstrated that TSC1 is important 
not only for astrocytes cell proliferation but also for astrocytes cell size [328]. By using the 
same model they demonstrated that TSC 1 AT astrocytes presented an increase in cell size
94
compared to WT animals and they demonstrated that this was due to increased activation 
of the S6-kinase pathway [328].The same group used the same strategy for silencing TSC1 
in the paper by Wong et al. [329]. In this report the authors demonstrated that astrocyte 
expression of glutamate transporters was downregulated in TSC 1 AT mice and that also 
physiological glutamate transporter currents from astrocytes in hippocampal slices were 
decreased in these mice [329].
Also Michael Wong’s group made use of a mouse model of glia-restricted TSC1 
inactivation by crossing TSC1 floxed mice with GFAP-CRE deleters [330-332]. In the 
paper by Jansen et al. [330] the authors showed that inward rectifier potassium (Kir) 
channels expression and current was reduced in TSC 1 AT astrocytes. Impairment of 
potassium uptake mediated by astrocyte Kir could take part in the epileptogenesis in 
TSC 1 AT mice. Hippocampal slices from TSC 1 AT mice, in fact, were characterized by 
increased sensitivity to potassium-induced epileptiform activity [330]. Zeng et al. [331] 
demonstrated that in the hippocampus of these conditional KO mice extracellular 
glutamate was elevated, in particular the elevated levels of synaptic glutamate led to 
impairment in hippocampal LTP and this was reflected in deficits in hippocampal 
dependent conditioning/learning tasks [331]. In the same mouse model Xu et al. [332] 
demonstrated that conditional KO mice had decreased expression of the astrocytic gap 
junction protein, Connexin 43. This was reflected by the fact that also astrocyte gap 
junction coupling was impaired in these mice leading to defects in potassium buffering. 
This could contribute to epilepsy characteristic of TSC1AT mice [332].
4.1.3 TSC/mTOR in the nervous system.
The severe neurological phenotype observed in TSC patients can be easily 
understood by thinking at the importance of the TSC/mTOR pathway in neurons, in 
particular in key processes such as neuronal development and synaptic transmission. In 
recent years many different labs started to study the role of mTOR in neuronal
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development and synaptic plasticity. mTOR has been shown to be important for axon 
guidance, dendrite development, dendritic spine morphogenesis and different forms of 
long-term synaptic plasticity.
The navigation of axons to their targets is an extremely regulated process that 
occurs because of different signals. Campbell and Holt [333] demonstrated the key 
importance for mTOR in this process. By using Rapa they showed that inhibition of mTOR 
prevents repulsive turning and collapse of axon growth cones in response to Semaphorin 
3A (a repellent molecule for the growth of axons). Inhibition of mTOR prevented also 
incorporation of 3H-leucine into newly translated proteins [333]. So probably mTOR can 
affect growth cone guidance by its activity on protein synthesis. Also the complex 
TSC1/TSC2 plays a key role in axon guidance and formation. Ephrin-A can induce growth 
cone collapse. Loss of TSC2 accompanied by hyperactivation of Rheb can prevent this 
effect of Ephrin-A [334]. The TSC complex is important not only for axon guidance, but 
also for axon formation. Choi et al. [335] demonstrated that overexpression of TSC inhibits 
axon growth in neurons in culture while TSC knockdown induces multiple axons. They 
demonstrated that the TSC complex can affect axon formation by regulating the mTOR 
pathway [335].
mTOR has an effect also on dendritic arborisation as demonstrated by Jaworski et 
al. [336]. The authors showed that a constitutively active form of the PI3K subunit p i 10 
and of Akt could increase dendrite branching in hippocampal neurons, in a similar way to 
PTEN silencing by RNAi. The effects of PI3K and Akt could be blocked by administration 
of Rapa and by silencing mTOR with RNAi strategies. They thus demonstrated that mTOR 
plays a key role in dendrite morphogenesis and by knocking down p70S6K they showed 
that mTOR could exert this function through activation of this kinase [336].
mTOR is not only involved in dendrite morphogenesis, it can also control dendritic 
spines morphology. Kumar et al. [337] showed that activation of the PI3K/Akt pathway 
resulted in increased soma size, increased dendritic size and complexity and alteration of
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dendritic spine morphology. Chronic inhibition of mTOR by Rapa led to a reduction in 
dendrite and soma size, reduced dendritic complexity and spine and filopodia density 
[337]. These findings correlated with results in PTEN null mice in which the authors 
demonstrated higher spine density in neurons of dentate gyrus [338]. Results from 
Sabatini’s lab uncovered the role of the TSC complex in neuronal morphology [339]. The 
authors demonstrated that the TSC complex could regulate both density and size of 
dendritic spines, in particular TSC1 lacking neurons showed increased size and decreased 
density of dendritic spines and increased AMPAR-mediated synaptic currents [339].
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Fig VII. mTOR is central to dendrite arborization. mTOR is sufficient to mediate the 
effects of PI3K on dendrite branching. A) Micrographs of hippocampal neurons transfected 
at 7DIV. B-E) Sholl analysis of neurons in A. mTOR-S2035R is a mutant of mTOR 
resistant to Rapa. PI 10* and P11CAAX are constitutively active forms of PI3K. mTOR- 
S2035R blocks the reduction in dendrite number and complexity caused by Rapa (A, D). 
Overexpression of constitutive active PI3K leads to increase in dendrite branching that is 
sensitive to Rapa, mTOR-S2035R prevents Rapa effect (A, B, C). mTOR-S2035R does not 
increase the elaboration of dendrites due to p i 10* and pllOCAAX. Jaworski J., The 
Journal of Neuroscience, 2005 [336]
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The TSC/mTOR pathway plays a crucial role also in another fundamental 
neurological process that is synaptic plasticity. Synaptic plasticity is at the basis of mental 
processes such as memory and learning. Mice deficient for S6K1 and S6K2 showed 
context-specific associative fear memory deficits, problems in taste learning and a slight 
deficit in spatial learning [340]. Synaptic plasticity is compromised also in different 
models of Tuberous Sclerosis. In rats heterozygous for TSC2, von der Breile et al. [341] 
observed alteration in short-term synaptic plasticity and reduced LTP and Long Term 
Depression (LTD), another kind of synaptic plasticity [341]. Goorden et al. [342], by using 
TSC1 heterozygous mice, showed that these mice did not present evident cerebral 
pathology, but displayed signs of impaired cognitive function. Interfering with TSC1 led to 
spatial learning deficiencies, defective context conditioning and diminished social 
functioning [342].
It is easy to figure out that having and TSC and mTOR such fundamental roles in 
the life of a neuronal cell, alteration of one of these proteins or of their signalling pathways 
can lead to severe neurological diseases. Beside the tuberous sclerosis complex described 
above, another syndrome caused by altered TSC/mTOR signalling is neurofibromatosis 
type 1 (NF1). Johannessen et al. [343] demonstrated that in NF1 KO MEFs the PI3K 
pathway was hyperactived, and this resulted in inactivation of TSC2. Also NF1 KO tumour 
cells showed increased mTOR activity and treatment with Rapa could decrease their cell 
growth [343]. mTOR and TSC play a role also in neurodegenerative disorders such as 
Parkinson’s disease (PD) and Huntington’s disease (HD).
Engrailed 1 is a transcription factor of vital importance for dopaminergic neurons. 
Mice that do not express this factor, in fact, show motor problems similar to PD patients 
[344, 345]. Di Nardo et al. [346] demonstrated that Engrailed 1 translation is dependent on 
mTOR, thus suggesting a link between mTOR and PD.
Ravikumar et al. [347], instead, demonstrated mTOR involvement in HD. They 
showed that mTOR was sequestered into huntingtin aggregates in cell models, transgenic
98
mice and human brain. They also demonstrated that polyglutamine expansion impaired 
mTOR kinase activity, measured by S6K1 and 4E-BP1 phosphorylation, and mTOR- 
dependent translation [347]. After increase of mTOR activity they observed increased 
polyglutamine toxicity both in cells and flies. What’s more, by inhibiting mTOR activity 
they observed improvements in behaviour and motor performance in a mouse model of 
Huntington disease [347].
4.1.4 The wtPC12/PC12-27 cell model.
wtPC12 cells resemble chromaffin cells and catecholaminergic neurons. In 1976 
Greene et al. [348] established this clonal line from pheochromocytoma cells. wtPC12 cells 
are endowed with neurosecretory functions [348-350] and the ability to differentiate into 
neuron like cells upon NGF stimulation [348-350]. PC12-27 cells are a spontaneous 
mutant clone defective for neurosecretion [350-352]. The isolation of this clone was the 
fortuitous result of a study for obtaining the permanent overexpression of a constitutively 
activated form of a s, a trimeric G protein subunit [351]. This clone, defective for 
neurosecretion, presents differences in morphology and in the proliferation ability 
compared to wtPC12 cells. Even if their rate of proliferation is quite different, proliferation 
of both clones is insensitive to Rapa administration (our results and [353]).
While wtPC12 cells are characterized by the low expression of the RE-1-specific 
Silencing Transcription factor (REST, or NRSF), PC 12-27 cells express high levels of this 
transcriptional repressor [350, 352]. Although REST has been previously described to 
work as an oncogene and as a tumour-suppressor gene [354-358], its main activity appears 
to be linked to the process of neuronal differentiation. REST is known to repress 
transcription of hundreds of genes, many of which specific for neurons and neurosecretory 
cells. During maturation of nerve cell precursors the high REST, typical of stem cells, 
rapidly declines to very low levels, and this allows nerve cells to acquire their specific 
phenotypes [359, 360]. In contrast, non-nerve cells keep REST at high levels. The latter
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property, which prevents the expression of REST target genes, has also been found to 
control cell proliferation, working as a tumour suppressor [354]. Rapidly proliferating and 
aggressive forms of cancer of non-nerve origin (lung, colorectum, breast, prostate) were 
shown in fact to lose REST expression and concomitantly acquire a faster proliferation rate 
and the expression of typical nerve-cell markers [355-358]. These events may be linked to 
a deregulation of Akt2 [361], induced by low REST. Kreisler et al. [361] demonstrated 
regulation of Akt2 by REST in a Small-Cell Lung Cancer (SCLC) cell line. In this 
particular model REST would act as a tumour suppressor. Its loss, in fact, would lead to 
deregulation of Akt ser473 phosphorylation and thus affect cell proliferation and survival.
The role of REST in controlling proliferation of nerve cells appears to be different. 
Low REST expression correlates to the low or absent proliferation of these cells. 
Medulloblastomas tumours and derived cell lines express high levels of REST, are poorly 
differentiated and capable of intense proliferation [355, 356, 362], which can be blocked 
by the forced expression of a dominant negative construct of REST [362].
Based on these premises we thus investigated the possibility that proliferation and 
neurosecretory functions of wtPC12 and PC 12-27 cells might be under the control of 
TSC/mTOR.
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Fig VIII. U ltrastructural analysis of PC12-27 and wtPC12 cells. Electron microscopy 
of PC 12-27 (A) and wtPC12 (B) cells. Cells in A lack vesicles in the cytoplasm near the 
plasmalemma. In B the same area is rich in typical dense granules. Malosio M.L., Journal 
of Physiology, 1999 [352]
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4.2 Material and methods 
4.2.1 PC12 cell cultures.
The wt PC12 and PC12-27 clones and subclones were grown at 37 °C. Media were 
supplemented with 2 mM 1-glutamine, 100 U/ml penicillin, and streptomycin (Cambrex 
Bio Science Verviers S.p.r.l., Verviers, Belgium). PC12 wt and PC12-27 were grown in 
DMEM with 10% horse serum (Euroclone, Wetherby, United Kingdom) and 5% fetal 
clone III serum (Hyclone Laboratories, Logan, UT). Cells were always kept in medium 
until lysis. This prevented inactivation of S6 phosphorylation.
4.2.2 Transient and stable transfections.
Lipofectamine 2000TM (Invitrogen, Carlsbad CA, USA), was used for both 
transient and stable transfections. PC 12-27 cells transfected with the Myc-tagged dominant 
negative construct DBD/REST together with the pcDNA3.1/hygro(+) vector carrying 
hygromycin resistance, were selected with the antibiotic. Stable subclones were grown in 
complete medium supplemented with 200 or 500 ug/mL of hygromycin B (Invitrogen), 
respectively. Upon transfection, the cells were grown in complete medium supplemented 
with puromycin 10 ug/mL.
The pcDNA3/Flag/TSC2 cDNA (gift of B. Manning) or the corresponding empty 
vector (for controls) was transiently transfected into PC 12-27 cells that were processed 
48h thereafter. To generate cells with stable TSC2 knockdown we transfected wtPC12 
cells with TRC1 lentiviral plasmid vector pLKO.l-puro (Sigma-Aldrich) expressing 
control or TSC2 shRNAs. Forty-eight hours after transfection we added 2.5 pg/ml 
puromycin and selected clones. Knock-down of TSC2 was confirmed by qPCR and 
immunoblotting. Clones were then cultured in the presence of 2.5 pg/ml puromycin.
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4.2.3 Western blot analysis.
wtPC12 and PC 12-27 cells were treated with Rapa (100 nM, Calbiochem), endo- 
IWR1 (10 uM, Tocris); la, 25-dihydroxy vitamin D3 (100 nM, Sigma-Aldrich); quercetin 
(100 uM, Sigma-Aldrich). Total cell extracts of wtPC12 and PC12-27 cells obtained by 
suspending cells in lysis buffer containing 1% Triton X-100, 50 mM Tris-HCl, pH 7.5, 250 
mM NaCl, 5 mM EDTA, 50 mM NaF, and protease inhibitors were rocked (15 min) and 
then centrifuged (13 000 g, 4°C, 15 min). Nuclear and cytoplasmic fractions were 
separated by gradient centrifugation. Proteins were quantified by BCA assay and 
appropriate amounts (30 or 50 pg) were separated on standard 10-15% SDS-PAGE. For 
Western blotting, gels transferred to nitrocellulose filters were first blocked for 1 h with 
5% nonfat dry milk in PBA, and then incubated o.n. with the primary antibody diluted in 
PBS with 5% bovine serum albumin (BSA), washed in PBST (3-fold for 10 min), 
incubated for 1 h with the peroxidase-conjugated secondary antibody, washed again in 
PBST as described above and once in PBS. Photographic development was by 
chemiluminescence (ECL, Amersham Bioscience or Immobilon substrate, Millipore). 
Western blot bands were quantified by the Image J program (rsb.info.nih.gov/ij).
The IgG2a, rat-specific anti-chromograninB (ChgB) monoclonal antibody (mAb), 
was generated in Prof. Meldolesi laboratory. Other Abs were from commercial sources: 
anti-REST and anti-H2B polyclonal Abs (pAbs): Upstate; antisynaptotagminl and anti-P- 
tubulin mAbs: Synaptic Systems; anti-SNAP25 mAb: Stemberger-Monoclonals; anti-GFP 
mAb: Roche; anti-p-catenin and anti-paxillin mAbs: BD Transduction; anti-Akt, anti- 
P(S473)-Akt, anti-P(T308)-Akt, anti-4E-BPl, anti-TSC2, anti-TSCl, anti-GSK3p, anti- 
P(S9)-GSK3p, anti- P(Ser235/236)-S6 and anti-S6, and actin, which were obtained from 
Santa Cruz Biotechnology Inc. Horseradish peroxidase-conjugated goat antimouse and 
anti-rabbit pAbs: Bio-Rad. The BCA Protein Assay Kit from Pierce.
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Antibody anti- Company Cat. N°
REST Upstate 09-019
H2b Upstate 05-1352
Synaptotagminl Synaptic Systems 105 311
P-tubulin Synaptic Systems 302 302
SNAP25 Stemberger-Monoclonals MMS-614R
GFP Roche 11 814 460 001
p-catenin BD Transduction 610153
Paxillin BD Transduction 610055
Akt Cell Signaling 4685
Phospho-Akt (Ser473) Cell Signaling 9271
4E-BP1 Cell Signaling 9452
TSC2 Cell Signaling 3990
TSC1 Cell Signaling 4906
Phospho-GSK3p (Ser9) Cell Signaling 9323
S6 Cell Signaling 2317
Phospho-S6 (Ser235/236) Cell Signaling 2211
Phospho-p70S6K (Thr389) Cell Signaling 9205
Actin Santa Cruz Biotechnology Sc-1616
4.2.4 Cell proliferation assay.
For the direct counting assays, wtPC12, PC 12-27, PC12-27/DBD5 and wtPC12 
cells transfected with ShRNAs and A90pCat constructs were plated at 1 x 104/well in a 24 
well dish, incubated in culture medium and counted after 3, 4 and 5 days. Medium was 
replaced every 48 h. Rapamycin, 0.1 pM, la,25-dihydroxyvitamin D3 , 0.1 pM, quercetin, 
100 pM, and endo-IWRl, 10 pM, were administered for 24 h during the 5th day of culture.
4.2.5 Luciferase assay.
P-Catenin transcription assay was performed using the Dual-luciferase reporter 
assay kit (Promega).
The assay was performed in 24-well dishes. Each well of a 24-well dish was 
cotransfected with lipofectamine 2000TM using standard conditions with the following 
constructs: 1 ug of the 16X TOPFLASH reporter plasmid (Oligos containing 4 TCF sites 
and an Ascl overhang were
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multimerized and cloned into Asc I/Mlu I sites of pTA (Clontech)) and 100 ng of 
SV40-Renilla-l.uc. Luciferase activity was measured 24 hr later, using a luminometer 
(GloMax Multi Detection System of Promega). All assays were normalized to Renilla 
levels.
4.2.6 Immunofluorescence.
Cell monolayers on coverslips were fixed with 4% formaldehyde for 10 min at 
room temperature and quenched in 0.1 M glycine, then permeabilized for 20 min in PBS 
containing 0.2% Triton X-100 and 1% BSA, and immunolabeled for 1 hr with either anti- 
paxillin mAb or phalloidin/FITC conjugate diluted in PBS with 1% BSA. Nuclei were 
stained with DAPI. Samples were studied in a Perkin-Elmer Ultraview ERS confocal 
microscope. Image deconvolution was performed in a wide field microscope of the Delta 
Vision system.
4.2.7 CFSE proliferation assay.
As reported in 2.2.5
4.2.8 Quantitative real-time RT-PCR (qPCR).
As reported in 2.2.6
4.2.9 Statistical analysis.
As reported in 2.2.8
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4.3 Results
4.3.1 PC12-27 cells show a proliferative advantage and an altered morphology 
compared to wtPC12 cells.
PC 12-27 cells are pheocromocytoma cells expressing high levels of the REST 
protein. These cells lack the neurosecretory phenotype typical of wtPC12 cells that are 
characterized by low levels of REST. Another important difference we observed was in 
their proliferative rate. First of all a viable count of these two clones was performed (Fig.
4.1 A). After 4 days it was clear that PC 12-27 cells proliferated better than wtPC12, and 
this was even more evident after 5 days in culture. Cell proliferation was also evaluated by 
CFSE labelling. After 5 days of culture the CFSE content of PC 12-27 cells was lower than 
that found in wtPC12 cells, indicative of faster proliferation (Fig. 4.1 B, C).
WT and defective cells did not differ only in their proliferative capacity but also in 
their morphology. PC 12-27 cells were bigger than their wt counterpart (Fig. 4.1 D, E) as 
shown by the larger cell size evaluated by flow cytometry. PC 12-27 cells contain also 
higher protein contents than wtPC12 cells (Fig. 4.1 F). Besides this PC 12-27 cells also 
showed a particular morphology. While wtPC12 cells were round in shape, PC 12-27 cells 
presented a flatter shape. Actin was distributed at the cortex of wtPC12 cytoplasm, while it 
was organized in thick fibers that crossed the whole cell in PC 12-27. Also paxillin was 
differently distributed in these cells, in wtPC12 it was found in small, adjacent puncta all 
over the plasma membrane, in PC 12-27 instead it formed larger structures at the tips of the 
actin fibers (Fig. 4.1 G). This phenotype was reminiscent of that acquired by HeLa cells 
following Rictor deletion [79].
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Fig 4.1 PC12-27 cells show a proliferative advantage and an altered morphology 
compared to wtPC12 cells. A) The same number of wtPC12 and PC 12-27 cells was 
plated and then the viable cells were counted after 3, 4 and 5 days in culture. The results 
were normalized by the 3rd day of culture. B, C) Cells were labelled with CFSE the first 
day of culture and then CFSE dilution was evaluated after 5 days of culture. In B) the 
histogram of a representative experiment. In C) the quantification of 3 independent 
experiments (±SE). D) Histogram showing FSC profile of wtPC12 and PC12-27 cells, in 
E) the quantification of 3 experiments (±SE). F) Protein concentration per cell, as 
determined by BCA assay, in wtPC12 and PC 12-27 cells. Data are mean (±SE) of protein 
extracts made from 3 separate experiments. Data are normalized on wtPC12 cells. G) 
Immunofluorescence staining of wtPC12 and PC 12-27 cells labelled with Paxillin (left), 
phalloidin (middle) and the merge of the two together with DAPI staining (right). In A 
statistical significance was evaluated with two-way ANOVA test with Bonferroni post test, 
in C, E and F with two-tailed t-Test.
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4.3.2 mTORCl and mTORC2 signalling are perturbed in PC12-27 cells.
We thus decided to investigate whether differences between wtPC12 and PC 12-27 
cells could be attributed to mTOR signalling. We analyzed mTORCl and mTORC2 
activity by looking at the phosphorylation of some targets of these two complexes. For 
mTORCl the phosphorylation of p70S6K (Thr389), 4E-BP1 and S6 (Ser235/236) and for 
mTORC2 of Akt in ser473 and its target GSK3P (Ser9) were assessed. An increase in S6 
(Ser235/236) and p70S6K (Thr389) phosphorylation and in the mobility shift of 4EBP1 in 
PC 12-27 cells compared to their wt counterpart was detected. This suggested constitutive 
mTORCl activity in PC 12-27 cells (Fig. 4.2). By looking at the phosphorylation of Akt 
(Ser473) and GSK3p (Ser9) it was found that these phosphorylation were decreased in the 
clone defective for neurosecretion compared to the wt one (Fig. 4.2). This was consistent 
with defective mTORC2 signalling. Fig. 4.2 A show representative blots, while Fig. 4.2 B 
depicts a pool of different experiments.
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Fig 4.2 mTORCl is hyperactivated and mTORC2 down-regulated in PC12-27 cells.
SDS-PAGE analyses were performed as detailed in Materials and Methods 4.2.3.
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Phosphorylation of the mTORCl targets 4EBP1 and p70S6K (Thr 389), of p70S6K 
substrate S6 (Ser 235/236), of the mTORC2 target Akt (Ser 473) and of Gsk3p (Ser9) were 
assessed by western blot analysis (A and B). p-tubulin is depicted as loading control, and 
relative migration of molecular weight markers is depicted. One of 3-8 independent 
experiments is depicted. Molecular weight markers are indicated in KDa.
B) Independent experiments were compared by densitometric analyses. Expression levels 
are shown as relative to wtPC12 cells (±SE). In B statistical significance was evaluated 
with two-tailed t-Test.
4.3.3 Reduced TSC2 levels account for P-catenin upregulation and increased 
nerve cell proliferation.
This unbalance between mTORCl and mTORC2 could be the consequence of a 
defect in TSC1/TSC2 signalling. As shown by Huang et al. [38], the TSC complex can 
regulate in an opposite way mTORCl and mTORC2. The levels of TSC1 and TSC2 in 
wtPC12 and PC 12-27 cells were thus investigated. While TSC1 was expressed to 
comparable extents in wt and PC 12-27 cells, TSC2 levels were significantly lower in 
PC 12-27 cells (Fig. 4.3 A, B).
PC 12-27 cells overexpress the transcriptional repressor REST. We thus asked 
whether REST could be responsible for decreased TSC2 levels. The levels of TSC2 were 
analysed in a clone of PC 12-27 cells stably transfected with a dominant negative construct 
able to inhibit the effect of REST, the PC12-27/DBD5 clone (Fig. 4.3 B). An increase in 
the levels of TSC2 was observed in the PC12-27/DBD5 clone compared to the PC 12-27 
cells, so a partial recovery in the levels of TSC2 appears to be due to a decrease in REST 
activity. The levels of TSC2 mRNA were then evaluated to check whether REST could 
have an effect in the transcription of the gene itself. Real time PCR experiments showed no 
difference in the transcription of TSC2 in wtPC12 and PC 12-27 cells, suggesting a post- 
transcriptional control of TSC2 (Fig. 4.3 C).
After we established that TSC2 levels were decreased in the defective PC 12-27 clone, we 
tried to understand which was the molecular mechanism responsible for the increased cell 
proliferation rate observed in these cells. We decided to assess if the hyperactivation of
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mTORCl could be responsible for this effect. While Rapa reduced S6 phosphorylation
levels and the mobility of 4E-BP1 (Fig. 4.3 D), it did not have a significant effect on the 
growth of wtPC12 or PC12-27 cells (Fig. 4.3 E). These results suggested that proliferation 
in these cells did not appear to be regulated by mTORCl, or at least not only by mTORCl, 
in accordance with results from Powers et al. [353].
A B
TSC1
Actin
—  200
TSC2
mRNA
lOvZ
- 1 5 0
B-tubulin
£  50
wtPC12 PC 12-27
Rapa (1 h) 
Pan-S6 
P-S6
(Ser235/238)
Actin
4E-BP1
B-tubuiin
n=3
200 n
- 3 2
-  32
-  38
-  20 
-  47
□  Day 4
□  Day5wtPC12 
■  Day5PC12-27
>v 160*
Fig 4.3 PC12-27 cells show reduced TSC2 levels and an increased Rapa-independent 
growth compared to wtPC12 cells. A, B, D) SDS-PAGE analyses were performed as 
detailed in Materials and Methods 4.2.3. Levels of TSC1 and TSC2 (A and B) and 
phosphorylation of the mTORCl target 4EBP1 and of p70S6K substrate S6 (Ser 235/236) 
(D), were assessed by western blot analysis. Cell were treated with Rapa (100 nM) for 1 
hour. P-tubulin and actin are depicted as loading controls, and relative migration of 
molecular weight markers is depicted. One of 3 independent experiments is depicted. 
Molecular weight markers are indicated in KDa. A, B) Independent experiments were 
compared by densitometric analyses. Expression levels are shown as relative to wtPC12 
cells (±SE). C) TSC2 mRNA was first normalized to the GAPDH housekeeping gene, and
110
then expressed relatively to wtPC12 cells using tlMCT method (±SE). E) The same 
number of wtPC12 and PC 12-27 cells was plated and then the viable cells were counted 
after 4 and 5 days in culture. The results (±SE) were normalized by the 4th day of culture. 
24h before counting the viable cells Rapa (100 nM) was administered. In B statistical 
significance was evaluated with one-tail ANOVA test with Dunns post test.
The TSC complex controls not only mTORCl but also other important pathways 
for cell proliferation. One of these, the p-catenin pathway, is of key importance in the life 
of nerve cells in general. First the levels of p-catenin in the wt and defective clones were 
analysed. The nuclear levels of p-catenin were increased in the defective clone compared 
to the wt one (Fig. 4.4 A) as well as its transcriptional activity as assessed by a luciferase 
assay that evaluates the ability of transcription of P-catenin (Fig. 4.4 B). p-catenin activity 
was evaluated also by looking at the mRNA levels of some of its target genes by real time 
PCR. The mRNA levels of c-Myc, Cyclin Dl and REST were evaluated. REST, in fact, is 
another target of p-catenin. Again a significant increase in the levels of all of these genes 
was detected in PCI2-27 compared to wtPC12 cells (Fig. 4.4 C). The increase in c-Myc 
mRNA levels in PC 12-27 cells is strikingly higher compared to the increase in Cyclin Dl 
mRNA levels. The Cts (the fractional PCR cycle number at which the reporter 
fluorescence is greater than the threshold) of c-Myc and Cyclin Dl in wtPC12 are 28.75 
and 21.75 respectively. These Cts indicate the presence of the mRNAs for these genes in 
the cells. The strong increase in PC 12-27 cells in c-Myc mRNA levels compared to Cyclin 
Dl can be explained by the difference in the Ct between wtPC12 and PC 12-27 cells. 7.61 
in c-Myc compared to 4.08 in Cyclin Dl (Fig. 4.4 D-F).
These results indicate that together with increased levels of REST and decreased 
levels of TSC2, the defective clone is characterized by increased levels of p-catenin. We 
tried to evaluate whether this increased P-catenin activity could be the reason for the higher 
rate of proliferation we observed in PC 12-27 cells. A viability count was thus performed 
by plating the cells with different p-catenin inhibitors. The drugs used for this assay were: 
la, 25-dihydrovitamin D3, known to induce the export of nuclear p-catenin to the
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cytoplasm [363]; quercetin, a blocker of the p-catenin/TCF-LEF transcription [364]; and 
endo-IWRl, which favours p-catenin degradation [365]. After 4 days of culture the 
inhibitors were added to the cells and the cells were counted at day 5. The administration 
of la, 25-dihydrovitamin D3 provoked an almost complete block in cell proliferation in 
both wtPC12 and PC 12-27 cells, suggesting that p-catenin plays a really important role in 
the proliferation of these cells. Quercetin and endo-IWRl, instead, caused a slight decrease 
in the proliferation of wtPC12 cells, but abrogated the proliferative advantage of the 
defective clone. The rate of proliferation of wtPC12 and PC 12-27, in fact, is comparable
(Fig.
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Fig 4.4 PC12-27 cells show increased p-catenin levels and an increased p-catenin 
dependent growth compared to wtPC12 cells. A) SDS-PAGE analyses were performed 
as detailed in Materials and Methods 4.2.3. p-catenin and REST protein levels were 
evaluated by western blot analysis in nuclear and cytoplasmic extracts of wtPC12 and
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PC 12-27 cells, p-tubulin and H2b are depicted as loading controls, and relative migration 
of molecular weight markers is depicted. One of 3 independent experiments is depicted. 
Molecular weight markers are indicated in KDa. B) A luciferase assay was performed on 
wtPC12 and PC 12-27 cells. The cells were co-transfected with the reporter and the 
luciferase plasmids and luciferase activity (±SE) was measured 24h later. C) c-Myc, REST 
and Cyclin D1 mRNAs were normalized to the GAPDH housekeeping gene, and then 
expressed relatively to wtPC12 cells using the AACT method (±SE). D, E) Ct (the point at 
which the fluorescence crosses the threshold of real time PCR) for c-Myc and Cyclin D l. 
F) Difference in Ct between PC 12-27 and wtPC12 cells for Gapdh, c-Myc and Cylin Dl 
genes. G) The same number of wtPC12 and PC 12-27 cells was plated and then the viable 
cells were counted after 4 and 5 days in culture. The results (±SE) were normalized by the 
4th day of culture. 24h before counting the viable cells the different inhibitors were 
administered. In B and C statistical significance was evaluated with two-tailed t-Test.
It has been proven that TSC1/TSC2 promotes the turnover of p-catenin [39-41, 
366]. We thus wanted to demonstrate a direct link between the two proteins in PC 12 cells 
as well. A full length construct of TSC2 was overexpressed by transiently transfecting 
PC 12-27 cells (Fig. 4.5 A). Restoring TSC2 levels led to a decrease in p-catenin protein 
levels, a decrease in the mRNA levels of c-Myc and a reduction in the levels of the REST 
protein (Fig. 4.5 B). These results seem to further point to a direct link between TSC2 and 
P-catenin.
To further prove this link we moved to the wtPC12 cells. This clone was stably 
transfected with different shRNAs silencing the TSC2 gene. Different subclones were 
generated and the expression of p-catenin and REST were analysed. By western blot 
analysis an increase in the levels of REST and nuclear p-catenin was observed in the 
clones transfected with the shRNAs for TSC2 compared to the control clone transfected 
with a control shRNA that does not silence any human or mouse gene. In Fig. 4.5 C a 
representative blot, while in Fig. 4.5 D the quantification of different experiments. The 
decrease in TSC2 and following increase in P-catenin and REST levels correlated with an 
increase in their activity, p-catenin transcriptional activity was assessed by the luciferase 
assay and by looking at the transcription of c-Myc and Cyclin Dl (Fig. 4.5 E, F). The 
TSC2 shRNA clones analysed showed an increase in the luciferase activity compared to 
the control clone and higher mRNA levels of both Cyclin Dl and c-Myc by real time PCR
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(Fig. 4.5 E, F). In order to evaluate whether the increase in REST levels was mirrored by 
an increase in its activity as well, the levels of two important REST targets, Synaptotagmin 
1 and SNAP 25, were evaluated. The levels of both of these proteins were decreased in the 
TSC2-shRNA clones compared to the control one (Fig. 4.5 G). These results further prove 
the direct link between TSC2 and P-catenin. At this point we wanted to link TSC2 to 
proliferation as well. First of all a viability count was performed and an increase in the 
proliferation rate of the shRNA clones compared to the control one was observed (Fig. 4.5 
H). To verify that this increase in proliferation was due to the effect of TSC2 silencing on 
P-catenin, the viability count was performed in the presence of quercetin and endo-IWRl, 
inhibitors of p-catenin. The administration of the inhibitors did not exert a strong inhibition 
on the control cells, but completely abrogated the proliferative advantage of the TSC2 KO 
clone (Fig. 4.5 I), thus indicating that the increased proliferation observed in the shRNA 
clones is probably due to the increase in p-catenin that was observed in these cells.
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Fig. 4.5 TSC2 regulates p-catenin levels and proliferation of PC12 cells. A and B)
PC 12-27 cells were transfected with an empty vector and with a construct overexpressing 
TSC2: pcDNA3/flag/TSC2 A) SDS-PAGE analyses were performed as detailed in 
Materials and Methods 4.2.3. Levels of TSC2 were assessed by western blot analysis. P- 
tubulin is depicted as loading control, and relative migration of molecular weight markers 
is depicted. One of 3 independent experiments is depicted. Molecular weight markers are 
indicated in KDa. B) p-catenin and REST protein and c-Myc mRNA levels (±SE) were 
expressed relatively to PC 12-27 cells transfected with the empty vector. C-I) wtPC12 cells 
were transfected with a control ShRNA (Sh Ctrl) and with a ShRNA silencing TSC2 (Sh 
TSC2). C and D) SDS-PAGE analyses were performed as detailed in Materials and 
Methods 4.2.3. Levels of TSC2, REST and p-catenin were assessed by western blot 
analysis, p-tubulin and H2b are depicted as loading controls, and relative migration of 
molecular weight markers is depicted. One of 3 independent experiments is depicted.
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Molecular weight markers are indicated in KDa. D, G) Independent western blot 
experiments were compared by densitometric analyses. Expression levels (±SE) are shown 
as relative to wtPC12 cells transfected with a Ctrl ShRNA. F) A luciferase assay was 
performed on wtPC12 cells transfected with the ShRNA construct. The cells were co­
transfected with the reporter and the luciferase plasmids and luciferase activity was 
measured 24h later. E) c-Myc and Cyclin Dl mRNAs (±SE) were expressed relatively to 
wtPC12 cells transfected with the Ctrl ShRNA. H, I) The same number of wtPC12 Ctrl and 
ShRNA transfected cells were plated and then the viable cells were counted after 3 ,4  and 5 
days in culture. The results (±SE) were normalized by the 3rd (H) or 4th (I) day of culture. 
24h before counting the viable cells the different inhibitors were administered (I). In B, D- 
G statistical significance was evaluated with two-tailed t-Test, in H with two-way ANOVA 
test with Bonferroni post test.
As discussed above PC 12-27 cells show morphological features typical of Rictor KO cells. 
The morphology of wtPC12 cells that were transfected with TSC2 shRNA was analysed by 
Immunofluorescence. While the clones transfected with a control shRNA do not show 
morphological differences compared to wtPC12 cells (Fig. 4.6), the TSC2 KO clones show 
morphological features typical of Rictor KO cells and are quite reminiscent of PC 12-27 
cells. Fig. 4.6 shows that these cells are flatter and more attached to the culture surface, 
phalloidin staining evidences the presence of actin fibers running through the whole 
cytoplasm. Also paxillin is redistributed with some accumulation in the peripheral 
cytoplasmic protusions.
PhalloidinPaxillin
Fig 4.6 TSC2 silencing affects PC12 cells morphology. Immunofluorescence staining of 
PC 12 cells labelled with Paxillin (left), phalloidin (middle) and the merge of the two 
together with DAPI staining (right). wtPC12 cells transfected with a Ctrl ShRNA (up) or a 
ShRNA silencing TSC2 (bottom).
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4.4 Discussion
By the analysis of wtPC12 and PC 12-27 nerve cells, we unveiled a new pathway 
linking TSC2 to proliferation and neurosecretory functions. Comparison of wtPC12 cells 
and PC 12-27 cells, the first characterized by low levels of REST and proper neurosecretory 
functions, and the latter expressing high levels of REST and lacking neurosecretory 
functions [350], led to the identification in the latter of the loss of TSC2, and a gain in 
proliferative capacity. Loss of TSC2 in PC 12-27 cells was paralleled by constitutive 
mTORCl and defective mTORC2 signalling, and increase in cell size and proliferative 
potential and augmented P-catenin activity. Similar results and biological responses were 
achieved by knocking down TSC2 in wtPC12 cells by RNAi. Also in this case cells were 
enlarged in size and proliferated to faster extents when compared to control wtPC12 cells. 
The proliferative advantage of PC 12-27 cells was insensitive to Rapa, suggesting that 
mTORCl might not be involved in nerve cells proliferation, as also reported previously 
[353]. This proliferative advantage was rather dependent upon P-catenin increased activity. 
Indeed, proliferation of PC12-27 cells was inhibited by P-catenin inhibitors.
Thus loss of TSC2, either spontaneous (PC 12-27) or mediated by ShRNA, allows 
P-catenin accumulation in the nucleus and confers a proliferative advantage. Decreased 
TSC2 also had a critical impact on cell morphology and neurosecretory functions. Indeed 
wtPC12 cells that were transfected with a TSC2 shRNA were flatter and more attached to 
the culture surface, phalloidin staining evidenced the presence of actin fibers running 
through the whole cytoplasm and paxillin was redistributed with some accumulation in the 
peripheral cytoplasmic protusions, thus showing morphological features typical of Rictor 
KO cells and were quite reminiscent of PC 12-27 cells. Furthermore lowering TSC2 levels 
also had an impact on expression of neurosecretory proteins such as Synaptotagmin 1 and 
SNAP-25. Thus TSC2 controls proliferation, morphology and neurosecretory functions of 
nerve cells.
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The ability of the TSC1/TSC2 complex to regulate p-catenin turnover was 
previously reported [39-41, 366]. The authors showed that p-catenin levels and activity is 
regulated by TSC1 and TSC2 and that p-catenin down-regulation could be due to the fact 
that TSC1 and TSC2 interact with components of the p-catenin degradation complex [40].
Also the link between p-catenin and REST was previously suggested, p-catenin has 
been shown to modulate transcription of the REST gene. Nishiara et al. [367] 
demonstrated that over-expression of p-catenin in chick spinal cord induces REST and 
Cyclin Dl [367].
The link between REST and TSC2, instead has never been reported in literature. 
We hypothesize that a possible mechanism through which REST could regulate TSC2 
could be through REST regulation of a miRNA that targets TSC2 mRNA. REST has been 
found to repress the expression of non-coding RNAs such as miRNAs and maRNAs, 
acting at various posttranscriptional levels including RNA processing, editing and 
trafficking [368-371]. The possible effect of REST on non-coding RNAs that control TSC2 
mRNA levels and/or stability could explain the fact that in PC 12-27 cells a reduction in the 
protein levels of TSC2 was observed while TSC2 mRNA levels were not altered between 
wtPC12 and PC12-27 cells.
In collaboration with Prof. Meldolesi’s group we have further studied the signalling 
loop composed by TSC2/p-catenin/REST. We demonstrated that favouring p-catenin 
activity mediates an increase in REST levels, a decrease in TSC2 and a faster proliferation 
rate. Likewise forcing REST expression in wtPC12 cells resulted in decreased levels of the 
TSC2 protein, p-catenin accumulation and again a proliferative advantage (Tomasoni et 
al., submitted).
By comparing wtPC12 and PC 12-27 cells and also by genetically controlling 
expression level or activity of the different proteins involved, we unveiled a new loop
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linking TSC2/p-catenin/REST. Of note this appears a feed forward loop as interfering with 
any of the players has direct consequences in the other two.
The consequences of the interconnection of the proteins of this loop should be 
further analysed as they could reveal of critical importance for the life of any cell. Further 
experiments performed in collaboration with Prof. Meldolesi’s group demonstrated the 
existence of the loop also in another model of neural cells, the human NT2/D1 cells. This 
suggests that the pathway described can be present in other cellular models beside the 
PC 12 cells. The existence of the TSC2/p-catenin/REST loop should be investigated in 
other cellular models such as primary cells, e.g. neurons or astrocytes. The existence of this 
pathway could be, in fact, a characteristic of transformed cells such as the PC 12 and 
NT2/D1. Preliminary experiments performed in non-transformed TSC1AT and TSC1WT 
Neural Stem Cells (NSCs) by Laura Magri, a PhD student in Dr. Galli’s group, suggest that 
there are no differences in p-catenin and REST levels in TSC1AT and TSC1WT NSCs.
The modification of the levels or activity of one of the three key players discussed above 
(such as nerve cell hyper-stimulation for REST [372]; activation of growth factor 
signalling for TSC2 [373]; activation of the canonical Wnt signalling for p-catenin [374]) 
would results in changes in the levels and activity of the others as well. So in analyzing the 
effect of the mutation of one factor researcher should take into consideration the possibility 
that the consequent responses could be on a bigger level.
Our results show how proliferation and neurosecretion can be regulated in opposite 
ways by a single signalling loop and it reflects what happens to rapidly proliferating nerve 
cells that lack almost completely neurosecretion.
The discovery of this new signalling loop could be of relevance also for therapeutic
reasons. It suggests the use of combination of drugs that can address the different
signalling pathways involved. The pathways we have studied are involved in a variety of
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conditions such as cell growth, differentiation, function and metabolism [375, 376]. So the 
clinical approaches that could derive from inhibiting these factors could be of relevance in 
controlling proliferation and differentiation of nerve cells and in the prevention of 
neurodegeneration [377, 378].
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Fig IX. TSC2/p-catenin/REST signalling loop. PC 12 cells (left) are characterized by 
high levels of TSC2 that lead to inhibition of p-catenin and consequently of REST. PC 12- 
27 cells (right) are characterized by lower levels of TSC2 that thus cannot decrease P- 
catenin levels, p-catenin increased levels are accompanied by higher REST levels as well. 
The increased p-catenin and REST levels in the PC 12-27 cells result in increased 
proliferation, positively controlled by p-catenin, and decreased neurosecretion, negatively 
controlled by REST.
120
5. General discussion
The TSC1/TSC2 and mTOR complexes are positioned at the crossroads of critical 
signalling cascades induced by growth promoting agents and energy and stress signals. The 
findings generated in this thesis underline some common mechanisms of regulation of 
proliferation and define new pathways by which TSC and mTOR might be interconnected 
to the acquisition or maintenance of functions typical of differentiated cells.
Under growth promoting conditions Akt becomes phosphorylated and by that 
inhibits the TSC1/TSC2 complex. This allows both mTORCl and mTORC2 signalling, 
which controls aspects of cell growth, proliferation, differentiation and survival. mTORCl - 
dependent activation of p70S6K, in turn, prevents uncontrolled Akt-dependent cell 
proliferation by a negative feedback loop, involving IRS/PI3K and also other yet to be 
defined signalling modules, and leading to the inhibition of Akt phosphorylation and thus 
reactivation of the TSC complex. The negative feedback loop was originally described in 
MEFs WT or KO for TSC2 [127], but our data support the notion that it is also active in 
primary TCR/CD28-activated primary T cells. In contrast, the negative feed-back loop 
cannot be operational in TSC deficient cells, in which mTORCl is constitutively active 
leading to increased proliferation.
Loss of TSC1 or TSC2 also hinders mTORC2 activity and by that Akt 
phosphorylation in Ser473, critical for full potential of the kinase. Indeed, reduced Akt 
signalling limits the uncontrolled growth of tumours lacking TSC2 [379, 380] and favours 
apoptosis because of the de-regulation of death-promoting factors such as the FoxO 
proteins.
Our data are in line with the model described above. We have shown that mTOR 
and TSC1/TSC2 are important for the proliferation of both primary T cells and established 
nerve cells. We have demonstrated that in cells in which mTOR is chemically inhibited by 
Rapa, proliferation is delayed and differentiation is strongly affected. Thymocytes and
121
mature lymphocytes in which TSC1 has been genetically silenced show an increase in 
proliferation. Moving to the PC 12 cells model of nerve cells we observed an increase in the 
proliferation of PC 12-27 cells that show reduced TSC2 levels compared to the wt clone 
and we proved TSC2 relevance for PC 12 proliferation also by ShRNA mediated silencing 
of TSC2.
The way TSC1/TSC2 complex and mTOR can control proliferation or survival may 
differ according to the cell type. While in mature T cells the increased proliferation seems 
to be dependent on hyperactivation of mTORCl as demonstrated by the fact that 
administration of Rapa could revert the increased proliferation of LCK-CRE/TSC1AT 
lymphocytes, in the PC 12 cells we have demonstrated that the increased cell proliferation 
was due to increased p-catenin signalling. Furthermore, in mature CD4+ T cells 
TSC1/TSC2 balances proliferation and cell death by regulating mTORCl and mTORC2, 
respectively. Whether loss of TSC 1 has a direct impact on mTORC2 activity or whether it 
is indirect via the feedback loop from mTORCl remains to be clarified. Regardless, loss of 
TSC1 favoured mTORCl hyperactivation and loss of mTORC2-dependent Akt 
phosphorylation of FoxOs, and by that increased TRAIL expression and TRAIL-dependent 
cell death.
In PC 12 cells loss of TSC2 leads to stabilization of p-catenin promoting cell 
proliferation, and caused an upregulation of REST (Tomasoni et al., submitted) leading to 
the shut off of neurosecretory functions. The effect of TSC2 on p-catenin in PC 12 cells 
seems to differ from the possible activity of the TSC1/TSC2 complex in thymocytes from 
LCK-CRE/TSC1AT mice. While p-catenin targets c-Myc and Cyclin Dl were lower in 
cells from LCK-CRE/TSC1AT mice, these targets were expressed at higher level in PCI 2- 
27 cells characterized by low level of TSC2. This could be explained by the fact that the 
TSC1/TSC2 complex controls p-catenin stability either by direct regulation or by its 
indirect activity on Gsk3p. From the results reported above it is reasonable to hypothesise
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that in LCK-CRE/TSC1AT mice low levels of TSC1/TSC2 complex lead to decreased 
phosphorylation and activation of Akt that in turn cannot phosphorylate and thus inhibit 
Gsk3p. This would lead to activation of Gsk3p that then would de-stabilize p-catenin. In 
PC 12-27 cells, instead, Gsk3p control of P-catenin does not seem to play a crucial role. 
Even if these cells show decreased phosphorylation of Gsk3p and thus the kinase should be 
more active on its target p-catenin, the PC 12-27 cells show increased levels and activity of 
P-catenin. Experiments performed on wtPC12 and PC 12-27 cells using LiCl, an inhibitor 
of Gsk3p, showed that while LiCl could increase p-catenin activity, evaluated by luciferase 
assay, in wtPC12 cells, LiCl treatment had little effect in PC 12-27 cells, again hinting at 
the fact that in these cells probably it’s the direct control of TSC2 on p-catenin levels that 
plays a critical role in the regulation of this protein.
The picture that appears from the results obtained with thymocytes, mature primary 
T cells and nerve cells clones depicts a situation in which the interaction among different 
signalling cascades can control in a coordinated way many different cellular processes. By 
touching one signalling pathway also the others are perturbed and thus the many diverse 
processes controlled by all of them. The different complexes thus orchestrate these most 
diverse processes in a finely regulated way. In case of alteration of this delicate balance the 
consequences for the cell can be severe. The unbalance towards excessive proliferation can 
lead to uncontrolled growth typical of many aggressive tumours. The loss of differentiation 
can have important effects during development and results in dysfunctions of many 
systems.
The processes described above are at the basis of most severe pathologies such as 
tumours growth, neurological and immune diseases. By understanding the molecular 
mechanisms underlying these conditions and how different signalling molecules are 
involved in the generation of these illnesses could help in finding new therapeutic
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protocols that act by addressing the different pathways involved in the generation of the 
diseases.
Cell death
Proliferation Effector function
-T cells —  Nerve cells
Fig X. TSC/mTOR pathway in T and nerve cells proliferation and differentiation. The
TSC1/TSC2 complex can control both mTORCl and mTORC2 and p-catenin. By 
inhibiting mTORCl and p-catenin and activating mTORC2 it can affect different cellular 
processes such as proliferation and differentiation of both T cells and nerve cells. In our 
model the effect of the TSC complex on the mTOR complexes plays a central role in T 
cells biology, while the effect of the TSC complex on P-catenin and REST is important in 
nerve cells functions.
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6. Abbreviations
3-phosphoinositide-dependent protein kinase 1 PDK1
AMP-activated protein kinase AMPK,
Antigen Ag
Antigen-Presenting Cells APCs
Bovine Serum Albumin BSA
Brain Lipid Binding Protein BLBP
ChromograninB ChgB
Cyclin-Dependent Kinase 1 CDK1
Cyclosporine A CSA
DEP-domain-containing mTOR-interacting protein Deptor
DNA methyltransferase Dnmt
Double Negative DN
Double Positive DP
Early-phase Long Term Potentiation E-LTP
Epidermal Growth Factor EGF
eukaryotic Elongation Factor 2 Kinase eEF-2K
eukaryotic Initiation Factor 4E eIF4E
eIF4E-binding protein 1 4E-BP1
Fibroblast Growth Factor 2 FGF2
FKBP12-Rapamycin Binding domain FRB
Glycogen Synthase Kinase 30 GSK30
Huntington’s disease HD
Immunoreceptor Tyrosine-based Activation Motifs ITAMs
Insulin Receptor Substrate 1 IRS1
Intermediate Single Positive iSP
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Linker for Activation of T cell LAT
Long Term Depression LTD
Lymphangioleiomyomatosis LAM
Lymphocytic choriomeningitis virus LCMV
Major Histocompatibility Complex MHC
mammalian Lethal with Sec 13 protein 8 mLST8
mammalian stress-activated protein kinase interacting protein mSIN 1
mammalian T arget of Rapamycin mTOR
medullary Thymic Epithelial Cells mTECs
messenger RNA mRNA
Methylated DNA Immunoprecipitation MeDIP
mTOR Complex 1 mTORCl
mTOR Complex 2 mTORC2
Negative Regulatory Domain NRD
Neural Stem Cell NSC
Neurofibromatosis type 1 NF1
p70S6 Kinase S6K
Parkinson’s disease PD
Peroxisome Proliferator-Activated Receptor-y PPARy
Phospho-Inositide 3-Kinase PI3K
PI3K-related Kinase PIKK
Pleckstrin Homology PH
PMA and Ionomycin P/I
Polymerase I Pol I
Programmed Cell Death 4 PDCD4
Proline-Rich Akt Substrate 40 kDa PRAS40
Promyelocytic leukemia PML
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Protein Kinase Ca 
Rapamycin
Ras homolog enriched in brain
RE-1-specific Silencing Transcription factor
regulatory-associated protein of mTOR
Retinoblastoma
Ribosomal Protein genes
RAPTOR-independent companion of mTOR
S6K1 aly/REF-like target
Serum- and Glucocorticoid-induced protein Kinase 1 
Signal Transducer and Activator of Transcription 
Single Positive 
Small-Cell Lung Cancer 
Stem Cell Factor
Sterol Regulatory Element Binding Protein 1 
Subventricular zone 
T Cell Factor 
T Cell Receptor
T Cell Receptor Interacting Molecule 
TRIM
Tract of oligopyrimidine 
Transcription Initiation Factor IA 
Tuberous Sclerosis complex 
Unfolded Protein Response 
Untranslated regions 
Very Late Antigen 4 
-chain associated protein of 70 kDa
PKCcc
Rapa
Rheb
REST
raptor
Rb
RP genes
Rictor
SKAR
SGK1
STAT
SP
SCLC
SCF
SREBP1
SVZ
TCF
TCR
TOP
TIF-IA
TSC
UPR
UTRs
VLA4
ZAP-70
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